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Abstract 
 
Pseudomonas aeruginosa, an increasingly multi-drug resistant human pathogen, is 
now one of the top three causes of opportunistic infection and there is much interest 
in identifying novel therapeutic targets for treatment. As a bacterial pathogen, P. 
aeruginosa encounters innate immune system defences and must continue to adapt to 
its defence strategies to accommodate the ever-changing environment. Though P. 
aeruginosa virulence determinants have been heavily characterised over the last 
several decades, most recent work acknowledges the complex interaction between the 
human host and the pathogen as an on-going dialogue of virulence factors adapting to 
the continuum that is the immune response.  A major challenge that P. aeruginosa 
must overcome are reactive oxygen species (ROS) that are released at all stages of 
infection. Based on previous work which demonstrated a role for soluble nitro- and 
quinone oxidoreductase (NQOR) enzymes in protecting a related bacterium 
(Pseudomonas putida) from oxidative stress, we hypothesized that P. aeruginosa 
would similarly utilize NQORs to withstand ROS. This thesis seeks to understand the 
role of ROS-protecting enzymes in pathogenesis as well as their potential applications 
in a therapeutic context. 
 
Several NQORs of P. aeruginosa were identified to possess biochemical characteristics 
consistent with the enzymatic capacity to indirectly reduce reactive species like H2O2. 
However, when individual genes encoding NQORs were deleted from P. aeruginosa, no 
apparent H2O2 sensitivity was seen. In contrast, when candidate genes were over-
expressed, certain NQOR enzymes conferred the ability to tolerate H2O2 challenge at 
low concentrations; indicating that these NQORs may play a protective role whose 
effects are masked in vitro by genetic redundancy as well as a highly active 
endogenous catalase. By developing a novel in vivo cell culture infection model, the 
survival of P. aeruginosa post exposure to immunocompetent murine macrophages 
was also assessed. This not only demonstrated that several putative NQORs were 
activated in the presence of macrophages but also that an in vivo modelling system is 
likely to be more appropriate for discovering virulence determinants. 
 
In a different aspect of this study it was investigated whether the reductive capacity of 
the P. aeruginosa-derived NQORs might hold potential for gene-directed enzyme-
prodrug therapy (GDEPT).   Prodrugs, such as 5-(aziridin-1-yl)-2,4-dinitrobenzamide 
(CB1954) or the nitro-chloromethyl benzindoline SN 26438, are nontoxic in their native 
form, but become highly toxic upon reduction of their nitro functional groups. The P. 
aeruginosa NQORs, were tested to identify enzymes capable of efficient activation of 
CB1954 or SN 26438. Although none of these enzymes exhibited greater activity with 
CB1954 than the “best in class” Eschericha coli enzymes NfsA or NfsB, the P. 
aeruginosa NfsB orthologue (PA5190) demonstrated greater than 20-fold improved 
activity over NfsB from Escherichia coli in its ability to sensitise human cells to SN 
26438. This finding offers promise for development of PA5190 and SN 26438 as a novel 
enzyme-prodrug paradigm for GDEPT. 
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Chapter 1: Introduction 
 
1.1. Overview 
 
The research described in this thesis began with a biochemical and genetic 
investigation into a novel antioxidant defence mechanism, aiming to discern whether 
the opportunistic bacterial pathogen Pseudomonas aeruginosa might rely on a 
substantial contribution from soluble quinone oxidoreductase enzymes to withstand 
assault by host-generated oxidative stress during the course of pathogenesis. This 
preliminary investigation (described in Chapter 3) provided a foundation for two quite 
different follow up studies, one examining more globally the response of P. aeruginosa 
to challenge by host macrophages (Chapter 4), and the other looking at potential 
applications of the oxidoreductase enzymes in activation of prodrugs for cancer gene 
therapy (Chapter 5). Owing to the quite different focus of each of these arms of the 
study, detailed chapter-specific introductions have been written for each of them. In 
contrast, this Introduction chapter seeks to provide a more general overview of how P. 
aeruginosa causes infection and the importance of reactive oxygen species to that 
process. 
 
1.2. Pseudomonas aeruginosa, an opportunistic pathogen 
 
Pseudomonas aeruginosa, a Gram-negative bacterium, has emerged as major cause of 
life-threatening secondary infections in medical care facilities. It is an opportunistic 
pathogen accounting for over 10% of all hospital-acquired infections (1).  Its genetic 
flexibility allows P. aeruginosa to survive in almost all environments and with minimal 
nutrition, resulting in an organism that is (i) phenotypically unstable and difficult to 
track epidemiologically, (ii) capable of persisting in different physical settings from 
community to hospital settings, and (iii) efficient in developing multi-drug resistance 
(2). P. aeruginosa is now one of the top three causes of opportunistic human infection 
and there is much interest in identifying novel therapeutic targets for treatment (3). 
In the US alone, care and treatment associated with hospital-acquired infections 
costs the medical community $28 -34 billion per annum (4). With hospital-acquired 
2 
 
infections now the 4th leading cause of death in the US (5), P. aeruginosa has become a 
key pathogen considered in medical infection control plans and is particularly 
prevalent in immunocompromised patients suffering from AIDS, cystic fibrosis, cancer, 
pneumonia, or those recovering from surgery (3). P. aeruginosa is also the most 
common Gram-negative bacterium isolated from nosocomial infections.  The 
International Federation for Infection Control found that “at any one time about 1 in 
10 patients in acute care hospitals have a nosocomial infection, and an additional 10-
60% of infections may present after discharge” (6). 
 
1.2.1. Oxidative stress increases the prevalence of P. aeruginosa infections  
 
Mechanical ventilation is a necessity for patients with respiratory difficulties. However, 
hyperoxia (95% O2 exposure) brought on by mechanical ventilation, vastly increases 
the occurrence of P. aeruginosa infections (2,7–9). P. aeruginosa has been identified as 
the causative agent for most ventilator associated pneumonias that commence post 
mechanical ventilation (10,11). Additionally, persons living with cystic fibrosis (CF) 
commonly require ventilation assistance and chronic P. aeruginosa infections are the 
primary cause of morbidity and mortality for CF patients (12,13). Due not only to the 
primary disease of the patient but also because of mechanical ventilation, P. 
aeruginosa has become the principal species colonizing CF tracheal aspirates (14). 
The incidence of pseudomonal pneumonia brought on by ventilation further 
increases in patients who had previously had some type of antibiotic course (8,9), as a 
consequence of this organism’s propensity for multi-drug resistance. P. aeruginosa is 
naturally resistant to most clinically available antibiotics making it difficult to treat; and 
surveillance finds the prevalence of the organism in nosocomial infections increasing 
despite aggressive antibiotic administration (7,12,15).  
 In addition to multi-drug resistance, P. aeruginosa produces a diverse array of 
virulence factors that may contribute to survival in the presence of hyperoxia and/or 
antimicrobial treatment; however, although such virulence determinants have been 
heavily characterised over the last several decades, most recent work acknowledges 
the complex interaction between the human host and the pathogen as an on-going 
dialogue of virulence factors adapting to the continuum that is the immune response.  
When surveying the literature from both a microbe-focused and immunological 
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perspective, it appears increasingly likely that a key offensive mechanism of P. 
aeruginosa may be to antagonise the human inflammatory immune response as one 
stage in establishing disease. This introduction aims to present an overview of selected 
host-P. aeruginosa interactions that may underpin a role for oxidoreductase enzymes 
in oxidative stress protection.    
 
1.3. Disease establishment  
 
P. aeruginosa requires a breakdown of the skin or mucosal barriers or an impaired 
immune system to establish disease (16).  Like most pathogenic bacteria, P. aeruginosa 
is assumed to have evolved a progression of virulence factors to adapt to and 
overcome the ever changing host immune responses.  Many of these virulence factors 
have been studied in isolation by reductionist approaches as well as in more complex 
in vivo investigations. Still, there are “significant gaps in the understanding of how P. 
aeruginosa survives the inflammatory-rich environment” (17). It has been 
hypothesised that P. aeruginosa infections comprise three stages: (i) attachment and 
colonisation, (ii) local invasion, and (iii) systemic disease. Each of these three stages are 
regulated by bacterial virulence factors and these virulence factors are involved in the 
development of the specific syndromes (i.e. different forms of the disease; (18)).  
 
1.3.1. Airway epithelial cell barriers  
 
The role of the host epithelial cell barrier has been studied primarily in the context of 
P. aeruginosa colonisation of cystic fibrosis patients. Upon initial interaction with the 
bacteria, the host epithelial cells mount a range of antimicrobial defence mechanisms 
to prevent P. aeruginosa attachment and colonisation (19). The first line of defence is 
the physical barrier of tight junctions between the epithelial cells, which, are 
impermeable in normal tissue (20,21). Secondly, epithelial cells can release 
antimicrobials like lactoferrin and ß-defensin, both cationic proteins capable of 
bacteriostatic and/or bactericidal activities (22–24). Epithelial cells also have a 
demonstrated ability to release reactive oxygen species (ROS; (25–27)).  Like 
antimicrobial peptides, ROS have a dual function in that they can peform bactericidal 
activities as well as stimulate the release of cytokines and chemokines to attract 
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immune active cells to the site of infection (28,29). Additionally, epithelial cells release 
other immunomodulatory compounds like interleukin (IL)-8, IL-10, tumour necrosis 
factor alpha (TNF-α), and interferon gamma (IFN-ɣ) which help regulate antigen 
presentation, leukocyte recruitment and activation (Figure 1.1).    
In mammals, the first line of active defence against bacterial invasion is the 
polymorphonuclear leukocyte (PMN) population including neutrophils and 
macrophages. These specialised white blood cells quell imposing bacteria through 
phagocytosis, and by release of microbiocidal compounds (16).  The first stage in this 
process occurs during the contact phase of infection where P. aeruginosa interacts 
with and binds receptors in epithelial cells and resident phagocytic cells, signalling the 
commencement of the complement cascade (30). Activation of the complement 
cascade releases a rigorous series of effector proteins that coat the bacterial 
membrane – collectively referred to as opsonins – allowing recognition of bacteria by 
phagocytes (31–33). The release of complement compounds impact the continued 
immune system in three ways: (i) by recruiting additional immune cells to the site of 
infection, (ii) by aiding in pathogen recognition (opsonisation), and (iii) by creating a 
multi-opsonin membrane attack complex which “punctures” the bacterial membrane 
leading to cell death.  
Opsonins act primarily by masking the ionic charge of the bacterial plasma 
membrane. With both the bacterial and phagocytic membranes being negatively 
charged, it is otherwise difficult for the two cells to come together (34,35). By 
concealing the bacterium’s membrane charge, phagocytes are more adept at initiating 
phagocytosis (36–38). Additionally, once phagocytic-opsonin recognition has occurred, 
the activated immune cell can then stimulate proximally located phagocytes to 
upregulate opsonin-specific receptors (39).   
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Figure 1.1. Summary of immunomodulation compounds released upon epithelia- P. 
aeruginosa contact 
Image based on Sadikot et al (40).  
 
 
1.3.2. P. aeruginosa evasion of epithelial defence mechanisms 
 
In the context of a cystic fibrosis-like infection, non-mucoid P. aeruginosa are thought 
to be the first form of P. aeruginosa to colonise the injured airway after mucociliary 
clearance (40). To colonise the epithelia, and subsequently injure the tight junctions 
and disseminate systemically, P. aeruginosa enacts multiple defence strategies to 
withstand challenge by the host; and for each stage of infection the bacteria must 
continue to adapt its strategies to the ever changing immune environment. 
Furthermore, the invading bacteria must continue to compete for growth-essential 
iron and avoid phagocytic leukocytes (40). It is here at the epithelial interface where P. 
aeruginosa cell-associated virulence factors like the flagellum and pili initiate the host 
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system’s innate immune response. Both P. aeruginosa pili and flagella act as ligands to 
bind epithelial toll like receptors (TLR) (41,42). Different receptors have different 
virulence determinants, but both pili and flagellar interactions alike stimulate 
downstream immune inflammatory actions. For example, the pilus can bind the 
epithelial TLR-2 which not only stimulates proinflammatory expression but also 
enables attachment to the host, creating a pathway for injecting toxins into the 
epithelia, which causes  damage  and a means of entry past the tight junction barrier 
(41,43,44). The flagella of P. aeruginosa can bind epithelial TLR-5 which stimulates IL-8 
production (Figure 1.1; (2)). IL-8 is a chemoattractant of macrophages and induces ROS 
generation (45). Flagella and pili can also act as ligands for phagocytic cells (e.g. 
resident macrophages) which stimulate the recruitment of neutrophils to the site of 
infection (40).  
P. aeruginosa also releases extracellular virulence factors to combat epithelial 
defence mechanisms. These consist of protolytic protease and elastase enzymes which 
act on the fibrin and elastin-rich adherence molecules between epithelia, thus 
disrupting the tight junctions and increasing permeability to bacteria (40,46–48). 
Persistent production works to break down the epithelial tight junction barrier thereby 
establishing a port of entry for P. aeruginosa to enter the blood stream, ultimately 
resulting in sepsis.  
Concomitant with attachment to TLRs, toxin injection, protease production, 
and the signalled recruitment of inflammatory response cells like macrophages and 
neutrophils, vascular leakage (oedema) occurs to allow passage of phagocytes from 
the blood to infected tissue. P. aeruginosa in turn exploits this oedema-induced 
swelling as yet another entry point to the blood stream causing sepsis (49,50). This 
dialogue between P. aeruginosa, the epithelia and immunocompetent cells 
(macrophages, neutrophils, etc.) operates in a continual feedback loop prolonging the 
immune system-driven inflammation to cause extensive tissue damage. 
Moreover, it has been shown that mucus production promotes and prolongs 
infection. Whereas non-mucoid P. aeruginosa are thought to be the first to directly 
interact with host epithelial cells by attachment, in many cases P. aeruginosa must 
undergo a conversion to the mucoid form, attributed by high alginate production 
(51,52). In the conversion to this mucoid form, P. aeruginosa releases its flagella and 
the O-saccharide chain of the lipopolysaccharide, thus preventing TLR stimulation and 
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therefore impeding recognition by phagocytes (40). The slimy surface from alginate 
production is also believed to make it harder for opsonins to “stick” to bacteria, further 
promoting immune system avoidance (53). Finally, the phenotypic conversion to 
alginate production has been shown to mediate P. aeruginosa antibiotic resistance by 
aiding in the development of biofilm (55–57) and to play a role in defending against 
ROS (40,58). 
 
1.4. Phagocytosis and a dual role for ROS production 
 
In the process of phagocytosis, the phagocyte changes morphology in response to 
encountering invading bacteria and engulfs the foreign organism by “wrapping” its 
plasma membrane around the bacterium. This phagocytic vesicle then combines with a 
lysosome to form the phagolysosome – a contained, plasma membrane enclosed 
environment where microbiocidal toxin release is confined to protect the rest of the 
phagocyte from experiencing self-damage.  
Although the exact killing methods vary by cell type, they can be broadly 
classified as either oxygen-independent or oxygen-dependent systems. Macrophages 
can secrete over 100 different types of substances into their environment (59) and 
utilize both oxygen-dependent and independent mechanisms for bacterial control and 
killing.  Oxygen-independent killing by macrophages appears to primarily involve the 
release of basic cationic proteins. It is known, however, that few of those molecules 
can directly cause damage to the bacterial membrane and are therefore causing death 
in an unknown manner (60,61).  
 
1.4.1. Oxygen-dependent killing mechanism of phagocytes 
 
Upon binding bacteria, the macrophage dramatically increases its O2 consumption 10 – 
20 fold relative to the normal “resting” state (62,63). This elevated oxygen uptake is 
not related to increases in mitochondrial respiration but instead the instigation of 
oxygen-dependent killing. The oxygen uptake depends on the activation of a plasma 
membrane bound enzyme complex which uses NADPH as an electron donor to convert 
O2 to superoxide (O2
-), released on the extracellular surface. Since the phagosome is 
essentially formed by “wrapping” the plasma membrane around engulfed bacteria, the 
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phagocyte cytoplasm is protected from the high flux of O2
- as this charged radical 
cannot passively diffuse across the lipid-rich membrane.  
The O2
- accumulation within the phagolysosome also results in a simultaneous 
influx of protons into the phagolysosome which are consumed to generate hydrogen 
peroxide (H2O2). The initial pH rises from 7.4 to 7.8 during proton consumption. This is 
essential for the activation of superoxide dismutase, which converts O2
- to the highly 
reactive H2O2. The pH of the phagolysosome then steadily decreases to 6.0-6.5 over 
the following 2 h, as protons continue to enter the phagolysosome (64,65). This 
collective release of concentrated ROS is referred to as the respiratory burst. 
Following engulfment by macrophages P. aeruginosa is therefore exposed to 
considerable oxidative stress (68,69), however, it is unlikely that increased superoxide 
concentration directly kills bacteria due to its inability to cross cellular membranes and 
its low reactivity in aqueous solution. H2O2, on the other hand, is a major constituent of 
the ROS generated within the phagolysosome and, being uncharged, is capable of 
crossing membranes making it more likely to be the source of direct bacterial killing 
(67). While H2O2 may not directly damage DNA, in the presence of certain metal ions, 
H2O2 is quickly converted via Fenton chemistry to the hydroxyl radical (OH
). The 
hydroxyl radical can directly attack DNA by interacting with both the purine and 
pyrimidine bases of DNA  to form adducts (68,69). OH can either disrupt the 
deoxyribonucleic sugar ring or add to double bonds to the bases thereby creating OH-
adduct radicals and interfering with DNA replication and transcription (68,70). OH also 
fragments the deoxyribose sugar backbone and attacks proteins. When sugar-derived 
and protein-derived radicals meet, crosslinks can be formed thus interfering with 
protein folding, DNA repair, replication and transcription (71). 
 H2O2 is generated at low levels during normal cellular respiration, however, 
when responding to bacteria, H2O2 release can swell  ~80 fold above metabolic levels in 
granuloctyes (72) and >1000 fold by PMNs (73) thus inhibiting bacterial growth (74,75). 
After bacterial internalization by the phagocyte, the membrane-bound enzyme 
respiratory burst oxidase, catalyses consecutive one electron reductions of oxygen to 
produce H2O2 within the phagosome potentially exposing the bacteria to even higher 
concentrations of H2O2 than have been measured extracellularly (76). Although it is 
currently not possible to quantitate levels of H2O2 released within intracellular spaces 
(i.e. mitochondria and phagosomes), qualitative observations made using redox 
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sensitive dyes have demonstrated rapid increase in H2O2 levels within organelles 
immediately after application of ROS generating compounds (77).    
H2O2, as well as being a potent antimicrobial, is a natural trigger of the innate 
immune system (78). H2O2, at low sub millimolar concentrations, signals increases in 
vascular permeability, macrophage proliferation, and stimulates macrophages to 
adhere, as adherent cells are better at making ROS (79). It has been demonstrated that 
even bacteria that are actively expressing strong antioxidant systems do not 
completely eliminate ROS but maintain a low level balance between oxidant and 
antioxidant (80,81).  It has been hypothesised that cells like B-lymphocytes perhaps 
use the NADPH oxidase systems to communicate through O2
- production (70). ROS also 
stimulates IL-8 secretion by epithelia which feed back into macrophage recruitment, 
thereby completing a cycle of phagocytosis and ROS production (54).   
 
1.4.2. Mechanisms by which P. aeruginosa can withstand phagocytosis 
 
P. aeruginosa has, within its repertoire of virulence factors, a broad selection of anti-
phagocytic options to draw upon when exposed to immunocompetent and ROS-
producing cells. These potentially include mechanisms to quench reactive species, to 
directly damage the attacking host cell, or to interfere with the phagocytic process at 
some stage (e.g. recognition and uptake). For example, as noted above, the production 
of alginate in biofilm formation masks the surface receptors (opsonins) required for 
phagocytic cell recognition, thereby disrupting phagocytosis and limiting the 
production of superoxide (82).  P. aeruginosa can likewise produce a series of 
extracellular proteases (83) that inactivate the complement cascade (opsonin 
production) and inactivate cytokines (chemical signals) required for immune response 
activation. Extracellular toxins (e.g. exotoxins A, S and U) produced by P. aeruginosa 
also act to inhibit phagocytic activity by causing direct damage to the host cell. For 
example, exotoxin A disrupts the eukaryotic elongation factor 2 which directly affects 
host cell protein synthesis (40).  
Like eukaryotic host cells, P. aeruginosa synthesises protective chaperone 
(“heat shock”) proteins to deal with stressful environments, such as those experienced 
during phagocytosis. In addition to oxidative stress, phagocytosis also induces slight 
fluctuations in temperature (natural inflammation, increase blood supply, etc.). Heat 
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shock proteins of P. aeruginosa are known to be transcriptionally upregulated under 
H2O2 exposure and other stressors (84). These proteins then act as molecular 
chaperones to protect protein folding mechanisms under stress (84). Furthermore, 
because heat shock proteins are highly conserved across bacterial species, they serve 
as major antigens for immune system microbial recognition (85). It has been 
hypothesised that microbe-specific heat shock determinants can then, through 
molecular mimicry (86,87),  become expressed on the cell surface of macrophages 
making the macrophage self-reactive (autoimmune) (88,89). 
Because H2O2 can cross the plasma membrane, it means that the macrophage 
is susceptible to damage as well, and it has antioxidant systems in place to contain the 
ROS that escape the phagolysosome. P. aeruginosa produces a bacteriocin called 
pyocin that interferes with these antioxidant systems by inhibiting catalases (90,91) 
and inducing apoptosis (92,93). At the same time, P. aeruginosa produces a pyocin 
immunity protein (94) which neutralises internal pyocin to prevent it from causing free 
radical damage within the bacterium (95,96). 
 
1.4.3. Antioxidant systems of P. aeruginosa 
 
The antioxidant systems available to P. aeruginosa can be categorised as either non-
enzymatic or enzymatic defence systems. Although most strategies to withstand 
oxidative stress involve an enzyme-based process, the production of alginate and 
biofilm is an example of a non-enzymatic ROS defence. Production of alginate not only 
stimulates the increase of other P. aeruginosa antioxidant systems (97,98) but also 
protects against and scavenges for ROS (51,99,100). Some of the most significant and 
best studied enzymatic antioxidant systems are superoxide dismutase (SOD), 
peroxidase and catalase which detoxify O2
-, H2O2, and peroxides respectively  during 
phagocytosis (101,102).  
 P. aeruginosa has two forms of SOD that scavenge for and catabolise O2
- 
radicals, and which are active in the presence of manganese (MnSOD) or iron (FeSOD) 
(103–105). Although both FeSOD and MnSOD expression can be detected in most 
clinical P. aeruginosa isolates when grown under in vitro conditions, MnSOD only 
appears to be active in (i) the presence of oxygen and (ii) the absence of iron 
(106,107). The absence of MnSOD in some clinical isolates suggests that MnSOD 
11 
 
activity may not be essential for virulence (107,108). FeSOD, on the other hand 
requires the presence of iron and has been shown to play a more important role in 
resistance to oxidative stress and pyocin biosynthesis (108). 
Peroxidase and catalase enzymes directly catabolise cytotoxic H2O2 to water 
and O2 and, like FeSOD, require the presence of iron (107,109,110). When challenged 
with H2O2, P. aeruginosa is known to use three catalase enzymes (KatA, KatB, and 
KatE) in the detoxification of H2O2 (109,110). KatA, the most potent of the three 
catalases, has been shown to be critical in the adaptation to H2O2 stress and for full 
virulence of P. aeruginosa (111). KatB and KatE, on the other hand do not appear to 
play a substantial role in P. aeruginosa in virulence (111).  KatA of P. aeruginosa has 
well demonstrated stability compared to major catalases of other bacterial organisms 
and has been shown to be particularly important to H2O2 resistance at high 
concentrations  (112,113). Conversely, at low concentrations, catalase has been shown 
to act like a peroxidase and require the presence of a hydrogen donor to oxidise H2O2 
(114). However, KatA has a very high Km for H2O2 (44.7 mM; (110)); based on this we 
hypothesised that P. aeruginosa might possess additional systems for quenching H2O2 
that have a greater affinity for this molecule, and that also contribute to P. aeruginosa 
virulence. 
 
1.4.3.1. NAD(P)H-dependent nitro- and quinone oxidoreductases (NQOR) - 
alternative bacterial antioxidant enzymes  
 
Nitro- and quinone- oxidoreductase enzymes (NQORs), also known as flavin-
dependent quinone reductases, can be capable of simultaneous two-electron 
reduction of quinones leading to formation of quinol, avoiding the highly reactive 
semi-quinone intermediate (Figure 1.2, (115–117)). NQORs, although largely 
recognised for their membrane-bound role in respiration, can also be found in the 
cytosol of prokaryotes and eukaryotes alike (118) where their biological role is less 
understood. However, NQORs that are obligatory two-electron reducers are thought 
to contribute to oxidative protection by direct quinone-mediated quenching of H2O2 
(119).  
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Figure 1.2. Schematic overview of quinone reduction 
Single electron reduction of the parental quinone compound results in a highly reactive and unstable 
semi-quinone radical capable of acting on the parental quinone to produce superoxide. In the presence 
of a two-electron reduction step, the parental quinone is reduced to a stable quinol.    
 
 
The soluble NAD(P)H quinone oxidoreductase enzyme of mammals, first 
described by Ernster et al in 1958 (NQO1, or DT-Diaphorase; (120)), is believed to have 
a primary role as an antioxidant (121). It has been extensively characterised as 
possessing the ability to detoxify thereby contributing to oxidative stress protection 
(116,117,120,122). DT-diaphorase has also been shown to have the chemical flexibility 
to donate electrons to a broad range of substrates in addition to quinones (115,123).  
Nearly four decades after Ernster et al began to establish the mammalian 
quinone oxidoreductase as a potent antioxidant; prokaryotic enzymes exhibiting DT-
diaphorase-like properties were identified.  In the mid-1990s, the tryptophan 
repressor-binding protein, WrbaA (124), was shown to have sequence identity and 
structural homology with the mammalian protein (125,126). Since then, several 
soluble bacterial quinone oxidoreductases have been identified and reported to 
display the biochemical properties necessary to perform simultaneous two electron 
reduction of quinones (Ackerley et al 2004 (127), Wang et al 2004 (128), Adams et al 
2005 (129), Gonzalez et al 2005 (130), Akhtar et al 2006 (131), Patridge et al 2006 
(132), and Guina et al 2007 (133)).The identification of NQORs in bacteria further 
suggests that NQORs may have a role in oxidative stress protection which will be 
explored further in Chapter 3.  
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1.4.3.2. NQOR metabolism of nitro-aromatic compounds 
 
Although highly promiscuous with regard to substrates that have been tested in vitro 
(e.g. chromate, quinone, and nitro-compounds; (127,134,135)), the above bacterial 
NQORs, like their mammalian DT-diaphorase counterparts, are believed to have a 
primary biological role of quinone metabolism. Even so, a number of these enzymes 
have been pursued for their ability to reduce nitro-aromatic anti-cancer prodrugs by 
the same simultaneous two electron transfer mechanism (136–139). This simultaneous 
two mechanism is important, as a large number of the prodrugs relevant to this field 
were originally developed as substrates for human 1-electron reductases, which can  - 
in analogous fashion to the 1-electron quinone reductases of Figure 1.2 - only reduce 
them through to their cytotoxic form in the absence of oxygen (i.e. under tumour 
hypoxia; (140). In contrast, the divalent bacterial NQORs can activate these prodrugs 
independent of the oxygen status of the cell, and are therefore of interest for gene 
therapy strategies that seek to target both aerobic and hypoxic tumour tissues.  
Whilst this work primarily sought to characterise the role of NQORs as 
antioxidant enzymes in P. aeruginosa, the opportunity arose to investigate P. 
aeruginosa NQORs for their possible application in activation of nitro-aromatic 
prodrugs as well. Reductive prodrugs such as 5-aziridinyl-2,4-dinitrobenzamide (CB 
1954), are relatively non-toxic in their administered form, but become highly toxic 
upon reduction (136,141,142). The focus on activation of such compounds by bacterial 
NQORs stems from the observations that 1) although mammalian DT-diaphorase gene 
expression is known to be elevated in tumour cells it is almost entirely inactive with 
CB1954, and far less active with other promising nitro-aromatic prodrugs than many 
bacterial NQORs; and 2) the ubiquitous presence of DT-diaphorase in normal tissue 
would likely cause severe side effects if a prodrug that was a good substrate for this 
enzyme were to be administered systemically (143). Development of effective vector 
systems that specifically target tumour cells and can therefore be used to deliver 
therapeutic genes such as bacterial NQORs is of great interest (139,140).  This anti-
cancer gene therapy strategy is generally known as gene directed enzyme prodrug 
therapy (GDEPT; (140,144–147)). The potential relevance of the P. aeruginosa NQORs 
to this strategy is explored further in Chapter 5. 
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1.5. Aims of this thesis 
 
Although NQORs have been proposed to play a role in bacterial virulence on the basis 
of biochemical and genetic evidence, a potential biological role for NQORs in P. 
aeruginosa antioxidant defence has yet to be determined; and given the need to 
better understand the mechanisms by which P. aeruginosa is able cause disease, we 
investigated the role of NQORs under oxidative stress as potential therapeutic targets. 
Additionally, because virulence involves a complex interplay between P. aeruginosa 
and immune system, we sought to examine the role of NQORs in the presence of 
murine macrophages to further examine a possible ROS-protective role for NQORs, as 
well as taking a more global view of the P. aeruginosa transcriptional response to 
challenge by activated macrophages. Finally, during the course of this thesis we had 
the opportunity to test the ability of the P. aeruginosa NQORs to activate a promising 
new prodrug for GDEPT. On the basis of some highly promising preliminary results this 
was pursued further and ultimately became a major aim of this study. The majority of 
the enzymes that were selected as the primary focus of this thesis have not previously 
been studied in P. aeruginosa in any context.  
 
The primary goals of this project were: 
 
1) To biochemically characterise NQORs of P. aeruginosa and assess the NQORs for 
their ability to protect against oxidative stress in vitro (Chapters 3 and 4). 
2) To develop a method whereby NQORs of macrophage-engulfed P. aeruginosa 
can be assessed for their ability to protect against phagocytosis and 
subsequently, to apply this method for genome-wide expression analysis 
(Chapter 4). 
3) To investigate the ability of P. aeruginosa NQORs to activate anti-tumour 
prodrugs for GDEPT (Chapter 5). 
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1.6. Flow chart: thesis overview 
 
 
 
 
 
 
  
Select NQORs  
capable of two  
electron reduction 
Select NQORs that  
reduce soluble quinone 
substrates 
Challenge NQOR-deleted 
or NQOR-complemented 
P. aeruginosa with 
oxidative stress in vitro 
Develop method to 
recover macrophage-
internalised P. aeruginosa 
Infect murine 
macrophages with  
P. aeruginosa 
Quantify 
P. aeruginosa 
survival 
Analyse  
transcriptional 
expression 
Optimise method to 
screen human cells for 
prodrug sensitivity in the 
presence of NQOR-
expressing bacteria  
Screen NTR-expressing 
bacteria in vitro activation 
of prodrugs 
Screen NQOR-prodrug 
combinations for human 
cell sensitisation efficacy 
Do NQORs confer resistance  
to oxidative stress in vitro? 
Can P. aeruginosa NTRs  
be applied to GDEPT? 
Start 
Identify NQORs of  
P. aeruginosa 
Do NQORs protect  
P. aeruginosa in vivo? 
End 
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Chapter 2:  General Methods and Materials 
 
2.1. Chemicals, enzymes, reagents, media 
 
All chemicals, reagents and media used in this study were obtained from Sigma-Aldrich 
(St. Louis. MO, USA) or Thermo Fisher Scientific (Waltham, MA, USA) unless otherwise 
stated. IPTG (isopropyl-D-thiogalactoside) and BioMix™ Red Mix were supplied by 
Bioline (London, UK). Restriction enzymes were supplied by New England Biolabs (NEB; 
Ipswich, MA, USA). T4 DNA ligase was supplied by Invitrogen (Carlsbad, CA, USA). 
Phusion™ high-fidelity DNA polymerase was supplied by Finnzymes (Espoo, Finland). 
 
2.2. Oligonucleotide Primers 
 
Oligonucleotide primers used in this study were synthesized by Integrated DNA 
Technologies (IDT; Coralville, IA, USA). Lyophilized primers were resuspended to 100 
μM in 1 × TE pH 8.0 (10 mM Tris-Cl pH 8.0, 0.1 mM EDTA) and stored at -20 oC. For 
working stocks, aliquots were diluted in autoclaved, 0.22 μm filter-sterilized distilled 
and deionised (ddH2O) water to 10 μM final concentration.  
 
Table 2.1.Oligonucleotide primers used in this study 
Bold sequences indicate restriction sites. Underlined sequences indicate regions of 
homology used in recombination. 
Primer name Sequence (5' to 3') 
Gene specific primers 
PA0853_Fwd GGGGCATATGGTTGAAACCGCCAAGACC 
PA0853_Rev GGGGGTCGACCTAGACCTGGCTGCCGAGCT 
PA0949_Fwd GGGGCATATGTTGAGCAGTCCCTACATCCT 
PA0949_Rev GGGGGTCGACTCAACTCCCCAGCTTGCCGG 
PA1204_Fwd GGGGCATATGAGCGACGACATCAAG 
PA1204_Rev GGGGGTCGACTCAACCGCGCAGGCGGCGCA 
PA1224_Fwd GGGGCATATGAACGTACTCATCGTC 
PA1224_Rev GGGGCGGCCGCTCATTCGGC 
PA1224_Rev_HindIII GGGGAAGCTTTCATTCGGCCA 
PA1225_Fwd GGGGCATATGCATGCCCTGATCGTC 
PA1225_Rev GGGGGTCGACTCAGGCCTCCAGCGGCTGCG 
PA1962_Fwd GGGGCATATGAAACTTTTGCATATCGAT 
PA1962_Rev GGGGGTCGACTCAGGCCGCGGCGAACTGCCC 
PA2357_Fwd CCCCCATATGACCAGCCCCTTCAAA 
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PA2357_Rev CCCGTCGACTCAGGCGATCTTCAACGG 
PA2580_Fwd CCCCATATGATGAAAAACATTCTCCTGC 
PA2580_Rev CCCGTCGACTCAGCCGGCGC 
PA2932_Fwd CCCCATATGTCCAACCTGCTCCTCTCCCCGCTC 
PA2932_Rev CCCCTCGAGGGGAATGCCAAGCACGGTGGCGGC 
PA3208_Fwd GGGGCATATGGAGGCTCTGACGCCT 
PA3208_Rev GGGGTCGACTCAGCCCGGCCAGGCGCT 
PA3223_Fwd GGGGCATATGTCCCGTGTCCTGGTTATC 
PA3223_Rev GGGGGTCGACTCACCGGAGCGTTGGCAGAGG 
PA4236_Fwd GGGGCATATGATGGAAGAGAAGACCCGCCT 
PA4236_Rev GGGGGCGGCCGCTCAGTCCAGCTTCAGGCCGA 
PA4975_Fwd GGGGCATATGAACGTACTGATCGTC 
PA4975_Rev GGGGGTCGACTCAGCGCGCCAGCGGCTGGA 
PA5190_Fwd GGGGCATATGCATATCGAAGACGCC 
PA5190_Rev GGGGGTCGACTCAGAAGCGGTCGCGAATGA 
  Gene deletion primers 
0949_KO_UL CCCCTCTAGACCAGCAGCGTC 
0949_KO_LL ACTGCTCAAGCGAGGATCTC 
0949_KO_UR TCCTGGAGATCCTCGCTTGAGCAGTGGGAGTTGAAATGGCCCGCA 
0949_KO_LR CCCCTCTAGACTGCATCGACG 
  1204_KO_UL GGGGTCTAGAATCGGAACGCCGCTTCGCCG  
1204_KO_LL GTCGTCGCTCATGCCGTGCT  
1204_KO_UR CGAGGAGCACGGCATGAGCGACGACCTGCGCGGTTGAATGCCTCG  
1204_KO_LR GGGGTCTAGACAGGTCGGGATGATGGTCGA  
  1224_KO_UL GGGGTCTAGAATTCGCGTCGGCGCCAGCTC 
1224_KO_LL GAGTACGTTCATGGCGGGTC 
1224_KO_UR CCGGAGACCCGCCATGAACGTACTCCTGGCCGAATGACCCCGGGG 
1224_KO_LR GGGGTCTAGACGCGCTTCGGCCTGGCCGAC  
  2580_KO_UL CCCCTCTAGACGGAGGCCATG 
2580_KO_LL AATGTTTTTCATGGTGTTCC 
2580_KO_UR TGTACGGAACACCATGAAAAACATTCGCGCCGGCTGAGTTCGACG 
2580_KO_LR CCCCTCTAGACAGGTCCCAGT 
  4236_KO_UL GGGGTCTAGA GACAGCGTCGCCAACCGTCG 
4236_KO_LL CTCTTCCATTTACTCTCTCC 
4236_KO_UR GTTGAGGAGAGAGTAAATGGAAGAGCTGGACTGATGGCCTGATGA 
4236_KO_LR GGGGTCTAGA CCAACTGGGCCTTGAGGATG 
  4975_KO_UL CCCCTCTAGATCGCCGAGCGC 
4975_KO_LL CAGTACGTTCATCGTGGTTT 
4975_KO_UR TTCGGAAACCACGATGAACGTACTGCTGGCGCGCTGACCCGGGCG 
4975_KO_LR CCCCTCTAGAACGAGCGCTTC 
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Sequencing and/or plasmid-specific  primers 
pMMBFwd GGCTCGTATAATGTGTGG 
pMMBRev  GACCGCTTCTGCGTTCTGAT 
T7promoter  TAATACGACTCACTATAGGG 
T7terminator  GCTAGTTATTGCTCAGCGG 
M13Fwd  GTAAAACGACGGCCAG 
M13Rev  CAGGAAACAGCTATGAC 
pEX18GFwd TGGGTAACGCCAGGGTTTTC 
pEX18GRev TGTGGAATTGTGAGCGGATA 
 
2.3. Bacterial strains (including clinical isolates) and plasmids 
 
Table 2.2. Bacterial strains used in this study   
Strain Relevant characteristics Source 
Escherichia coli strains 
 DH5α λpir F- endA1 glnV44 thi-1 recA1 relA1 gyrA96 
deoR nupG  Φ80dlacZΔM15 Δ(lacZYA-
argF)U169, hsdR17(rK
- mK
+), λ(pir) 
Invitrogen 
S17-1 λpir  TpR SmR recA, thi, pro, hsdR-M+RP4: 2-Tc:Mu: 
Km Tn7 λ(pir) 
Lab stock 
BL21 F– ompT gal dcm lon hsdSB(rB
- mB
-) λ(DE3 *lacI 
lacUV5-T7 gene1 ind1 sam7 nin5]) 
Novagen 
SOS-R2 ADA520 ΔnfsA ΔnfsB ΔtolC Prosser et al, 2010 (139) 
∆6KO W3110 ΔnfsA ΔnfsB ΔazoR ΔyieF ΔycaK 
ΔmdaB 
created by Claire Horvat  
ΔAB  ADA510 ΔnfsA ΔnfsB  Prosser et al, 2010 (139) 
W3110 Wild type Escherichia coli Lab stock 
AKN98 Conjugative helper strain containing the 
mobilizing plasmid pRK600 carrying the 
RP4/RK2 conjugation system 
Lab stock 
   Pseudomonas aeruginosa strains 
 PAO1 Wild type genome sequenced strain (148) 
ARL 1024 Clinical sample: catheter, urine  ESRb 
ARL 1205 Clinical sample: left thigha ESRb 
ARL001 1323 Clinical sample: cystic fibrosis sputum ESRb 
ARL 1079 Clinical sample: tracheal aspiratea ESRb 
ARL 1236 Clinical sample: blood ESRb 
afrom same patient 
bEnvironmental Science and Research Culture Collection, Porirua, NZ 
   
KT2440 
Wild type genome sequenced Pseudomonas 
putida strain 
Lab stock 
  
Pseudomonas aeruginosa gene-deleted strains 
 ΔkatA PAO1 ΔkatA This study 
Δ1204 PAO1 Δ1204 This study 
ΔkatA, Δ1204 PAO1 ΔkatA, Δ1204 This study 
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Table 2.3. Plasmids used in this study   
Plasmid Relevant characteristics Source 
pEX18Gm GmR, sacB. Suicide vector for gene deletion. Hoang et al, 1998 
(149) 
pET28a(+) KanR. Expression vector for 6His-tagged 
enzyme purification. T7 promoter. 
Novagen 
pUCX AmpR. E. coli expression vector. tac promoter, 
lac operator, pET28a(+) RBS 
Prosser et al, 2010 
(139) 
pDM4 ChlR, sacB. Suicide vector for gene deletion.  Milton et al, 1996 
(150)  
pSX GmR.  pUCP22 backbone with expression 
region from pUCX, allows IPTG regulated 
expression of His-Tagged proteins in 
Pseudomonas species. 
Owen et al, 2011 (151) 
 
 
2.4. Bioinformatics  
 
Protein homology searches were carried out using the alignment search algorithm 
BLAST, hosted by the National Centre for Biotechnology Information (NCBI) protein 
database (http://blast.ncbi.nlm.nih.gov/; (152)) or the Pseudomonas Genome 
Database (http://www.pseudomonas.com/; (153)).  
Sequence alignments were performed using the ClustalW2 Multiple Sequence 
Alignment (http://www.ebi.ac.uk/Tools/msa/clustalw2/; (154))  with input sequence 
data from the Pseudomonas Genome Database (3). Microarray data analysis was 
performed using BRB ArrayTools (155) in conjunction with DAVID Bioinformatics 
Resources 6.7 (http://david.abcc.ncifcrf.gov/; (156)).  
 
2.5. Bacterial growth and maintenance 
 
2.5.1. Bacterial growth media 
 
All media used to support bacterial growth in this study was prepared using the 
appropriate volume of ddH2O unless otherwise stated. Sterilization was achieved 
either by autoclaving for 30 min at 121 oC or by sterile filtration using a 0.22 μm filter 
(Millipore; Billerica, MA, USA) prior to use. Media were stored at room temperature 
(no supplements) or at 4 oC (supplemented or heat sensitive). 
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2.5.1.1. Luria-Bertani (LB) Broth 
 
Compound Final Concentration 
Tryptone 1% (w/v) 
Yeast extract 0.5% (w/v) 
NaCl 1% (w/v) 
 
2.5.1.2. TYM Broth 
 
Compound Final Concentration 
Tryptone 2% (w/v) 
Yeast extract 0.5% (w/v) 
NaCl 
MgCl2
a 
100 mM 
10 mM 
a 
Solution was added after autoclaving 
 
2.5.1.3. Solid growth media 
 
Solid media was prepared by adding molecular-grade agar to LB at 1.5% (w/v) prior to 
sterilization by autoclaving for 30 min at 121 oC. Media was allowed to cool to 50 oC 
prior to the addition of antibiotic supplements. Cooling media was then aseptically 
distributed to 90 mm diameter Petri dishes at 20 mL per plate and allowed to solidify 
at room temperature. All agar plates were stored at 4 oC and subsequently warmed to 
room temperature prior to use. 
 
2.5.1.4. Media supplements 
 
All stock solutions for antibiotic and other media supplements in this study were made 
up in the appropriate solvent to the indicated concentration and stored at -20 oC. 
Except for those compounds resuspended in absolute ethanol, all were filter sterilized 
using a 0.22 μm filter. The final concentration used for routine growth or selection of 
P. aeruginosa and/or E. coli strains are listed below. 
Table 2.4. Media Supplements 
Compound Stock Solution Solvent P. aeruginosa  E. coli  
Ampicillin 100 mg/mL ddH2O - 100 (μg/mL) 
Kanamycin 50 mg/mL ddH2O - 50 (μg/mL) 
Chloramphenicol 34 mg/mL ethanol 200 (μg/mL) 34 (μg/mL) 
Gentamycin 50 mg/mL ddH2O 100 (μg/mL) 10 (μg/mL) 
IPTG 100 mg/mL ddH2O - - 
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2.5.1.5. Bacteria growth and storage 
 
Unless otherwise stated, bacterial cultures used in this study were prepared by 
inoculating LB medium (containing the appropriate supplements) from glycerol stocks; 
bacteria in liquid media containing 40% (w/v) glycerol stored at -80 oC. Inoculated 
cultures were incubated at 37 oC under rotational agitation at 250 revolutions per 
minute (rpm). Bacteria on solid media were stored at 4 oC for up to 3 weeks. 
 
2.6. Routine molecular biology 
 
2.6.1. Preparation of genomic DNA 
 
Bacterial genomic DNA (gDNA) was extracted from stationary-phase culture using the 
DNeasy™ Blood & Tissue kit (Qiagen, GmbH, Germany) and prepared according to the 
manufacturer’s specifications. Genomic DNA was stored at -20 oC. 
 
2.6.2. Miniprep  
 
Plasmid DNA was prepared according to the manufacturer’s instructions using either 
Zyppy™ Plasmid Miniprep kit (Zymo Research; Irvine, CA, USA) or Geneaid High-Speed 
Plasmid Mini Kit (Geneaid Biotech Ltd.; Sijhih City, Taiwan). 
 
2.6.3. PCR 
 
For amplification of all genes for cloning, Phusion™ high-fidelity polymerase was used. 
For all other PCRs, including colony screening, diagnostic and overlap PCR for gene 
knockout, BioMix™ Red was used. 
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Table 2.5. PCR Reactions 
Phusion™ Mixture Volume per 20 μL reaction 
5x Phusion™ GC buffer 4 μL 
10 mM dNTPs 0.4 μL 
10 μM primer 1 1 μL 
10 μM primer 2 1 μL 
Template gDNA 1 μL 
DMSO 0.6 μL 
ddH2O Add to 20 μL final volume 
  
BioMix™ Red Mixture Volume per 20 μL reaction 
2x BioMix™ Master Mix 10 μL 
10 μM primer 1 1 μL 
10 μM primer 2 1 μL 
Template DNAa 0.2-1 μL 
DMSO 1 μL 
ddH2O Add to 20 μL final volume 
a
For colony PCR screens, a small amount of E. coli colony, picked directly from an agar plate with a 
sterile toothpick or pipette tip, was used as template DNA  
 
 
Table 2.6. PCR Programmes 
Temperature (oC) Time Cycles 
Phusion™   
 98 1 min  
 98 30 sec  
 65
a 30 sec 9 
 72 30 sec per kb  
 98 30 sec  
 55 30 sec 25-30 
 72 30 sec per kb  
 72 5 min  
 12  Hold  
    
BioMix™ Red   
 94 5 min  
 94 30 sec  
 65
a 30 sec 9 
 72 1 min per kb  
 94 30 sec  
 55 30 sec 25-30 
 72 1 min per kb  
 72 5-10 min  
 12  Hold  
a
Touchdown PCR protocol reduces annealing temperature -1 
o
C each cycle. 
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2.6.4. PCR Purification 
 
PCR products were purified using DNA Clean and Concentrator™ columns (Zymo 
Research; Irvine, CA, USA) according to the manufacturer’s instructions. Products were 
eluted using sterile-filtered (0.22 μm) ddH2O and stored at -20 
oC. 
 
2.6.5. Gel electrophoresis 
 
Qualitative assessment of DNA size and purity was performed by agarose gel 
electrophoresis (1% agarose (w/v) in 1x TAE buffer, 1 μg/mL ethidium bromide) run in 
1x TAE buffer at 100-140 V for 30-60 min. HyperLadder™ (Bioline; London, UK) DNA 
marker was used for size comparison and DNA was visualized using ultra-violet light.  
 
2.6.6. Restriction enzyme (RE) digests 
 
To reduce supercoiling, DNA for restriction digests was incrementally heated from 23 
oC to 70 oC for 15 min and then cooled to 37 oC prior to the addition of restriction 
enzyme and mixture components. Mixtures were then incubated at 37 oC for 6 h and 
subsequently heat inactivated at 65 oC for 20 min. Successful DNA digestion was 
confirmed by gel electrophoresis before being purified by DNA Clean and 
Concentrator™ kit (Zymo Research; Irvine, CA, USA) according to the manufacturer’s 
instructions. Purified product was either used immediately or stored at -20 oC.  
 
Table 2.7. RE Reactions 
Solution Volume per 20 μL reaction 
10x Restriction buffer 2 μL 
20x Bovine Serum Albumin 0.2 μL 
RE 1 1U/μg DNA 
RE 2 1U/μg DNA (if required) 
DNA 50-1000 ng 
ddH2O Add to 20 μL final volume 
 
 
2.6.7. Ligation 
 
Ligation reactions were performed at room temperature overnight.  Each individual 
reaction contained no more than 100 ng total DNA at a concentration of <10 ng total 
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DNA per μL. Vector and insert DNA was combined using a molar ratio of 1:3 vector: 
insert. Products were then used directly to transform chemically competent E. coli. 
 
Table 2.8. Ligation Reactions 
Solution Volume per 10 μL reaction 
5x Ligation buffer 2 μL 
T4 DNA ligase 1U 
Digested vector DNA 40-60 ng 
Digested insert DNA 10-50 ng 
ddH2O Add to 10 μL final volume 
 
 
2.6.8. Bacterial Transformation 
 
2.6.8.1. Preparation of chemically competent E. coli 
 
Overnight cultures of E. coli strains, inoculated from glycerol stocks, were grown in 
TYM broth to late-stationary phase then diluted to an optical density of OD600 0.1  in 50 
mL fresh TYM broth. Cultures were grown at 37 oC, 250 rpm for 2-3 h until the OD600 
reached between 0.5 and 1.0. Cells were then chilled on ice for 20 min and centrifuged 
at 4,000 rpm for 10 min at 4 oC. The cell pellet was resuspended in 1 volume ice-cold 
TFB I and left on ice for 2-3 h. Centrifugation was repeated and the cell pellet then 
resuspended in 0.1 volumes of TFB II and distributed to 100 μL aliquots in sterile 1.5 
mL microfuge tubes, snap frozen in a pre-chilled -80 oC metal tube rack, and finally 
stored at -80 oC. 
 
Table 2.9. E. coli competent cell solutions 
Compound Final Concentration 
TFB I  
Potassium acetate 30 mM 
MnCl2 50 mM 
CaCl2 10 mM 
Glycerol 15% (v/v) 
TFB II  
MOPS, pH 7.0 10 mM 
CaCl2 75 mM 
KCl 10 mM 
Glycerol 15% (v/v) 
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2.6.8.2. E. coli transformation 
 
For each transformation reaction, one 100 μL aliquot of chemically competent cells 
was thawed on ice for 5 min. Plasmid DNA was added (no more than 0.1 the volume of 
competent cells being used) to the cells and the mixture was chilled on ice for 30 min. 
Cells were then heat shocked at 42 oC for 90 sec on a heating block, returned to ice for 
5 min, and recovered in 600 μL LB at 37 oC, 250 rpm for 45 min. Recovered cells were 
then spread onto solid media plates containing the necessary antibiotics for selection 
and incubated at 37 oC overnight until colonies became visible. 
 
2.6.8.3. Preparation of chemically competent P. aeruginosa  
 
Competent P. aeruginosa cells were made chemically competent by treatment with 
either sucrose or TG salts. These cells were used for transformation with 
complementation vectors.  
 
2.6.8.3.1. Sucrose method 
 
Overnight cultures of P. aeruginosa strains, inoculated from glycerol stock, were grown 
to late-stationary phase and diluted 1:10 in fresh LB. Cultures were allowed to 
continue growth at 37 oC, 250 rpm until optical density reached OD600 1.0 at which 
point 6 mL aliquots of the cells were made in 15 mL conical tubes on ice. The bacteria 
were then pelleted by centrifugation at 5,000 rpm for 3 min and washed twice in 4 mL 
of room temperature 300 mM sucrose. Competent cells were stored on ice (up to 1 h) 
until ready for transformation. 
 
2.6.8.3.2. TG salts method 
 
P. aeruginosa cells to be made competent by treatment with TG salts were grown 
overnight in LB and diluted 1:10 in fresh LB. Upon returning to an optical density of 
OD600 1.0, 1 mL aliquots of the culture were prepared in 1.5 mL microfuge tubes on ice. 
The cells were then pelleted at room temperature for 30 sec, 10,000 rpm, the 
supernatant discarded, and the pellet resuspended in 1 mL ice-cold 100 mM MgCl2. 
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Centrifugation was repeated and the cell pellet then resuspended in 1 mL ice-cold TG 
salts. The suspension was left to stand on ice for 10 min, pelleted at 10,000 rpm for 30 
sec, and resuspended in 200 μL TG salts. Competent cells were stored on ice (up to 1 h) 
until ready for transformation. 
 
Table 2.10. P. aeruginosa competent cell solutions (TG salts) 
Component Final Concentration 
Glycerol 10% (v/v) 
MgCl2 6 mM 
CaCl2 75 mM 
 
 
2.6.8.4. Pseudomonas spp. Transformation 
 
For each aliquot of freshly prepared competent P. aeruginosa cells, 600 ng of plasmid 
DNA was added and the mixture allowed to sit on ice for 15 min before being heat 
shocked at 37 oC for 4 min in a water bath. Transformation mixtures were then 
recovered in 600 μL fresh LB for 45 min at 37 oC, 250 rpm. Recovered cells were spread 
onto solid media plates containing the necessary antibiotics for selection and 
incubated at 37 oC overnight until colonies became visible. 
 
2.6.9. DNA quantification 
 
Quantification of DNA in solution, including PCR products and purified plasmids, was 
performed using a NanoDrop ND-1000 spectrophotometer (Thermo Scientific), 
according to the manufacturer’s instructions. 
 
2.6.10. Sequencing 
 
All DNA sequence confirmation in this study was carried out by Macrogen Inc. (Seoul, 
South Korea). 
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2.7. SDS-PAGE 
 
For qualitative assessment of protein products by SDS-PAGE, 15% polyacrylamide gels 
(1 mm thickness) were prepared and run in the Bio-Rad Protean II™ apparatus. Each 
gel was constructed by loading 5 mL of 12% separating gel into the casting system and 
overlaying with 1 mL of 100% drum isopropanol. After the separating gel had set (30 
min), the isopropanol was removed and replaced with 1.5 mL 4% stacking gel. A multi-
well comb was inserted into the gel cast and the stacking gel allowed to set (30 min).  
Samples run on SDS-PAGE were prepared in 3 × SDS-loading buffer (total 
volume 30 μL) and boiled at 95 oC for 5 min. Gels were run in 1 × SDS-Run buffer at 200 
V for 45 min. Protein bands in gels were stained by soaking in Coomassie blue stain 
solution for 30 min. Visualization was achieved by removing the Coomassie by gentle 
agitation in destain solution.  
 
Table 2.11. SDS-PAGE materials 
Component Final Concentration 
15 % separating gel   
40% acrylamide solution 36.5% (v/v) 
2% Bis-acrylamide solution 20.1% (v/v) 
Tris-Cl, pH8.8 375 mM 
SDS 0.1% (w/v) 
APSa  
TEMEDa  
  
4% stacking gel  
40% acrylamide solution 9.6% (v/v) 
2% Bis-acrylamide solution 5.2% (v/v) 
Tris-Cl, pH6.8 125 mM 
SDS 0.1% (w/v) 
APSa  
TEMEDa  
  
3x SDS loading buffer  
Tris-Cl, pH6.8 150 mM 
SDS 6% (w/v) 
Bromophenol blue 0.3% (w/v) 
Glycerol 30% (v/v) 
ß-mercaptoethanol 300 mM 
  
1x SDS Running Buffer  
Glycine 14.4g 
Tris 3.03g 
SDS 1g 
28 
 
Coomassie blue stain solution 
Coomassie Brilliant Blue 2.5g 
Abs. ethanol 450mL 
Acetic acid 100mL 
  
Destain Solution  
Methanol 400mL 
Acetic acid 100ml 
a Compound added immediately prior to use 
 
 
2.8. Purification of recombinant His6-tagged enzymes 
 
2.8.1. E. coli enzyme expression and biochemical characterization 
 
E. coli BL21 cultures containing pET28a(+) constructs were  grown overnight to late-
stationary phase in 3 mL LB at 37 oC, 250 rpm. Cultures were then diluted to OD600 0.1 
in 50 mL 1 M sorbitol, 2.5 mM betaine, LB and incubated at 18 oC, 200 rpm until the 
OD600 reached 0.5 at which point enzyme expression was induced by addition of IPTG 
(0.5 mM final concentration). Induced cultures were returned to incubation at 18 oC, 
200 rpm for an additional 9 h. Bacterial cultures were then placed on ice for 15 min 
before being collected by centrifugation for 15 min at 4,000 rpm, 4 oC.  Cell pellets 
were either promptly processed or stored at -80 oC until required for lysis.  
 
2.8.1.1.  Cell lysis 
 
The lysates for the extraction of protein were prepared by either three passages 
through a French press in ice-cold 1x phosphate buffered saline (PBS) or by the 
commercially available BugBuster™ protein-extraction reagent (Novagen; Merck, 
Darmstadt, Germany) according to the manufacturer’s instructions.  
 
Table 2.12. PBS (pH 7.4) 
Component Final Concentration 
NaCl 1.45 M 
Na2HPO4 - 12H2O 20 mM 
NaH2PO4 – 2H2O 2 mM 
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2.8.1.2. Protein purification and storage 
 
Soluble protein fractions for purification were collected by centrifugation at 13,000 
rpm, 4 oC for 15 min and the aqueous layer transferred to a fresh 15 mL conical tube 
on ice.  Recombinant His6-tagged NQORs were then purified by nickel-affinity 
chromatography using the His•Bind Kit (Novagen) and following the manufacturer’s 
instructions. Eluted protein was collected in 1.5 mL microfuge tubes on ice and 
incubated with 100 mM FMN cofactor at 4 oC overnight. Purified proteins were then 
desalted using a 5 mL HiTrap™ Desalting column (GE Healthcare, Chalfont St. Giles, UK) 
into 40 mM Tris-Cl, pH 7.0 according to the manufacturer’s instructions. Samples were 
added to 40% glycerol (v/v) final concentration and stored at -20 oC indefinitely. 
 
2.8.1.3. Quantification 
 
Quantification of purified protein was performed by using the Dc™ protein assay kit 
(Bio-Rad) according to the manufacturer’s instructions. Comparative protein standards 
of bovine serum albumin (BSA) were used for standard curve calculations.  
 
2.8.1.4. In vitro enzyme kinetics 
 
2.8.1.4.1. Quinone substrate specificity  
 
Bacterial NAD(P)H oxidoreductase activity in the presence of quinone substrates was 
measured spectrophotometrically, following diminishing NADPH absorbance at 340 nm 
using a Helios UV-Vis spectrophotometer. One ml reaction mixtures consisted of 25-
250 μM quinone substrate, 0.1-5.0 μg of purified recombinant NQOR in 50 mM Tris-Cl 
buffer pH7.4 and were initiated by the addition of 250 mM NADPH. Benzoquinone was 
added from 10 mM stock in double-distilled water, menadione from 10 mM stock 
dissolved in ethanol, and coenzyme Q1 from a 200 mM stock in N,N-
dimethylformamide that was  subsequently diluted to a 10 mM working stock in 
ethanol. For steady-state kinetic analysis, non-linear regression and Michaelis-Menten 
curve fitting was performed using GraphPad™ Prism 5 (GraphPad Software, La Jolla 
California USA). 
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2.8.1.4.2. Cytochrome c trap  
 
In order to measure simultaneous two electron transfer by NQORs during 
benzoquinone reduction, the substrate cytochrome c was used as a trap for 
semiquinone generation as it can only be reduced by univalent electron transfer. The 
reactive mixture consisted of 0.1-5.0 μg of purified NQOR proteins or control lipoyl 
dehydrogenase from Clostridium kluyveri (Sigma) and 75 μM cytochrome c from horse 
heart (Sigma) in 50 mM Tris-Cl pH 6.0. The reaction was activated by addition of 250 
μM NAD(P)H and monitored at 550 nm for increased absorbance indicating reduction 
of the cytochrome c substrate.  
 
2.8.1.4.3. Determination of SN 26438 extinction coefficients  
 
100 μM SN 26438 in 10 mM Tris-Cl pH 7.0, 4 % DMSO was scanned for total 
absorbance between 325 and 500 nm wavelength, with a 1 cm path length, using a 
Helios ɣ UV-Vis spectrophotometer (Thermo-Fisher). The same concentration of SN 
26438 was then incubated with 300 μM NADPH and ~1 μg purified recombinant NfsA 
(this enzyme has innate NAD(P)H oxidase activity, so will convert any residual NADPH 
to NADP+ thus eliminating the absorbance background from NADPH at OD340). This 
reaction was left to run for 20 min until NADPH oxidation had terminated as measured 
by decrease in.  This reaction was then scanned for total absorbance as above. The 
wavelength at which the difference in absorbance between parent and reduced 
substrate was greatest was chosen for determination of the extinction coefficient (ε). 
This was calculated by using Beer-Lambert Law adjusting for substrate concentration, 
so that the final constant was expressed in units of M-1 cm-1. 
 
2.8.1.4.4. In vitro purified NQORs kinetics with prodrug  
 
Steady-state enzyme kinetics with purified enzymes were measured as reported 
previously by Prosser et al (139) with minor modifications. Briefly, prodrug reduction 
was monitored spectrophotometrically at 420 nm for CB1954 ( = 1200 M-1cm-1) and 
340 nm for SN 26438 ( = 4770 M-1cm-1). Reactions were performed in a total of 60 l 
reactions in UVettes (Eppendorf, Hamburg, Germany) containing reaction buffer (10 
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mM Tris-Cl (pH 7.0), 4% DMSO, 0.25 mM NAD(P)H and varying concentrations of 
CB1954 (0 μM - 2400 μM) or SN 26438 (0 μM – 100 μM). Six l of the appropriate 
purified enzyme dilution was added to 54 l of reaction buffer and changes in 
absorbance were measured at 10 s intervals over 30 s.  For calculation of Km and kcat 
values, substrate concentrations were varied from ~0.2 × to 5 × Km.  Non-linear 
regression analyses and Michaelis-Menten curve fitting were performed using 
GraphPad Prism (Graph-pad software, Inc). 
 
2.9. Gene-deletion 
 
A two-step overlap PCR was used to generate a truncated NQOR gene to be integrated 
to host bacteria genome by a recombination event during bacterial conjugation. Using 
a modified touchdown protocol, KO PCR I, sequence 500 – 1000 bp upstream and 
downstream of the target sequence was amplified, including the first and last three 
codons of the NQOR gene sequence. The downstream forward primer (UR primer) 
contained (5’ to 3’) 20 nucleotides homologous to the 3’-end of the upstream 
sequence. The upstream forward primer (UL primer) and the downstream reverse 
primer (LR primer) were both flanked by XbaI restriction sites for cloning purposes.  
 In the second-stage overlap KO PCR II, purified upstream and downstream PCR 
products from KO PCR I were added to a primer-less PCR reaction. At a lowered 
annealing temperature of 55 oC, the two homologous regions were allowed to self-
anneal for three cycles before adding the upstream forward (UL) and downstream 
reverse (LR) primers to amplify the complete truncated NQOR gene sequence. 
Truncated gene sizes were confirmed by gel electrophoresis.  
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Figure 2.1. Schematic overview of KO PCR I and II 
(A) Amplification of regions upstream and downstream of the target gene to be truncated. (B) Self-
annealing of upstream and downstream products in a primer-less PCR prior to amplification of the full 
length construct using gene primers. 
 
 
The truncated NQOR gene was cloned into either the pDM4 or pEX18Gm P. 
aeruginosa replication vector and transformed into competent DH5alpha λpir E.coli. 
Tri-parental conjugation was then used to integrate the smaller gene form into host P. 
aeruginosa strain. In summary, competent host recipient (e.g. wild type P. aeruginosa) 
was combined with the donor strain (DH5 containing replication vector) and helper 
strain (ANK98 containing pRK600 mobilization vector carrying the RP4/RK2 conjugation 
system).   
Donor and helper strains were inoculated from glycerol stock and grown 16 h in 
nutrient broth (containing the appropriate antibiotic) at 37 oC, 250 rpm. The recipient 
strain (PAO1) was grown 16 h in antibiotic-free nutrient broth supplemented with 0.4% 
A 
 
 
 
 
 
 
 
 
 
 
B 
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KNO3 at 42 
oC under static conditions. Each log-phase liquid culture was then diluted 
10-fold and returned to shaking incubation at 37 oC until OD600 1.0 was reached (~2-3 
h).  Helper and donor strains were let to settle at room temperature for 15 min while 
the recipient was heat shocked at 50 oC for 4 min and settled on ice until required.  
The tri-parental conjugation mixture (0.75 mL recipient, 0.5 ml donor, 0.2 ml 
helper) was combined by gentle inversion and centrifuged briefly (10,000 rpm for 30 
sec) at which point the supernatent  was discarded and the bacterial pellet 
resuspended in 50 μL LB (no antibiotic). The suspension was then gently added to dry 
nutrient agar plate an incubated for 16 h at 37 oC to allow for conjugation.  The 
conjugation culture was then scraped from the agar and resuspended in 2 mL PBS at 
room temperature. Dilutions of the conjugation culture were seeded onto two nutrient 
agar plates containing a) no antibiotic as control or b) chloramphenicol (100 ng/mL), 
kanamycin (20 ng/mL) for pDM4 vectors and gentamycin (200 ng/μL), kanamycin (20 
ng/μL) for pEX18Gm vectors. These plates were then incubated at 37 oC for 16-24 h to 
select for primary integration of the truncated gene into the host genome. The initial 
integration step was selected on plates containing 100 μg/mL Chl and 20 μg/mL Kan 
presence of the mutagenic plasmid confirmed by colony PCR. 
The second recombination event was then forced by growing primary 
integrants overnight in nutrient broth supplemented with 5% sucrose (w/v) incubated 
at 37 oC, 250 rpm. Serial dilutions were plated on solid medium containing 10% w/v 
sucrose and incubated at 37 oC until colonies appeared. After development, 20-40 
colonies were patched onto LB medium with and without 100 μg/mL Chl and 20 μg/mL 
Kan. Colonies which had reverted to Chl sensitivity were taken to be double crossover 
events and were confirmed by PCR.  
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Figure 2.2. Schematic overview of primary and secondary recombinant integration 
Primary integration is selected for by the acquisition of antibiotic resistance. After incubation with 
sucrose, recombinants that have lost the sacB-containing vector and completed full integration of the 
truncated NQOR are selected for by loss of antibiotic resistance.  
 
 
2.10. H2O2 challenge and Amplex® Red hydrogen peroxide assay 
 
Three mL overnight cultures were diluted to OD600 0.1 in fresh LB containing the 
appropriate antibiotic supplements, dispensed at 200 μl per well in a 96 well-plate, and 
allowed to recover for 45 min, 37 oC, 250 rpm. At this point, time zero, the OD600 was 
measured. Serial dilutions of 100 – 0.1 mM H2O2 (final concentration) were added to 
the bacterial cultures to a final volume of 120 μL. The cultures were returned to 
incubation and the OD600 recorded every 60 min for 9 h. Bacterial strain viability was 
measured as a percentage of growth relative to the unchallenged replicate. 
For the Amplex® Red hydrogen peroxide assay, to measure quenching of H2O2 by 
P. aeruginosa strains, cultures were prepared as above. At each 60 min OD600 
measurement, 50 μL of bacterial culture was removed and mixed 1:1 with Amplex® 
Red reaction mix (10 mM Amplex Red reagent, 10 U/mL horseradish peroxidase, 1x 
reaction buffer). Reactions were developed at room temperature for 30 min protected 
from light. Using an EnSpire™ 2300 Multilabel Reader (PerkinElmer, Waltham, MA, 
USA) microplate reader equipped for excitation in the range of 530–560 nm and 
fluorescence emission detection at ~590 nm, H2O2 concentrations were calculated 
using a standard curve of H2O2 serial dilution controls in the same reaction mix.  
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2.11. Cell culture 
 
The established macrophage-like cell lines, RAW264.7 and J774.1, were generous gifts 
from the Malaghan Institute for Medical Research (MIMR; Wellington, NZ).  HCT-116, a 
colorectal carcinoma cell line was a gift from the Auckland Cancer Society Research 
Centre, New Zealand.  All cell lines in this study were maintained as described below.  
 
Table 2.13. Mammalian strains used in this study   
Strain Organism & Characteristics Source 
J774A.1 Murine, BALB/cN derived adherent macrophage MIMRa 
RAW-264.7  Murine, BALB/C derived adherent macrophage MIMRa 
HCT-116 Human, colorectal carcinoma adherent epithelium ACSRCb 
a Malaghan Institute for Medical Research 
b Auckland Cancer Society Research Centre 
 
 
2.11.1.  Long term storage 
 
All cell lines used in this study were stored in aliquots of 2 x 106 cells per 1 mL freezing 
solution containing heat inactivated and filter sterilized Foetal Calf Serum (FCS), and 
10% (v/v) DMSO. Aliquots were kept in 1.8 mL Nunc Cryo Tubes™ (Nunc GmbH & Co. 
KG ; Germany) and stored long term in liquid nitrogen.  
 
2.11.2. Culture initiation 
 
Frozen liquid nitrogen stocks were revived by pre-warming 10 mL of complete culture 
media (CMEM; 1x Penicillin-streptomycin, 25 mM HEPES Buffer solution, 10% FCS in 
basal media Gibco®DMEM; Invitrogen) to 37 oC in a water bath for 30 min. The cryo 
vial of frozen cells was quickly thawed in 37 oC water and immediately transferred to 
the pre-warmed CMEM and centrifuged for 4 min at 400x g, room temperature. The 
DMSO-containing supernatant was discarded and the cell pellet resuspended in fresh 7 
mL CMEM and seeded into a CELLSTAR® 25 cm2 cell culture flask and incubated for 72 
h at 37 oC, 5% CO2.  
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2.11.3. Propagation and maintenance 
 
Routine cell line cultures were maintained every 72 hours as follows: 
Nutrient-exhausted media was aseptically removed from the cellular monolayer. The 
monolayer was then rinsed with 1x Dubelco’s Phosphate Buffered Saline (DPBS). The 
monolayer was then mechanically disrupted (RAW-264.7, J774A.1) or lifted using 
0.05% trypsin-EDTA (HCT-116). Cell suspensions were then transferred to a sterile 15 
mL conical tube, centrifuged at 400x g for 4 min, and then resuspended in fresh 
complete media before seeding into a new CELLSTAR® 75 cm2 cell culture flask at 
1x106 cells per 15 mL CMEM.  
 
2.12. Reactive oxygen release by RAW-264.7 macrophages 
 
RAW-264.7 macrophages were seeded at 8.4 x 103 cells per well in a 96 well microtitre 
plate. Approximately 48 h later positive control cells were treated with 10 μM H2O2 for 
2 h. Untreated and H2O2 treated cells washed twice in PBS and then incubated in the 
dark in 10 μM CM-H2DCFDA, PBS at 37 oC, 5% CO2 for 30 min to load the dye (N.B. 
Untreated cells not loaded with dye were used as a negative control to examine 
cellular autofluorescence.). Wild type P. aeruginosa at MOI 50, MOI 100 or 200 ng/100 
μL LPS was applied to the dye-loaded RAW-264.7 cells in PBS and then incubation 
continued for ~8 h. Fluorescence was measured at 30-60 min intervals using an 
EnSpire™ 2300 Multilabel Reader (PerkinElmer, Waltham, MA, USA) microplate reader 
equipped for excitation at 495 nm and fluorescence emission detection at 520 nm.  
 
2.13. Griess reaction 
 
To measure the release of the effector molecule, nitric oxide (NO), by macrophages, a 
Greiss reaction was used to measure the more stable NO breakdown product nitrite in 
a 96-well microtitre plate format. RAW264.7 macrophages were seeded at 8.4 x 103 
cells per well and applied with MOI 100 P. aeruginosa, 8 μg lipopolysaccharide (LPS), or 
8 μg LPS + 100 U/mL interferon-gamma including media only controls in triplicate. 50 
μL of supernatants were removed at time intervals 0 – 11 h and added to a new 96-
well microtitre plate. Griess solutions A and B were mixed in equal volumes and 50 μL 
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added to each well, final volume of 100 μL, and measured spectrophotometrically at 
absorbance 570 nm. Nitrite concentration was determined by a standard curve 
prepared with sodium nitrite standards (500 μM – 0 μM) in culture media and 
calculated using GraphPad Prism (Graph-pad software, Inc).  
 
2.14. Flow cytometry 
 
Bacteria cultures for flow cytometric analysis were washed 3 times in 1x PBS to remove 
all traces of nutrient media and transferred to a round-bottom 5 mL polystyrene tube 
(BD Falcon, BD Biosciences; USA). The washed bacteria were then collected by 
centrifugation at 4000x g for 4 minutes at room temperature and the supernatant 
removed. Cell pellets were then resuspended by vortex in 500 μL normal saline 
viability staining solution containing 20 μg/mL propidium iodide, 1x SYTO®BC and 1x 
microsphere standards (Bacteria Counting Kit, Molecular Probes, Invitrogen). Stained 
cells were incubated in the dark for 15 min before being processed on a FACSCanto II 
flow cytometer (BD Biosciences). Analysis was performed using FlowJo 7.6.1 software 
(Tree Star, Inc.). 
 
2.14.1. Live P. aeruginosa population analysis by flow cytometry – a gating 
strategy for quantification 
 
To gauge the survivability of P. aeruginosa using the FACSCanto II flow cytometer (BD 
Biosciences), all samples were first normalised against single stained and unstained 
controls to set collection parameters of threshold, mode, and voltage (Figure A4.1). For 
all analyses, forward scatter (FSC) and side scatter (SSC) were set log mode. Initial 
cellular debris discrimination was achieved by triggering events on SSC at a threshold 
of 2.0. Further event discrimination is described below. FSC and SSC voltages were set 
to 380-410. FL1 (SYTO® BC) and FL2 (PI) channels were also set to log mode with 
voltages at 310-410. Acquisition-derived fluorescence compensation, as determined by 
the unstained and single-stained controls, was set at FL1-FL2 = 7.50% and FL2-FL1 = 
2.10%. Minor adjustments to compensation post-collection were achieved using 
FlowJo v7.6.1 Compensation Editor Wizard.  
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Figure 2.3.  P. aeruginosa flow cytometry controls 
P. aeruginosa cultures grown overnight in LB and washed in PBS were either left untreated, stained only 
with SYTO® BC (1:1000), or only with PI (1:20). All staining solutions prepared in 0.9% NaCl, were stained 
for 15 min at room temperature in the dark as described in Chapter 4. Samples were then run on 
FACSCanto II flow cytometer (BD Biosciences) at the medium collection setting (60 µl /min) having an  
acquisition rate of ~1000 events/second.  
 
 
To quantify live (SYTO® BC) events, as represented on a dot plot cytogram, 
fluorescent bacterial signals were first differentiated from Bacteria Counting Kit 
microsphere bead standards by size using FSC and SSC (Figure A4.2a). The laser noise 
was then removed by excluding double negative events on FL1 (SYTO® BC) versus FL2 
(PI) plots therefore selecting all bacteria-only signals (Figure A4.2b). Because the cell 
sorting determined that SYTO® BC+PI+ populations were viable, total “live” 
populations for quantification were determined by gating all SYTO® BC+ events of all 
bacteria-only signals on a histogram (Figure A4.2c). 
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Figure 2.4. P. aeruginosa event selection for quantification 
(A) P. aeruginosa stained with the flow cytometry staining solution as described in Chapter 4, were 
differentiated from Bacteria Counting Kit bead standards using FSC vs. SSC in log mode. (B) False (laser 
noise) events were then excluded by gating FL1 vs. FL2. (C) All true bacterial flow signals were then 
displayed in a histogram of SYTO® BC+ events.  
 
 
The ratio of SYTO® BC+ bacterial signals (Figure A4.2c) to bead signals (Figure A4.2a) 
was then calculated and adjusted for dilution to accurately quantify the number of 
bacteria present.  
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2.15. Confocal Microscopy 
 
Both bacterial and mammalian cell cultures were visualized using the laser-scanning 
confocal microscope FlowView® FV1000 (Olympus; USA). Images were analysed using 
Olympus FV10-ASW Viewer Ver.2.0b. 
 
2.15.1. Pure bacterial cultures 
 
Washed and pelleted bacteria in 5 mL polystyrene tubes were resuspended in 50 μL 
normal saline viability staining solution (minus microsphere standards) and developed 
in the dark for 15 min. As mounted on pre-cleaned 2 mm microscope slide, 5 μL of 
stained cells were mixed 1:1 with 4% paraformaldehyde in normal saline.  Samples 
were excited sequentially at 473 nm and 559 nm for viability on FlowView® FV1000.  
 
2.15.2. Mammalian cell monolayers 
 
For the visualization of P. aeruginosa uptake by murine macrophage cells, pure 
bacterial cultures were washed and prepared as above but stained only with 2 μL 
SYTO®BC in 50 μL normal saline. Murine macrophage cell cultures were prepared by 
seeding 7.5x105 macrophages per 3 mL Gibco®DMEM (Dubelco’s Modified Eagle 
Medium) culture media free of phenol red indicator (Invitrogen) supplemented with 
10% foetal calf serum, 0.25 mM HEPES in a 35 mm glass-bottom FluoroDish™ cell 
culture dish (World Precision Instruments, Inc.; Sarasota, Florida, USA). Cellular 
monolayers were washed twice with fresh, room temperature media and infected with 
stained P. aeruginosa as described in Chapter 4.  Post-infection monolayers were 
gently washed with room temperature 1x PBS and stained with the counterstain 
Image-iT™ LIVE Plasma Membrane and Nuclear Labelling Kit (Molecular Probes, 
Invitrogen) according to the manufacturer’s instructions and imaged as above.  
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2.16. RNA Extraction and Purification 
 
All samples in the preparation of purified bacterial RNA for microarray analysis were 
treated with one millilitre of Trizol® (Invitrogen) per cm2 culture surface. Trizol®-
treated samples were stored at -80oC overnight before being thawed at room 
temperature for RNA extraction. Room temperature chloroform was added at 0.2 mL 
per 1 mL Trizol®.   The extraction solution was then shaken, incubated at room 
temperature for 3 minutes, and centrifuged at 4000x g for 15 min.  The aqueous layer 
was collected to a new RNase-free tube and 2 volumes of room temperature absolute 
ethanol was added while gently vortexing. The ethanol mixture was then applied to an 
RNeasy Mini Kit spin column (QIAGEN; Germany) by centrifugation at 13,000 rpm in a 2 
mL collection tube.  The column was washed with 350 μl Wash Buffer RW1, 
centrifuged for 15 seconds at 13,000 rpm, washed with 500 μl Wash Buffer RPE and 
centrifuged for another 15 seconds at 13,000 rpm. After discarding the flow through, 
the column was washed for a second time with 500 μl Wash Buffer RPE and 
centrifuged for 2 minutes at 13,000 rpm. The washed column was then placed in a new 
collection tube and centrifuged for an additional 1 minute at 13,000 rpm to completely 
dry the RNA and remove traces of ethanol. The column was then transferred to an 
RNase-free 1.5 mL microfuge tube. RNA was eluted from the column by twice applying 
30 μl of RNase-free H2O (for microarray application) or RNase-free 1x TE buffer (for 
enrichment). Internal PAO1 RNA was eluted in TE buffer (pH 7.4) for prokaryotic RNA 
enrichment using Ambion® MICROBEnrich™ Kit (Life Technologies - Applied 
Biosystems/Ambion).  
 
2.16.1. Prokaryotic RNA Enrichment  
 
Bacterial RNA samples harvested from host macrophage cultures were enriched for 
using the Ambion® MICROBEnrich™ Kit (Life Technologies - Applied 
Biosystems/Ambion; Austin, TX, USA) according to manufacturer’s specifications. 
MICROBEnrich™ uses magnetic separation to remove the 18S rRNA, 28S rRNA, and 
polyadenylated mRNA of eukaryotic tissue. Final enriched Internal PAO1 RNA was 
resuspended in 25 μL RNase-free water for direct microarray application. For each RNA 
preparation, an aliquot of 1.5 μL was removed for quality control. 
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2.16.2. RNA Quality Control 
 
The Agilent 2100 Bioanalyzer and Agilent RNA 6000 Nano Kit (Agilent Technologies; 
Santa Clara, CA, USA) were provided by Environmental Sciences and Research (ESR; 
Porirua, NZ) and used to assess the quality of purified RNA according to manufacturer’s 
specifications. 
 
2.17.  Microarray 
 
The GeneChip® Pseudomonas aeruginosa Genome Arrays (Affymetrix Inc., Santa Clara, 
CA, USA) were prepared and processed at according manufacturer’s specifications by 
Liam Williams at the Centre for Genomics and Proteomics at the University of 
Auckland, New Zealand.   
 
2.17.1. Chips 
 
“The GeneChip® P. aeruginosa Genome Array contains probe sets for over 5,500 ORFs 
from the PAO1 strain of P. aeruginosa, 199 probe sets corresponding to 100 intergenic 
sequences, and 117 additional genes from P. aeruginosa strains other than PAO1. 
During the design process, the P. aeruginosa sequences were pruned against the 
GeneChip Human Genome U95 Genome Array, facilitating experiments on the P. 
aeruginosa samples isolated from human tissues. The P. aeruginosa Genome Array 
includes probe sets to intergenic sequences which may lead to the identification of 
new genes. In addition to sequences from the P. aeruginosa strain PAO1, the array also 
includes unique sequences from other strains to broaden the research possibilities 
with the array. Genes encoding serological determinants and pathogenicity islands4 
are included on the array and have proven useful in genotyping P. aeruginosa strains 
isolated from human infections originating from different tissues” (157). 
 
2.17.2. Preparation and processing 
 
cDNA preparation and hybridisation was performed by the Centre for Genomics, 
Proteomics and Metabolomics (CGPM) at the University of Auckland. Processing and 
43 
 
scanning was completed according to the manufacturer’s recommendations 
(www.affymetrix.com/support/technical/manual/expression_manual.affx).   
 
2.17.3. Data analysis 
 
Raw data normalisation and initial analysis was performed by Donia Macartney-
Coxson, at Environmental Science and Research, using Bioconductor package V2.9 with 
R V2.14 (open source software, http://www.bioconductor.org/). Analysis was made by 
fitting data to a linear regression. The initial hypotheses were for differences in 
sample: Internal vs Control, External vs Control and Internal vs External. Many probes 
reached significance at an adjusted (for multiple testing using the Benjamini and 
Hochberg (method to control false discovery rate) p value of < 0.05. Further analysis 
RMA (robust multi-array chip averaging) as instigated in the Affy and Oligo 
Bioconductor packages uses quantile normalisation. This method was introduced by 
Bolstad et al 2003 and is one of the most commonly used methods. The method aims 
to give each chip the same empirical distribution, and brings the quantiles for each 
chip together. As RMA (with quantile normalisation) is often the method used in the 
literature, subsequent analyses used this method and all defaults background=True 
(rma), normalisation =True (quantile), pmcorrect (probe specific correction) = pmonly 
and summary.method (summarisation of probe level data for a probe set) = median 
polish. 
 
2.18. SOS assay 
 
Individual wells of 96-well microtitre plates, containing 150 l LB amended with 100 
mg/mL ampicillin and 0.4% glucose, were inoculated with SOS-R2 strains expressing 
candidate nitroreductases in pUCX, together with a pUCX (empty plasmid) control. 
Cultures were incubated for 16.5 h at 30 C with shaking at 200 rpm. Fifteen l of 
overnight cultures were transferred to individual wells of a 96-well microtitre plate 
containing fresh 200 l of LB amended with 100 mg/mL ampicillin, 0.05 mM IPTG and 
0.4% glucose (LB-AIG) per well for a final volume of 215 L. Cells were grown at 30C, 
200 rpm for 3 h, at which point they were diluted 1:1 in LB-AIG containing 20 M 
CB1954 or 5 M SN26438 in the final volume of 200 L. Cells were then challenged  for 
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3.5 h at 30 C, 200 rpm. At this point the OD600 for each well was recorded and 20 l 
from each well were added to 130 l ZOB buffer (Table 2.13.) in a new 96-well 
microtitre plate for -galactosidase analysis. Reactions were then incubated at 37 C 
for 25 min, or until the yellow colour of o-nitrophenyl--D-galactopyranoside (ONPG) 
substrate was clearly visible. The assay was terminated by addition of 50 l of 1 M 
Na2CO3 and the OD420 and OD550 were recorded. Miller units were calculated using the 
modified Miller equation described by Prosser et al (139). 
Table 2.14. SOS buffers 
Component Final Concentration 
1 M Sodium phosphate buffer pH7.0  
Na2HPO4 0.577 M 
NaH2PO4 0.423 M 
  
Z-buffer  
Na2HPO4 0.126 M 
NaH2PO4 0.126 M 
MgSO4 2 mM 
MnSO4 0.4 mM 
CTAB 399 mg/mL 
Sodium deoxycholate 199.5 mg/mL 
ß-mercaptoethanola 0.174 M 
  
T-base  
(NH4)2SO4 15.1 mM 
K2HPO4 0.08 M 
KH2PO4 0.044 M 
Sodium citrate 1 g/L 
o-nitrophenyl-ß-D-galactopyranosidea 8 mg/mL 
  
ZOB buffer  
T-base 1 part 
Z-buffer 4 part 
a add just before use 
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2.19. Sensitisation of HCT-116 cells to CB1954 and SN 26438 using E. coli 
expressing candidate NQORs 
 
HCT-116 colorectal carcinoma cells (American Type Culture Collection, Manassas, VA, 
USA) were seeded into 96-well microtitre plate wells at 5 x 103 per 100 μL of culture 
media [CMEM (Gibco, Invitrogen Corporation, Grand Island, NY, USA) supplemented 
with 5% FCS and 10 mM HEPES (Gibco)] and incubated at 37 C, 5% CO2 for 48 h.  E. 
coli ∆6KO and SOS-R2 strains expressing candidate NQORs from plasmid pUCX were 
prepared by inoculating 150 μL LB + 100 μg/mL amp + 0.4% (w/v) glucose and 
incubating 16.5 h at 30oC, 200 rpm. 15 μL of overnight cultures were then used to 
inoculate 200 μL fresh culture media amended with 100 μg/mL amp + 0.05 mM IPTG + 
0.4% (w/v) glucose (CMEM-AIG). NQORs-expressing E. coli were then grown at 30 oC, 
200 rpm for an additional 3 h. Meanwhile dilutions of CB1954 (200 M – 0 M) and SN 
26438 (10 M – 0 M) were prepared in CMEM-AIG. Day cultures of E. coli ∆6KO and 
SOS-R2 strains expressing NQORs were mixed 1:1 with prodrug dilutions (SN 26438 
and CB1954 respectively) in a final volume of 210 μL. HCT-116 monolayers were then 
washed twice with PBS. 100 μL of E. coli:prodrug mixtures were applied to the washed 
HCT-116 monolayer and incubated 4 h at 37 C, 5% CO2, after which the bacteria were 
removed from the HCT-116 monolayer by washing four times in PBS. The HCT-116 cells 
were then allowed to recover at 37 C, 5% CO2 for 48 h in culture media amended with 
100 μg/mL chloramphenicol. 20 L of CellTiter 96® AQueous One Solution (Promega) 
was added to the cell culture and incubated for 2 h at 37 C, 5% CO2. The OD490 was 
recorded to measure formazan levels, indicative of the number of respiring HCT-116 
cells present in the culture. The IC50 values were then calculated by comparing OD490 of 
the challenged cells with the unchallenged cells using GraphPad Prism (Graph-pad 
software, Inc).  
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Chapter 3: Characterisation of the antioxidant role of P. 
aeruginosa NQORs  
 
3.1. Introduction 
 
During the course of P. aeruginosa infections the bacterium encounters many forms of 
oxidative stress, with a major constituent being the highly reactive H2O2. P. aeruginosa, 
like most aerobes (including mammals), possess the potent antioxidant defence 
enzymes SOD and catalase. The P. aeruginosa-specific catalase, KatA, has previously 
been described as an H2O2-quenching virulence factor (111); and like SOD enzymes, is 
able to scavenge for and reduce ROS. Together, the bacterial SOD and catalase 
enzymes are thought to be the first line of defence when it comes to oxidative stress, a 
challenge P. aeruginosa must overcome at all stages of infection. The phagocyte-
derived oxidative burst, and primary source of concentrated ROS exposure, can be 
considered to occur in two overlapping stages whereby the host phagocyte (i) initially 
produces superoxide through the NADH oxidase, succeeded then by (ii) sequential 
one-electron reductions of the superoxide radical to form hydrogen peroxide (158). 
SOD enzymes in general have a high affinity for the superoxide radical (159) and the 
superoxide reduction creates the H2O2 substrate that catalase is highly efficient at 
degrading into water and O2 (Figure 3.1; (160)). Therefore, SOD and catalase have 
complementary activities and act in tandem to protect the bacterium (161). 
 
 
Figure 3.1. The major ROS components produced by the phagocyte-derived oxidative 
burst 
Upon stimulation, phagocytes produce large amounts of O2
- which is quickly converted by SOD to 
oxygen and H2O2 (Reaction (i)). The H2O2 that is thereby generated is rapidly broken down into water 
and oxygen by the P. aeruginosa catalase, KatA (Reaction (ii)). 
 
 
 
Reaction (i) 
 
Reaction (ii) 
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As noted previously, the superoxide radical is unlikely to be the source of direct 
bacterial damage due to its inability to cross lipid membranes. Rather, it is believed 
that H2O2 is the toxic species most likely to require control by phagocyte-engulfed 
bacteria. By acting as both the hydrogen acceptor and donor, catalase enzymes rapidly 
detoxify otherwise lethal concentrations of H2O2. Catalase enzymes also are attractive 
defence mechanisms in terms of their efficiency and low energy expenditure, enabling 
catalytic degradation of H2O2 at times of stress without redirecting energy from 
alternative defence systems (80). Additionally, catalases can have a very high turnover 
rate (162) and are therefore not easily saturated, allowing for H2O2 control over a wide 
range of intracellular concentrations (114).  
While the P. aeruginosa catalase KatA has a very high kcat for H2O2, it also has a 
very high Km (the substrate concentration at which half maximal velocity is achieved, 
and therefore an approximate measure of an enzyme’s affinity for that substrate; for 
KatA the Km for H2O2 has been measured at 44.7 mM (110)). Although KatA can 
function at low concentrations of H2O2, this requires an additional hydrogen donor and 
the enzyme drops several orders of magnitude in catalytic efficiency (114,163). 
Moreover, low concentrations of H2O2 (< 0.6 mM) have actually been shown to be 
more dangerous in terms of forming oxidative DNA lesions (164). Therefore, it is 
possible that antioxidants with greater affinity for H2O2 may also contribute to 
guarding against oxidative stress. However, other P. aeruginosa catalases do not 
appear to fulfil this role (111). At low concentrations KatB is also upregulated by 
exposure to H2O2 but unlike KatA, does not demonstrate protective catalase activity 
(113). Studies by Elkins et al (1999; (113))and  Ma et al (1999; (110)), also established 
that in the absence of KatA not only is KatB not catalytically active, but that P. 
aeruginosa still shows a high degree of tolerance to H2O2 assault, and therefore it was 
concluded that catalase activity alone is not the sole determinant of H2O2 resistance. 
More recently, water-soluble NQORs have been shown to confer H2O2 tolerance via an 
indirect mechanism of detoxification. 
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3.1.1. Soluble nitro- and quinone oxidoreductases 
 
Soluble NQORs are thought to play important roles in direct defence against quinone 
cytotoxicity; whereby redox cycling of quinone compounds can result in the production 
of high levels of H2O2 (165,166). Quinones are widely distributed compounds that 
share a core structure of a central six-carbon aromatic ring with two ketone 
substituents, and are best understood for their role in respiration as membrane bound 
electron acceptors in the electron transport chain. These compounds can exist in three 
distinct forms depending on their degree of oxidation-reduction: fully-oxidised 
(quinone); one-electron reduced (semi-quinone); two-electron reduced (quinol) 
(Figure 1.2). The semi-quinone form can react with molecular oxygen to produce the 
O2
- radical which, as described above (Figure 3.1), is a primary source of biological 
H2O2. This superoxide radical also reduces iron which, in the presence of H2O2 can 
catalyse formation of the particularly damaging hydroxyl radical (OH) via Fenton 
chemistry (167). 
NQORs catalyse the reduction of quinones by accepting electrons from either 
NADH or NADPH thereby either (i) reducing the quinone by one electron to form the 
reactive semi-quinone, or (ii) simultaneously transferring two electrons to the quinone 
substrate to directly form quinol. These enzymes are typically flavoproteins, defined by 
possession of one or more bound flavin adenine dinucleotide (FAD) or flavin 
mononucleotide (FMN) cofactor per enzyme complex. NQORs can exist as either lipid 
membrane bound or soluble cytoplasmic flavoproteins (46, 47). It is the latter that are 
generally implicated in antioxidant defence. NQORs that employ a simultaneous two 
electron transfer mechanism for quinone reduction not only avoid formation of the 
highly reactive semi-quinone intermediate, but may also play a key role in maintaining 
a pool of reduced quinones that are in turn able to quench H2O2 directly (115,117). 
 Although several soluble NQORs have now been identified based on structural 
and/or sequence conservation with mammalian DT-diaphorase, a 2005 study by 
Gonzalez et al was the first to demonstrate an overt role for NQORs in guarding 
bacteria against oxidative stress when challenged with H2O2 (Figure 3.2; (130)). The 
soluble chromate reductase (ChrR) from Pseudomonas putida was demonstrated to be 
important for H2O2 tolerance. Over-expression of chrR was able to quench exogenously 
added 3 mM H2O2 and reinitiate growth in 6 h, whereas the ∆chrR mutant took nearly 
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12 h to commence growth recovery in the presence of H2O2, a time point that 
corresponded with the extracellular H2O2 level dropping below 5 μM.  Based on this 
previous work in a related Pseudomonas species, we hypothesized that P. aeruginosa 
would similarly utilise NQORs to withstand oxidative stress, particularly at lower levels 
where KatA is not so efficient.  
 
 
Figure 3.2. H2O2 -scavenging compared to growth in P. putida 
Strains of P. putida wild type (■), chrR mutant (▲), and chrR+ overexpression (♦) were inoculated to an 
initial OD660 0.1 in LB amended with 3 mM H2O2. Growth (closed symbols) was monitored at OD660 while 
residual H2O2 (open symbols) was assayed with the fluorescent dye Amplex® Red via excitation/emission 
at 540 nm and 585 nm respectively. This experiment was repeated in triplicate, with consistent results. 
The figure presents representative data from one of the replicates. Reproduced with permission from Dr 
David Ackerley (130).  
 
 
Similar to ChrR of P. putida, enzymes from other bacterial species have also 
been characterised as divalent quinone reductases with antioxidant potential. WrbA, 
NfsB, and NfsA of E. coli have been shown to exhibit divalent reduction of quinone 
substrates (132,168,169). Similarly, MdaB of Helicobacter pylori, an enzyme that 
shares high levels of amino acid identity with mammalian DT-diaphorase, has also 
been shown to contribute to oxidative stress defence, both in vitro and in a mouse 
model (128,170). Although NQORs are distributed widely throughout bacterial species, 
at the time this work began no roles for soluble NQOR-like enzymes in P. aeruginosa 
virulence had previously been described. 
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3.2. Objectives 
 
 Identify promising NQOR candidates of P. aeruginosa and characterise their ability 
to reduce quinone substrates as well as their mechanism of electron transfer (one 
electron vs. simultaneous two electron).  
 Determine whether P. aeruginosa NQORs can confer protection against oxidative 
stress when the host cell is challenged with hydrogen peroxide in vitro. 
 
3.3. Results 
 
3.3.1.  Biochemical characterisation of P. aeruginosa NAD(P)H quinone 
oxidoreductase enzymes (NQORs) 
 
3.3.1.1. Selection of NQOR candidates for this study 
 
NQORs for this study were chosen based on (i) shared identity with P. putida ChrR; (ii) 
shared identity with mammalian DT-diaphorase; or (iii) shared identity with E. coli 
WrbA, MdaB, NfsA or NfsB, other bacterial quinone oxidoreductases that have been 
described as having a likely antioxidant role. In conducting BLAST searches of the P. 
aeruginosa genome, it became apparent that P. aeruginosa possesses several NQORs 
with shared protein identity to most of the above described enzymes from other 
species (although no NfsA-like enzyme was identified; Table 3.1).  Using an arbitrarily 
selected cut off of >25% protein identity with their closest NQOR orthologue, the 
following P. aeruginosa genes were selected for a targeted investigation: PA0949, 
PA1204, PA2580, PA4975, and PA5190 (Table 3.2). 
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Table 3.1. Summary of NQORs found in P. aeruginosa 
Familya Organismb Locus IDc %IDd 
NfsA  Escherichia coli  - - 
NfsB  Escherichia coli  3208 28% 
5190 25% 
MdaB Escherichia coli  2580 64% 
4975 26% 
1224 29% 
WrbA Escherichia coli  0949 39% 
ChrR Pseudomonas putida 1204 46% 
3223 31% 
DT-
Diaphorase 
Homo sapiens 4975 35% 
1224 34% 
1225 31% 
0853 28% 
aFamily names were determined based on protein homology grouping with previously identified NQOR 
enzymes. 
 bOrganisms listed refer to the species origin of the previously identified NQOR orthologue.  
cLocus ID describes the position of each P. aeruginosa gene within the annotated genome database 
(www.pseudmonas.com). 
d%ID indicates the amino acid identity as calculated by the ClustalW program of each NQOR to the 
originally characterised species sequence.  
 
 
Table 3.2. Targeted NQOR selection for this study 
Gene NQOR Family Reference 
PA0949 WrbA  (132,171–173) 
PA1204 ChrR This study 
PA2580 MdaB  (129) 
PA4975 DT-diaphorase  This study 
PA5190 NfsB  This study 
 
 
3.3.1.2. In vitro quinone reduction by P. aeruginosa NQOR-like enzymes 
 
To investigate the ability of the P. aeruginosa NQORs to reduce quinones, as well as 
their mechanism of reduction (one electron vs. simultaneous two electron), purified N-
terminal His6 tagged recombinant proteins were expressed from each target gene and 
purified by nickel chromatography as described in section 2.8. SDS-PAGE was used to 
confirm that the mass of the expressed enzyme was consistent with the predicted 
mass and also to examine the relative level of purification of soluble protein prior to 
commencing biochemical analysis (Figure 3.3).  Each enzyme appeared yellow during 
and post purification, indicating that the flavin cofactors were co-purifying; however 
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previous work in the Ackerley laboratory has demonstrated that there is always partial 
loss of cofactor during nickel affinity chromatography (Gareth Prosser, personal 
communication). Therefore each purified enzyme was incubated with FMN cofactor 
overnight (FAD for MdaB) prior to desalting and buffer exchange.  
 
 
Figure 3.3. Purified His6 tagged NQORs on SDS-PAGE 
Sequence-verified NQOR genes were over-expressed from pET28a(+) with as described in Section 2.8, 
purified by nickel affinity chromotography and run on SDS-PAGE. Each lane was loaded with ~1 μg of 
total protein as determined by the Bio-Rad Dc™ protein assay.  
 
 
Each purified NQOR was tested for activity with three different quinone 
substrates, exhibiting varying degrees of water solubility: benzoquinone (BQ) – most 
soluble (logP = 0.265); menadione (Men) – intermediate solubility (logP = 1.6); 
coenzyme Q1 (CoQ1) – least soluble (logP = 2.2; Figure 3.4). Where activity was 
detected in preliminary assays, detailed measurements of the steady state (Michaelis-
Menten) kinetics were conducted. All five enzymes were quite active with BQ, but 
varied widely in their ability to metabolise the more lipophilic quinone substrates 
(Table 3.3). The most active enzymes, PA4975 and PA1204, had specificity constants 
for benzoquinone that were comparable to previously reported values for the H2O2 -
quenching ChrR of P. putida (kcat/Km = 8.5 x 10
6 M-1s-1; (130)). The remaining NQORs, 
PA2580, PA5190, and PA0949, were also able to reduce benzoquinone but at 
substantially reduced rates compared to PA4975 and PA1204. However, PA2580 was 
able to turn over the least soluble substrate, CoQ1, with a kcat/Km 25-fold higher than 
PA1204, the only other NQOR that exhibited CoQ1 reduction.  
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Figure 3.4. Structures of quinone substrates used to measure steady-state kinetic 
parameters 
Three different quinone substrates were used in this study, each exhibiting different degrees of water 
solubility: benzoquinone (BQ) – most soluble menadione (Men) – intermediate solubility; coenzyme Q1 
(CoQ1) – least soluble. 
 
 
 
Table 3.3. Steady-state Michaelis-Menten kinetic parameters 
Protein Substrate Vmax(μmol/min/mg)   Km (μM)
b kcat (s
-1)b kcat/Km (M
-1s-1) 
PA4975 
BQ 608 ± 75 321 ± 52 405 ± 50 1.3x106 
Men 0.03 ± 0.01 1371 ± 481 0.02 ± 0.01 1.6x101 
CoQ1 N.D.a N.D.a N.D.a N.D.a 
  
PA1204 
BQ 877 ± 63 288 ± 35 585 ± 42 2.0x106 
Men 190 ± 19 775 ± 93 127 ± 13 1.6x105 
CoQ1 15 ± 5.4 1495 ± 603 10 ± 3.5 6.8x103 
      
PA2580 
BQ 0.1 ± 0.04 0.3 ± 0.28 0.1 ± 0.03 3.0x105 
Men 0.1 ± 0.02 0.4 ± 0.27 0.1 ± 0.01 2.2x105  
CoQ1 0.4 ± 0.29 2.6 ± 2.3 0.2 ± 0.2 1.4x105 
 
PA5190 
BQ 0.03 ± 0.01 0.9 ± 0.4 0.02 ± 0.01 2.3x104 
Men 0.03 ± 0.01 2.6 ± 0.8 0.02 ± 0.01 6.8x103 
CoQ1 N.D.a N.D.a N.D.a N.D.a 
 
PA0949 
BQ 0.1 ± 0.03 1.5 ± 0.8 0.04 ± 0.02 3.4x104 
Men N.D.a N.D.a N.D.a N.D.a 
CoQ1 N.D.a N.D.a N.D.a N.D.a 
a 
Not detectable 
b These are apparent values as measured at 250 μM NADH 
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3.3.1.3. Simultaneous two electron transfer by P. aeruginosa NQORs 
 
With all NQOR candidates selected for this study having been shown to actively reduce 
quinone substrates, the mode of electron transfer was determined by implementation 
of a cytochrome c trap. Previous work has indicated that cytochrome c is rapidly 
reduced by benzo-semi-quinone, but not by benzoquinol; and that this reduction leads 
to a quantifiable increase in absorbance at OD550 nm that can be monitored 
spectrophotometrically (130). Therefore, appearance of the reduced cytochrome c 
species in the presence of an NQOR-catalysed reaction indicates a preference for 
univalent electron transfer, while lack of reduced cytochrome c signifies exclusive two-
electron transfers.  Lipoyl dehydrogenase (LpDH), an obligate one-electron reducer 
from Clostridium kluyveri (purchased pre-purified from Sigma-Aldrich) was used as a 
positive control for cytochrome c reduction (Figure 3.5). In this experiment, all five 
target NQORs demonstrated a preference for simultaneous two electron transfer. 
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Figure 3.5. Determination of simultaneous two electron transfer - cytochrome c trap 
Recombinant purified NQOR proteins (black) or control LpDH (red) at 0.1 – 5.0 μg/mL were mixed with 
75 μM cytochrome c in the presence of 100 μM benzoquinone substrate. Reactions were instigated by 
the addition of 250 μM NADH and were monitored over 5 min at OD550 for reduction of cytochrome c 
(increase in absorbance). Inset, in each graph is the same reaction monitored at OD340 to observe the 
NADH consumption rate (y-axis shows OD340 and x-axis shows time in seconds). Each graph presents the 
mean of three replicates ± 1 standard deviation.   
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3.3.2. Assessment of NQOR H2O2-protective phenotypes in vitro 
 
With all NQOR candidates having demonstrated a primarily simultaneous two electron 
mechanism of BQ, these were further assessed for their ability to actively protect P. 
aeruginosa from H2O2 challenge in vitro. Preliminary trials to establish appropriate test 
concentrations for P. aeruginosa growth in media amended with H2O2 demonstrated 
that PAO1 is substantially less sensitive to H2O2 challenge than the P. putida strain 
(KT2440) that ChrR studies were conducted in. PAO1 exhibited substantial tolerance to 
H2O2 until concentrations exceeded 100 mM (e.g. Figure 3.6A), whereas P. putida was 
unable to sustain growth in concentrations >3mM (this study and (130); e.g. Figure 
3.6B). At the very high concentrations of H2O2 required to impair growth of wild type 
PAO1, no protective effect conferred by NQOR gene over-expression was discernible 
(not shown). This in turn led us to consider whether or not the activity of the unusually 
active P. aeruginosa catalase, KatA, might potentially be interfering with any 
prospective NQOR phenotype in the presence of H2O2.   
To test whether KatA might be “masking” NQOR contributions to H2O2 
quenching, a ∆katA mutant in PAO1 was generated by in-frame gene deletion as 
described in section 2.9. When the ∆katA strain was challenged with 50 mM H2O2 no 
growth at all was evident across a 9 h time course, whereas a wild type PAO1 control 
grown in parallel recovered normally (Figure 3.6A). In contrast, when the ∆katA 
mutation was complemented by a katA gene over-expressed from plasmid pSX, H2O2 
tolerance and a wild type growth phenotype were restored (Figure 3.7A). Likewise, 
when the P. aeruginosa katA gene was over-expressed in P. putida KT2440, the ability 
of this bacterium to tolerate 6 mM H2O2 challenge was greatly enhanced, although it 
did not achieve the same levels of growth as the unchallenged control (Figure 3.7B). 
Nonetheless, these findings together provide evidence that P. aeruginosa PAO1 is 
inherently more resistant to H2O2 challenge than P. putida KT2440 due to its powerful 
KatA catalase. 
 
 
57 
 
0 2 4 6 8 10
0.0
0.5
1.0
1.5
PAO1 - 100 mM  H2O2
PAO1 - unchallenged
Time (h)
O
D
66
0
0 2 4 6 8 10
0.0
0.2
0.4
0.6
0.8
1.0
KT2440 - 6 mM H 2O2
KT2440 - unchallenged
Time (h)
O
D
6
6
0
A
B
***
***
***
***
***
***
***
***
****** *** *** *** *** ***
***
 
Figure 3.6. Growth of wild type P. aeruginosa PAO1 and P. putida KT2440 in H2O2 
amended media 
Wild type strains of (A) PAO1 or (B) KT2440 were inoculated to an initial OD660 of 0.1 in LB amended with 
100 mM H2O2, or 6 mM H2O2 respectively, and growth was monitored at OD660 over 9 h. The plotted 
OD660 data are means of 3 independent experiments, each performed in duplicate, and error bars are ± 
1 standard deviation. Significance is reported where p < 0.001 (***) is compared to unchallenged 
controls. 
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Figure 3.7. Effect of katA over-expression in different P. aeruginosa PAO1 and  
P. putida KT2440 backgrounds 
(A) Growth of wild type P. aeruginosa PAO1 bearing an empty control plasmid (PAO1 + pSX::empty) and 
the ∆katA mutant bearing either an empty control plasmid (∆katA + pSX::empty) or pSX over-expressing 
the katA gene (∆katA + pSX::katA) in the presence of 50 mM H2O2. (B) Growth of wild type P. putida 
KT2440 bearing an empty control plasmid (KT2440 + pSX::empty) and the ∆chrR mutant bearing either 
an empty control plasmid (∆chrR + pSX::empty) or pSX over-expressing the katA gene (∆chrR + 
pSX::katA) in the presence of 6 mM H2O2. Growth of an unchallenged wild type P. putida KT2440 control 
is also indicated. In both (A) and (B) the pSX plasmids were induced and maintained by amending the 
growth media with 0.25 mM IPTG and 10 μg/ml gentamycin. Strains were inoculated to an initial OD660 
of 0.1 in LB amended with H2O2 as indicated and growth was monitored by hourly OD660 readings over a 
9 h timecourse. The plotted OD660 data are means of 3 independent experiments, each performed in 
duplicate, and error bars are ± 1 standard deviation. Significance is reported where p < 0.05 (*), p < 0.01 
(**), and p < 0.001 (***) is compared to (A) ∆katA + pSX::empty, and (B) ∆chrR + pSX::empty controls. 
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3.3.2.1. NQOR Gene-deletion 
 
Having shown that KatA would be likely to “mask” any H2O2-sensitive phenotype 
resulting from NQOR gene-deletion, we aimed to investigate NQOR mutants in katA-
null strains of PAO1. Creation of a gene knockout mutant strain for each of the NQORs 
listed in Table 3.2 was attempted, and an in-frame gene deletion of ∆1204 was 
successfully generated in both wild type PAO1 and the ∆katA mutant. Unfortunately, 
we were unable to replicate this success for any of the remaining four NQOR 
candidates, despite employing a large number of different mutagenesis strategies and 
culture conditions, including: use of four different suicide vectors bearing different 
antibiotic markers; increasing the regions of homology used to create recombination 
events; testing of a variety of selection media; and use of a range of historical and 
contemporary mating protocols, such as triparental and biparental filter mating, 
electroporation and heat shock transformation. Ultimately we were therefore only 
able to test the single mutant ∆1204 and double mutant ∆katA∆1204 strains of PAO1 
for heightened sensitivity to challenge by H2O2.  
Based on the ability of PA1204 to reduce all three quinone substrates tested in 
the purified protein assays, its apparent preference for simultaneous two electron 
transfer, and 46% amino acid identity with ChrR of P. putida KT2440 which has a 
proven antioxidant role, there was strong biochemical evidence to suspect PA1204 
would, like ChrR, perform as an antioxidant enzyme in vitro.  However, the single 
mutant, ∆1204, grew no differently from wild type PAO1 at all concentrations tested (0 
mM to 275 mM; e.g. Figure 3.7). Moreover, the double mutant ∆katA ∆1204 did not 
appear to be more sensitive to H2O2 than the ∆katA mutant (e.g. Figure 3.7.). At 
micromolar H2O2 concentrations as low as 0.4 mM, the ∆katA ∆1204 mutant began to 
appear slightly more sensitive than ∆katA, however, this difference was not 
statistically significant at any time point or concentration of H2O2 tested. 
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Figure 3.8. Growth by mutant PAO1 strains in 0.4 mM H2O2 
The wild type PAO1, ∆1204, ∆katA, and ∆katA ∆1204 strains were inoculated to an OD660 0.1 in LB 
amended with 0.4 mM H2O2 and monitored at OD660 over 9 h. These graphs indicate growth measured 
by OD660 and are the means of 3 independent experiments, each performed in duplicate, and error bars 
are ± 1 standard deviation. Significance is reported where p < 0.01 (**) and p < 0.001 (***) are 
compared to ∆KatA. 
 
 
3.3.2.2. Effect of P. aeruginosa NQOR over-expression on P. aeruginosa PAO1 
and P. putida KT2440 survival in H2O2-amended media 
 
We next sought to determine whether over-expression of the P. aeruginosa NQOR 
candidates in the ∆katA strain might reveal contributions to oxidative stress resistance 
that were not discernible in the wild type background. These NQOR candidates were 
also over-expressed in the ∆chrR mutant of P. putida to determine whether they could 
restore tolerance to H2O2 challenge in a manner consistent with the activity of ChrR as 
depicted in Figure 3.2.  
 When the NQOR candidates PA0949, PA1204, PA4975 and PA5190 (omitting 
PA2580 for reasons that are discussed in section 3.3.2.3) were individually over-
expressed from pSX in the P. aeruginosa ∆katA strain at a range of H2O2 concentrations 
(0 mM, 0.2 mM, 0.4 mM, 0.8 mM, 1.5 mM, 3 mM, 6 mM, 12.5 mM, 25 mM, 50 mM, 
and 100 mM), it was found that in each case the over-expression strain was able to 
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tolerate micromolar and low-millimolar concentrations of H2O2. Surprisingly however, 
the ∆katA strain containing an empty vector control now tolerated these H2O2 
concentrations just as well. This was in stark contrast to the growth phenotype of the 
∆katA strain depicted in Figure 3.7, with the only experimental difference being the 
presence of the pSX plasmid and the addition of 0.25 mM IPTG and 10 μg/mL 
gentamycin to the growth medium to maintain that plasmid.  Using PA4975 as an 
example, the ∆katA strain containing pSX::PA4975 reached an optical density similar to 
wild type PAO1 by 9 h post challenge with 0.8 mM H2O2, but so did the empty plasmid 
control ∆katA + pSX::empty (Figure 3.8A). The only instance where NQOR over-
expression in the ∆katA strain appeared to reproducibly confer protection to H2O2 
challenge relative to the empty plasmid control was for PA0949 at 1.5 mM (Figure 
3.8B). 
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Figure 3.9. PA4975 and PA0949 over-expression in PAO1 
(A) Growth of wild type P. aeruginosa PAO1 bearing an empty control plasmid (PAO1 + pSX::empty) and 
the ∆katA mutant bearing either an empty control plasmid (∆katA + pSX::empty) or pSX over-expressing 
the PA4975 gene (∆katA + pSX::PA4975) in the presence of 0.8 mM H2O2. (B) Growth of wild type P. 
aeruginosa PAO1 bearing an empty control plasmid (PAO1 + pSX::empty) and the ∆katA mutant bearing 
either an empty control plasmid (∆katA + pSX::empty) or pSX over-expressing the PA0949 gene (∆katA + 
pSX::PA0949) in the presence of 1.5 mM H2O2. In both (A) and (B) the pSX plasmids were induced and 
maintained by amending the growth media with 0.25 mM IPTG and 10 μg/mL gentamycin. Strains were 
inoculated to an initial OD660 of 0.1 in LB amended with H2O2 as indicated and growth was monitored by 
hourly OD660 readings over a 9 h time course. The plotted OD660 data are means of 3 independent 
experiments, each performed in duplicate, and error bars are ± 1 standard deviation. Significance is 
reported where p < 0.01 (**) and p < 0.001 (***) are compared to ∆katA + pSX::empty. 
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The apparent ability of the pSX::empty plasmid and concomitant IPTG and 
gentamycin to promote H2O2 tolerance in the ∆katA strain was proven by a head-to-
head comparison of the plasmid free ∆katA strain grown in unamended LB vs. the 
∆katA + pSX::empty strain grown in LB containing 0.25 mM IPTG and 10 μg/ml 
gentamycin, across a wide range of H2O2 concentrations (Figure 3.9). 
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Figure 3.10. The influence of the pSX over-expression vector on H2O2 tolerance by the 
∆katA strain 
The ∆katA and ∆katA + pSX::empty strains were inoculated to an initial OD660 of 0.1 in LB or LB amended 
with 0.25 mM IPTG and 10 μg/mL gentamycin, respectively, and 2-fold serial dilutions of 100 mM down 
to 0.1 mM H2O2, as well as an unchallenged control for each strain. Cultures were monitored at OD660 
over 9 h. These graphs indicate end-point growth measured by OD660 at 9 h post treatment, and are the 
means of 9 independent experiments, each performed in duplicate, with error bars ± 1 standard 
deviation. 
 
 
Even more curiously, the induction of H2O2 tolerance conferred by the presence 
of pSX/IPTG/gentamycin appeared to be a P. aeruginosa specific phenomenon, which 
did not manifest in P. putida KT2440. Moreover, with the exception of PA1204 over-
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expression of all P. aeruginosa NQORs in the ∆chrR mutant of P. putida was found to 
improve tolerance of H2O2. For example, PA4975 was reproducibly able to recover the 
P. putida ∆chrR strain to near wild type levels of growth at ≤0.8 mM H2O2, whereas the 
∆chrR pSX::empty control strain remained sensitive (Figure 3.10). PA5190 had a fairly 
similar effect to PA4975, but PA2580 and PA0949 had an even more profound effect, 
conferring H2O2 tolerance to the P. putida ∆chrR strain at concentrations as high as 6 
mM (not shown).  
The reason for a P. aeruginosa-specific growth advantage for the pSX-
containing strain in the presence of H2O2 is not understood. However, as the 
phenomenon is undoubtedly complex, and likely to be primarily of technical interest, it 
was not pursued further in this study. 
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Figure 3.11. PA4975 over-expression in KT2440 at 0.8 mM H2O2 
Growth of wild type P. putida KT2440 bearing an empty control plasmid (KT2440 + pSX::empty) and the 
∆chrR mutant bearing either an empty control plasmid (∆chrR + pSX::empty) or pSX over-expressing the 
PA4975 gene (∆chrR + pSX::PA4975) in the presence of 0.8 mM H2O2. The pSX plasmids were induced 
and maintained by amending the growth media with 0.25 mM IPTG and 10 μg/mL gentamycin. Strains 
were inoculated to an initial OD660 of 0.1 in LB amended with H2O2 as indicated and growth was 
monitored by hourly OD660 readings over a 9 h time course. The plotted OD660 data are means of 3 
independent experiments, each performed in duplicate, and error bars are ± 1 standard deviation. 
Significance is reported where p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***) is compared to ∆chrR + 
pSX::empty. 
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3.3.2.3. Over-expression of PA2580 in P. aeruginosa PAO1 
 
The PA2580 over-expression strain of P. aeruginosa was not discussed in section 
3.3.2.2 because for an unknown reason over-expression of PA2580 (from pSX::PA2580) 
was found to inhibit growth of P. aeruginosa relative to either plasmid-free P. 
aeruginosa, or cells containing the empty plasmid (pSX::empty), independent of 
whether H2O2 challenge was applied (Figure 3.11A). Thus, growth of this strain could 
not be directly compared to growth of the empty plasmid control in any meaningful 
way.  However, it was shown that if PA2580 growth data in response to H2O2 challenge 
is presented as a ratio of growth compared to its own unchallenged control (as per 
Figure 3.11C), PA2580 appears to confer substantial tolerance to ≤6 mM H2O2 whereas 
the ∆katA + pSX::empty strain remains sensitive (e.g. Figure 3.11C).  
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Figure 3.12. Conversion of OD660 to percentage growth for PA2580 over-expressing  
P. aeruginosa PAO1 relative to the empty-plasmid control 
(A) ∆katA + pSX::empty and ∆katA + pSX::PA2580 were inoculated to an initial OD660 of 0.1 in LB 
amended with 0.25 mM IPTG, 10 μg/mL gentamycin and ± 3 mM H2O2. The OD660 of challenged and 
unchallenged cultures was measured hourly for 9 h. The plotted OD660 data are means of 3 independent 
experiments, each performed in duplicate, and error bars are ± 1 standard deviation.  (B) The OD660 data 
for the ∆katA + pSX::PA2580 strain from graph (A) is plotted on an OD660 scale 0.0 to 0.4 and the ratio of 
growth between challenged and unchallenged strains is calculated as the difference in OD at each time 
point measured. (C) The ratios of OD660 for unchallenged to challenged strains for each of ∆katA + 
pSX::empty and ∆katA + pSX::PA2580 are presented as a percentage of survival at each time point 
measured. 
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3.4. Discussion 
 
A wealth of genome sequence data released over the last few years has revealed that 
soluble NQOR enzymes are ubiquitous in bacteria. Despite this, there is a dearth of 
information regarding their primary biological role(s).  A few biochemical studies have 
focused on the simultaneous two electron quinone metabolising mechanisms of 
individual enzymes to speculate about a possible role in oxidative stress protection; 
these include WrbA from E. coli (132); ChrR from P. putida (130); and MdaB from H.  
pylori (128,170) and  M. tuberculosis (Rv3303c; (131)). However, only ChrR in P. putida 
and MdaB in H. pylori have ever actually been found to exhibit an antioxidant 
phenotype.  Here we demonstrate that protein identity, soluble quinone metabolism, 
and simultaneous two electron transfer alone does not directly implicate soluble 
NQORs as H2O2-protecting virulence factors in P. aeruginosa; but that nonetheless a 
contribution toward H2O2 tolerance can be observed for certain enzymes in an 
appropriate genetic background. In P. aeruginosa PAO1 this required a deletion of the 
gene encoding the potent KatA catalase, which was otherwise found to “mask” any 
contribution to H2O2 tolerance provided by individual NQORs. 
 Although PA1204 had the highest specificity constant for benzoquinone, the 
most soluble quinone substrate, gene-deletion of PA1204 failed to produce an H2O2-
sensitive phenotype in even the ΔkatA background.  Despite our best efforts, gene-
deletion in PAO1 was largely unsuccessful; and we believe this is more likely to be a 
technical issue rather than due to the essential nature of the target genes, as the 
genes encoding PA0949, PA2580 and PA4975 have all been successfully knocked out 
by transposon insertion in P. aeruginosa strain PA14 (174). PA14 is widely regarded as 
being substantially more genetically tractable than PAO1, and may have proved a 
much easier strain to work with (Dr Jane Hill, personal communication); however PAO1 
is still the most widely used strain for study of P. aeruginosa physiology and 
pathogenesis, and primarily for that reason was selected for this research. .  
 Greater success was observed when candidate NQORs were tested by over-
expression from a broad host range plasmid. In the ΔkatA background we found that 
PA2580 (as measured by percent survival relative to the unchallenged isogenic control) 
and PA0949 conferred significant improvements in growth relative to the empty 
plasmid control at up to  6 mM and at 1.5 mM H2O2 challenge respectively. The same 
68 
 
two NQORs were also found to be the most effective at promoting H2O2 tolerance in 
the P. putida ∆chrR strain, but in this heterologous host PA4975 and PA5190 were also 
found to promote growth at sub-millimolar levels of H2O2 challenge. An important 
difference between the two scenarios is that the P. aeruginosa ΔkatA strain still 
contained endogenous copies of all the NQOR genes, which may have lessened the 
effect of candidate NQOR over-expression; whereas P. putida KT2440 does not appear 
to contain the same level of redundancy of soluble NQOR genes. Another possible 
explanation for PA5190 and PA4975 being found to confer protection in P. putida and 
not P. aeruginosa is that there may be a different complement of quinone substrates 
available for reduction between the two organisms. Studying this hypothesis further 
would require access to metabolomics equipment and expertise. 
 Although PA2580 did appear to provide the most substantial improvement in 
H2O2 tolerance of any NQOR in the P. aeruginosa ΔkatA strain, this interpretation was 
complicated by the substantial reduction in growth caused by over-expression of this 
NQOR. PA2580 was the most promiscuous of our NQOR candidates, exhibiting fairly 
consistent levels of activity (specificity constant ca. 1-3 x 105 M-1s-1) with each of the 
three quinone substrates tested in our in vitro kinetic assays, despite their quite 
different partition coefficients (logP). Although highly speculative, it may be that the 
retarded growth of the PA2580 over-expressing strain was a consequence of this 
ability to effectively reduce less soluble, and perhaps membrane associated, quinone 
substrates. As the membrane associated quinones play key roles in the electron 
transport chain and therefore cellular respiration (175), an undesirable perturbation of 
this homeostasis may have promoted a detrimental growth phenotype. Another P. 
aeruginosa specific growth anomaly came in the form of the apparent ability of the 
pSX plasmid and/or associated IPTG and gentamycin to promote H2O2 tolerance in the 
P. aeruginosa ΔkatA strain. Although this phenomenon was also not pursued further it 
does serve to highlight the profound influence (and potential for artefactual results) 
that slight variations in growth conditions can have on phenotype; a theme that is 
expanded upon in Chapter 4 also. 
Although NQORs are distributed widely throughout bacterial species, at the 
time this work began, no roles for soluble NQOR-like enzymes in P. aeruginosa 
virulence had previously been described. However, the large selection of NQOR-like 
genes in the PAO1 genome, and the likelihood that, with the genetic flexibility of P. 
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aeruginosa, many of these enzymes may display an overlap in function, suggested that 
adopting a more global strategy to interrogate NQOR function might prove more 
fruitful. Furthermore, as alluded to above there is an ever-present danger that an in 
vitro phenotype may not hold meaning for an in vivo scenario, as the choice of culture 
conditions may profoundly alter the complex and flexible response of P. aeruginosa. 
An alternative approach to understanding the role of NQORs in P. aeruginosa, and the 
one pursued in the next chapter of this thesis, was to establish a method for exposing 
P. aeruginosa to macrophages and then recovering the viable bacteria for analysis. This 
also enabled the employment of microarray techniques to monitor the genome-wide 
transcriptional profile of PAO1 in the presence of biologically relevant oxidative stress.    
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Chapter 4: The P. aeruginosa response to challenge by murine 
macrophages 
 
4.1. Summary 
 
In the previous chapter, it was determined that the native P. aeruginosa catalase 
enzyme, katA, masks protective phenotypes that NQORs may confer toward H2O2 
exposure even though individual purified NQORs were confirmed as efficient 2-
electron quinone reducing enzymes with potential to mediate the quenching of 
reactive species like H2O2. Because of this we decided to take a more global approach 
and assess how P. aeruginosa interacts with immunocompetent cells which would, in 
an infectious environment, expose P. aeruginosa to H2O2 as well as other immune 
defensive compounds (e.g. cytokines, complement, etc.). We hypothesised that this 
would not only allow us to investigate the effects of a biologically relevant immune 
challenge on the expression of individual NQOR genes, it would also allow us to take a 
more global view of the genetic responses that P. aeruginosa employs to defend itself 
against such a challenge. This approach to infection biology is technically challenging, 
and albeit previously employed successfully with Salmonella, Brucella, and 
Mycobacterium  (176–179), had not been attempted with P. aeruginosa prior to this 
work. This chapter describes the development of an infection model and method for 
studying P. aeruginosa gene expression as well as a microarray analysis of the global 
transcriptional events taking place during exposure to the macrophage. 
 
4.2. Introduction 
 
The development of a high-throughput infection model for assessing P. aeruginosa 
responses to challenge by immunocompetent murine macrophages was achieved 
using a fluorescence-based assay to quantify bacterial survival without the 
requirement for modifying the bacteria by insertion of reporter genes.  Screening in 
this manner allowed for a high-volume characterization of several P. aeruginosa gene-
deleted and gene over-expression strains under different infection conditions. Results 
obtained were, for the most part, consistent with the biochemical assessment of 
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several NQORs in Chapter 3. Finally, this infection assay was employed for 
transcriptional analysis of the genome by microarray.  
 
4.2.1. Microarray technology overview 
 
The development of microarray technologies has allowed for advances in genome-
wide transcriptional profiling, through its capacity to explore the expression of 
thousands of genes in a single experiment (180). In one of its most common forms, a 
microarray is a method by which thousands of oligo fragments are immobilized to a 
glass or silicon surface. Fluorophore labelled test sample cDNA fragments are then 
washed over the fixed oligos. Where complementary band hybridisation occurs, a 
measurable fluorescence intensity is emitted (Figure 4.1). The intensity measurement 
is then converted to a numerical value and normalized against the technical standards 
within the chip.  
 
 
Figure 4.1. Schematic overview of Affymetrix GeneChip® technology 
Multiple oligo fragments are immobilised on a glass or silicon surface. Oligos are then washed with 
biotinylated test cDNA and where hybridisation occurs, biotin-bound fluorophores emit measured 
fluorescence intensity. Recreated from Affymetrix GeneChip® Microarray Curriculum (181).  
 
 
The Affymetrix Pseudomonas GeneChip® intensity array was chosen for this 
study based on the following characteristics: in silico probe design, a predesigned P. 
aeruginosa specific gene set, and inclusion of clinically relevant genome transcripts. 
The Affymetrix platform involves a high-density oligonucleotide matrix meaning that 
multiple biotinylated probes (10 - 20) target each gene. These probe sets for each gene 
72 
 
target are selected in silico to be unique in the genome (acknowledging species specific 
codon usage) and non-overlapping in sequence (182). Additionally, the chip has been 
predesigned to represent 99.6% of the possible protein coding regions, tRNA genes, 
and intergenic regions of the P. aeruginosa laboratory strain, PAO1. The array also 
contains 117 genes present in P. aeruginosa strains other than PAO1, facilitating 
analysis of strains isolated from human infections (157).  
Though now an accepted and widely used tool, microarray studies, if not 
designed properly, can still provide artificial and/or misleading results. Major sources 
of error in arrays can come from 1) technical variation within the chip, 2) inaccurate 
experimental design, or 3) errors in analysis (183). Because the fluorescence intensity 
of each probe set is assumed to be proportional to transcription, each Affymetrix 
probe has a corresponding mismatch probe (single base difference). By correcting for 
the hybridisation of the mismatch probes, non-specific events can be removed from 
the analysis. Though commercially prepared and processed microarrays do come with 
their own technical variation in probe generation and processing, through the 
implementation of housekeeping genes and the computational standards, microarray 
data can provide a robust starting point for expression profiling (184). 
The applications of microbial genome arrays have been growing since their 
inception.  Once strictly a measure of RNA transcription levels, microarrays are now a 
dominant tool in functional genomics not only to enable target downstream studies 
but to also relate molecular differences to a specific biological event, clinical strain or 
environmental stressor (185–187). One of the major caveats of studying bacterial 
transcription, however, is the instability and rapid turnover of microbial mRNAs (188–
192). With bacteria able to degrade expressed RNA in less than 3 minutes, and 
sometimes even during translation, methods of prokaryotic RNA isolation need to be 
highly efficient to prevent false readings of expression (191,193–195). For this, 
microbial expression profiles should be carefully considered in the context of the 
experimental design.  
 
4.2.2. Previous microarray studies of oxidative stress in P. aeruginosa 
 
In the research domains of clinical microbiology and emerging infectious disease, 
transcriptional analysis of Pseudomonas spp. using the Affymetrix Pseudomonas 
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GeneChip® is becoming common practice with over 240 reported studies listed in the 
NCBI Gene Expression Omnibus (196). The vast majority of these studies are 
comparative assessments of clinical Pseudomonas spp. isolated from cystic fibrosis 
patients. Aside from profiling clinical Pseudomonas spp., the majority of the published 
transcriptional research involving P. aeruginosa infections has been carried out using 
the laboratory strain PAO1. 
 
4.2.2.1. In vitro studies with oxidative stress as a constituent of culture media 
 
At the time of this study, three groups (Chang et al., Palma et al., and Salunke et al.) 
have previously published studies using transcriptional profiling of the laboratory 
strain PAO1 in response to challenge with exogenous H2O2 at varying concentrations 
and exposure times, as a purported model for how P. aeruginosa responds to oxidative 
challenge by mammalian immune defences (Table 4.1).   
 
Table 4.1. Summary of PAO1 microarrays investigating oxidative stress in vitro 
Author Date Stressor Media Densitya Exposure 
Palma et al (197) 2004 1 mM H2O2 TSB
b  0.5 10 min 
Palma et al (198) 2005 0.5 mM H2O2 TSB
b 0.5 10 min 
Chang  et al (199) 2005 1 mM H2O2 LB 0.8 20 min 
Salunkhe et al (78) 2005 10 mM H2O2 LB 2.7-3.0 2 h 
Goldová et al (200) 2010 10 mM H2O2 M9
c 0.8 15 min 
a Density is reported as an optical density at 600 nm. 
b Tryptic soy broth, like LB, is a nutrient rich bacterial growth medium. 
c 
M9 is a minimal growth medium. 
 
 While each project was able to justify their selection of experimental 
conditions, few comparable patterns were revealed between the studies. Additionally, 
while H2O2 is a major component of secreted ROS by the immune system, technical 
methods have not yet evolved to a point where we can appropriately quantify the 
concentration of H2O2 and other ROS compounds within the phagocytic environment. 
Though previous studies may have demonstrated H2O2 sensitivity by P. aeruginosa 
strains at distinct concentrations, these may not be relevant to a natural infection 
process for P. aeruginosa because of 1) the culture media, 2) the population density of 
the bacteria, and 3) the H2O2 concentration tested. For example, many of the above 
studies used bacteria cultured in some form of nutrient broth where, among other 
compounds, iron is readily available. In vertebrate systems, cells typically store iron in 
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the cytoplasm thus forcing invading bacteria to  develop a means of actively 
sequestering iron from its host to support growth (201). Similarly, it is well known that 
P. aeruginosa is sensitive to its population size and uses a density-dependent quorum 
sensing system to coordinate biological activities and expression of virulence factors 
such as biofilm formation (202).  
 
4.2.2.2. In vivo cell culture studies involving eukaryotic cell interaction with P. 
aeruginosa 
 
While the previous microarray work used constituents in the media to challenge PAO1, 
it must be appreciated that no simple system can reasonably be expected to model the 
complex interplay between P. aeruginosa and its host. As an isolated cell system may 
provide information regarding individual gene function, a more multifaceted approach 
needs to be implemented and perhaps complemented through the use of the 
microarray. In using the microarray to globally examine the complete transcriptome 
during stress responses, known relationships between genes with previously identified 
functions may be supported as well as identifying new target genes that give more 
understanding into P. aeruginosa-host interactions.  
 Frisk et al (2004; (203)) was arguably the first study to use a whole-genome 
transcriptional profile to assess how P. aeruginosa responds to eukaryotic host cells 
(30).  During early stages of infection, P. aeruginosa must overcome interaction with 
the epithelium and find a way past the epithelial tight junctions. This study 
investigated the response of PAO1 (labelled with a GFP reporter gene) when exposed 
to airway epithelial cells. Later Chugani et al (2007; (204)) expanded upon this method 
by addressing PAO1 gene activation at ¼ the bacterial cell density of the Frisk et al 
study only to find that, for example, iron-responsive genes were differentially 
expressed (31).  
 In 2009, Alhede et al (2009; (205)) first published work investigating the 
interaction between PMNs and PAO1, based on the fact that PMN cells play a role in 
the initial host response to P. aeruginosa infection (32). Unlike Frisk et al and Chugani 
et al, Alhede’s work sought to identify the gene regulation of PAO1 in a high cell 
density biofilm when exposed to human PMNs. The experimental design of these three 
studies is briefly summarised in Table 4.2. 
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Table 4.2. Summary of PAO1 microarrays involving eukaryotic cell interaction 
Author Date Stressor MOIa Exposure Control 
Frisk et al (203) 2004 Human respiratory epithelia 100:1 4 hrs DMEM 
Chugani et al 
(204) 2007 Human respiratory epithelia 25:1 5 hrs 
TSB 
Alhede et al (205) 2009 Human PMNs 1000:1 2 hrs ABT 
a 
MOI refers to the number of bacteria for every eukaryotic cell; multiplicity of infection. 
b
 Control refers to the media in which baseline samples were cultured; DMEM-F-12, a eukaryotic cell 
culture medium containing 0.4% glucose, 13 μM Fe2/3+, 2 mM L-glutamine, 15 mM HEPES, and 2% 
Ultroser G supplement, a serum substitute; TSB, a nutrient rich bacterial growth medium; ABT, a 
minimal medium supplemented with 0.5% (w/v) glucose). 
 
 
 Although PMNs are more abundant in the blood, macrophages naturally reside 
at the epithelial interface in normal lung tissue, produce more ROS, and play an 
essential role in killing and controlling attacking bacterial pathogens (206–212). Based 
on this, we sought to develop a means to examine the PAO1 in the presence of 
macrophages. We focused on studying the initial macrophage phagocytic interaction 
that infecting non-mucoid P. aeruginosa may encounter in the early stages of 
pathogenesis.  
 Our approach incorporated the use of an in vivo cell culture model whereby 
viable bacteria were engulfed by macrophages and then isolated and assessed for 
survival or transcriptional response. The term “in vivo” is this case was used to indicate 
that the bacteria were in an environment different from in vitro LB cultures even 
though this model is still an “in vitro” model for the macrophages. All instances of the 
term “in vivo cell culture” refer to this infection model. Though the laboratory strain 
PAO1 has been highly passaged at a potential cost to its virulence (213),  we chose to 
employ the PAO1 strain so that we could directly compare to transcriptional data from 
the above mentioned in vitro studies (Table 4.1.); and, unlike the earlier Frisk et al 
study (203) we chose not to incorporate a GFP tag, to keep the PAO1 as close to wild 
type as possible and thereby avoid any perturbation of standard transcriptional 
profiles arising from accumulation of non-native proteins in the cell. To achieve this it 
was first necessary to develop a method to isolate RNA from live P. aeruginosa located 
within the macrophage. Similar studies with Salmonella, Brucella, and Mycobacterium 
have indicated that this approach can be highly effective in identifying oxidative stress-
responsive genes and enzymes (176–179); however, equivalent experiments had not 
previously been described for P. aeruginosa.  
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  In Chapter 3 P. aeruginosa was identified as possessing numerous NQORs, most 
of which have not been experimentally characterised with regard to their biological 
role, and our results did not definitively identify whether these enzymes contribute to 
oxidative stress resistance. To further investigate this, the work described in this 
chapter sought to identify, at a global level, which genes or gene-groups in P. 
aeruginosa are activated in response to incubation with macrophage cells (the initial 
immune system responders to bacterial infection, which fight bacteria by releasing a 
transient “oxidative burst”). This analysis was conducted by using Affymetrix 
microarray technology to compare the gene expression of P. aeruginosa cells that have 
been incubated with macrophages against that of control cells which have not been 
exposed to oxidative stress (214,215). As well as accumulating evidence for NQORs 
that may play a role in virulence, this study aimed to provide a global perspective on 
how this important human pathogen responds to the initial challenge of the human 
immune system.  
 
4.3. Objectives 
 
 Develop a macrophage infection model using flow cytometry to quantify survival in 
the absence of a GFP reporter system. 
 Screen P. aeruginosa strains using in vivo cell culture infection model. 
 Assess transcriptional profile of P. aeruginosa internalised by macrophages.  
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4.4. Development of an in vivo cell culture infection model to evaluate the P. 
aeruginosa response to challenge by murine macrophages 
 
4.4.1. Using flow cytometry to quantify bacteria 
 
A standard means of quantifying bacterial survival is to use colony forming unit (CFU) 
counts of samples exposed to different conditions. This approach, although effective, is 
low throughput and was not practical for the volumes of strains and conditions 
included in this study. We therefore sought to develop a more rapid means of 
quantifying P. aeruginosa survival. To do so, we adapted the Bacterial Counting Kit 
(Molecular Probes, Life Technologies; Grand Island, NY, USA) for use with P. 
aeruginosa cultures and optimised a protocol for assessing P. aeruginosa viability using 
flow cytometry. In short, the Bacteria Counting Kit incorporates a live cell dye (SYTO® 
BC) and microsphere bead standard used in conjunction with propidium iodide (PI; a 
“dead cell” stain). SYTO® BC is a cell wall permeable nucleic acid stain that produces a 
bright green fluorescence in viable cell populations. In contrast, PI is not cell 
permeable, and is therefore commonly used to identify dead cell populations in the 
red-fluorescence channel, allowing differentiation between live and dead cells within a 
mixed population. The kit includes microsphere standards that are also fluorescently 
labelled and can be used to quantify the bacteria by determining the ratio of bacterial 
signals to microsphere signals.  
Fluorescence activated cell sorting (FACS) was initially employed to confirm 
that the cytometric populations indicative of positive SYTO® BC staining accurately 
identified the live bacterial population. Cell sorting was performed by Kylie Price at the 
Malaghan Institute for Medical Research, such that each cell population (separated by 
quadrant, Figure 4.2) was collected for recovery on agar and in liquid culture. Although 
there was overlap in signal from SYTO®BC and PI populations (quadrant 2 and 3), it was 
confirmed by CFU counting that these “double positive” populations were indeed 
representative of a live cell group (Figure 4.2b). 
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Figure 4.2. P. aeruginosa quantification by flow cytometry and CFU 
(A) Cytogram representation of PBS-washed PAO1 stained with both 1x SYTO® BC and 10 μg/mL PI in 
0.9% NaCl and processed on a FACSVantage DiVa cell sorter where quadrant Q1 theoretically represents 
SYTO® BC+PI- cells, Q2 and Q3 the double positive bacteria, and Q4 the non-labelled bacteria.  (B) PAO1 
populations from each quadrant were collected to sterile polystyrene tubes containing 5 mL 5% FCS, 
0.9% NaCl. The bacteria were then harvested by centrifugation (4000x g, 4 min, room temperature) and 
quantified by serial dilution on solid agar for CFU counts. Cell sorting was performed twice with 
consistent results. This figure presents representative data for (A) one cell sort, and (B) the CFU counts 
performed in quadruplicate ± 1 standard deviation.  
  
 
Quantification via CFU counts post cell sorting validated that the Bacteria 
Counting Kit could indeed be used to measure P. aeruginosa survival. However, due to 
differences in laser strength and signal output between the commercial cell sorter 
(FACSVantage DiVa) and the laboratory benchtop analyser (FAC FACSCanto II), two 
modifications were made to the viable population selection gating on the cytogram. 
Firstly, because Q2 and Q3 from the cell sort (Figure 4.2A) both appeared to be viable 
populations, we found that increasing the PI concentration from 10 μg/mL to 20 μg/mL  
reduced non-specific binding of PI (commonly observed with PI in the presence of 
Syto® dyes; (216–219)) and therefore eliminated the Q3 “double positive” population 
(data not shown). (216)Secondly, the cytogram population gating methods were 
adjusted to accommodate increased laser noise associated with routine flow 
cytometry analysis on a benchtop analyser (complete gating strategy description in 
Section 2.14.1). The final, optimised, flow cytometry staining solution used in this 
study consisted of 1x SYTO® BC, 1x (106) microsphere beads, and 20 μg/mL PI in 0.9% 
NaCl.  
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To validate this gating protocol, overnight cultures of P. aeruginosa were 
diluted 1:10 in fresh LB and incubated for a further 4 h before being washed twice in 
PBS. Washed bacteria were then incubated in either PBS (Live) or 70% isopropanol 
(Dead) for 30 min at room temperature before being washed again in PBS. Triplicates 
of each sample were then a) serially diluted then plated on LB agar, or b) stained with 
the flow cytometry staining solution and enumerated using flow cytometry. After 
normalising the flow count to the bead standards within the Bacteria Counting Kit, the 
number of bacteria recorded was sufficiently within the standard error of each 
quantification method (Figure 4.3). This was repeated, with similar results, on multiple 
occasions. 
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Figure 4.3. Live and dead PAO1 quantification by flow cytometry versus CFU counts 
Live and dead cell controls were prepared in triplicate by washing overnight cultures of PAO1 twice in 
PBS then dividing each sample into two replicates. One of these was untreated PAO1 in PBS (“live”), the 
other PAO1 in 70% isopropanol (“dead”) for 30 min at room temperature. After incubation, both live 
and dead cell samples were washed another two times in PBS, combined at ratios of 0:1 and 1:1 (live to 
dead), stained with the optimised flow cytometry staining solution, and either collected on the 
FACSCanto II flow cytometer or serially diluted on LB agar for CFU counts. The quantification of flow 
events was achieved through an optimised flow gating strategy (Section 2.14.1) or by standard CFU 
calculations and plotted as the average of triplicate samples ± 1 standard deviation.  
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4.4.1.1. Proof of Principle: Using flow cytometry and confocal microscopy to      
quantify antimicrobial properties of nanoparticle-coated wool 
 
During the optimisation phase of our flow cytometry protocol the opportunity arose to 
collaborate with Professor Jim Johnston and his team of chemists at VUW, seeking to 
evaluate the antibacterial properties of wool that they had coated with immobilized 
palladium nanoparticles. Due to surface plasmon resonance effects, the immobilized 
nanoparticles confer unusual, attractive and permanent coloration to the wool, as well 
as an expectation of antimicrobial effects. To assist with their study we proposed that 
using flow cytometry to enumerate the proportion of viable E. coli cells remaining after 
their standard test (a seven-day room temperature incubation of bacteria that had 
been washed and resuspended in PBS then adsorbed onto the surface of different 
wool samples) might prove a far more rapid and equally reliable method of 
quantification than plating dilution series of bacteria and counting the CFUs. 
To test this, the antimicrobial properties of identical preparations of 
nanoparticle-coated wool were quantified using either (i) conventional CFU 
measurements; or (ii) flow cytometry, backed up with qualitative analysis by confocal 
microscopy. Wool was loaded with nanopalladium particles grown at different 
temperatures ranging from 23 oC to 100 oC where temperature directly regulates 
particle size: the lower the temperature, the bigger the particle (220). We 
hypothesised that larger sized particles (prepared at 23 oC) would have more surface 
area available and therefore more palladium available for bacterial killing. Samples of 
wool, prepared under different nanoparticle growth conditions, were subjected to the 
standard E. coli incubation test as described above, following which the bacteria were 
collected and assessed for survival by both CFU and flow cytometry measurements 
(Figure 4.4A). The bacteria stained with the flow cytometry staining solution were also 
subjected to qualitative assessment using scanning laser confocal microscopy (Figure 
4.4B). The survival imaging of nanopalladium wool-challenged E. coli was shown to 
qualitatively reflect CFU / flow cytometry enumeration where sample B and C were 
most viable and E was least viable post treatment. A detailed summary of the 
complete study is presented in Appendix A1.  
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Figure 4.4. Bacterial survival assessment by flow cytometry, CFU and confocal 
microscopy 
(A) Identical samples of E. coli W3110 were recovered from nanopalladium coated merino wool, stained 
with 1x SYTO® BC and 10 μg/mL PI in 0.9% NaCl, and quantified by either flow cytometry (grey bars) or 
CFU counts (black bars). Wool treatments B – E represent different conditions whereby nanoparticles 
were immobilised on the wool fibres (100 oC, 80 oC, 50 oC, and 23 oC respectively). The data presented is 
a representative of three experimental replicates and error bars depict ± 1 standard deviation. (B-E) 
Corresponding confocal microscopy images of wool-treated W3110 samples were obtained by fixing the 
stained bacteria (as above) in 2% (final) paraformaldehyde, PBS and acquiring images by a laser-scanning 
confocal microscope (FlowView® FV1000, Olympus). Samples were excited sequentially at 473 and 559 
nm. Images were processed using Olympus FV10-ASW Viewer Ver.2.0b. 
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The reproducibility of the two quantitative methods was high, with no statistical 
difference between them. Therefore flow cytometry was deemed an acceptable 
means of bacterial quantification and appropriate for the higher throughput 
application of assessing viability of bacterial strains in different treatment conditions. 
In developing the infection model, initial P. aeruginosa cultures were also quantified 
using both methods to confirm that P. aeruginosa, like E. coli in the wool study, could 
be reliably quantified with flow cytometry.  
 
4.4.2. Collection method of macrophage-engulfed P. aeruginosa  
 
Having shown that flow cytometry could be used to accurately quantify bacterial 
viability, we next sought to develop a means for recovering viable, non-GFP labelled P. 
aeruginosa for assessment. We sought to utilise established murine macrophages for 
initial method optimisation. For one, the immortal cell lines would provide ease of 
proliferation and maintenance versus primary cell lines while still exhibiting classic 
phagocytic and macrophage-like characteristics (221–223) .  Secondly, the repeated 
optimisation steps likely to be required would benefit from using genetically identical 
progeny of the immortalised cell lines. The intended microarray study had a technical 
requirement of 30 μg of RNA for each test sample (10 μg for each of three replicates) 
in the microarray application. Therefore, the murine macrophage line was chosen 
based on the ability to recover the greatest number of viable P. aeruginosa post-
phagocytosis. 
To achieve this we adapted protocols from multiple sources (Eriksson et al 
(2003; (176)), Srivastava et al (2007; (178)), and Dietrich et al (2000; (179)) that had 
previously employed related techniques to study Salmonella and Mycobacterium spp.  
The key concept was to allow enough time for macrophages to phagocytose P. 
aeruginosa and produce ROS, during which time the bacteria located externally to the 
macrophage would be removed by antibiotic treatment and washing. Subsequently, 
the bacteria-containing phagosomes would then be allowed to mature before lysis of 
the macrophages to harvest viable P. aeruginosa.  
To achieve this required the optimisation of a number of parameters. In short, 
the initial infection conditions tested were as follows. Macrophage-like RAW-264.7 or 
J774A.1 cells were seeded at 8.4 x 103 per well in antibiotic-free complete cell culture 
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media (CMEM; 25 mM HEPES Buffer solution, 10% FCS in basal media Gibco® DMEM; 
Invitrogen) and incubated at 37 oC, 5% CO2 for 48 h. Overnight cultures of PAO1 in 
antibiotic-free LB were washed twice in room temperature PBS and diluted to OD660 
1.0 which equates to roughly 1 x 109 bacteria/mL (based on multiple preliminary serial 
dilution tests, data not shown).  A PAO1 multiplicity of infection (MOI) of 100 (i.e. 100 
bacteria: 1 macrophage in 100 μl per well) in complete CMEM was then applied to a 
PBS-washed macrophage monolayer. To promote bacteria-macrophage interaction, 
the culture plates were centrifuged at 1000x g for 2 min at room temperature after 
addition of bacteria-containing media and before commencing a 2 h infection period at 
37 oC, 5% CO2. After infection, gentamycin was added to the CMEM (final 
concentration 50 μg/mL) for 45 min to kill the non-engulfed P. aeruginosa. This 
concentration was sufficient to kill >98% of P. aeruginosa while having no deleterious 
effect on macrophage viability (Figure 4.5) 
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Figure 4.5. Gentamycin protection assay 
Replicate cultures of RAW-264.7 macrophages (A) and PAO1 (B) were treated for 45 min at a range of 
concentrations of gentamycin (0 μM – 400 μM) in CMEM at 37 
o
C, 5% CO2 and assessed for survival 
using flow cytometry. Both macrophages and PAO1 were stained with the flow cytometry staining 
solution (1x SYTO® BC, 20 μg/mL PI, 1x microsphere beads in 0.9% NaCl). The SYTO® BC dye is a nucleic 
acid dye that can stain either eukaryotic or prokaryotic cells but at different fluorescent intensities 
allowing for both cell types to be assessed. Data is indicative of three replicates ± 1 standard deviation. 
Similar observations were made with gentamycin-treated J774A.1 macrophages (data not shown).   
 
After gentamycin treatment, infected macrophage monolayers were washed 
four times in PBS to remove the extracellular P. aeruginosa. This point equated to time 
point zero (T0).  To subsequently release the internalised bacteria at different time 
A                 B 
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points, washed monolayers were lysed for 5 min in macrophage lysis solution (0.1% 
SDS, 0.1% Tween-20, 0.9% NaCl). The lysate was then removed in 2 vol PBS and 
transferred to a fresh 96-well plate. The bacteria were then collected by differential 
centrifugation, first spinning at 400x g for 4 min to pellet the macrophage cellular 
debris, then by transferring the bacteria-containing supernatant to a new 96-well plate 
and spinning at 4000x g for 4 min to pellet the bacteria. The bacterial pellet was then 
resuspended in flow cytometry staining solution and incubated in the dark at room 
temperature for 15 min before being assessed for viability by flow cytometry.  
Initially, established RAW-264.7 and J774A.1 macrophage-like cell lines were 
compared for their ability to internalise P. aeruginosa at different MOI from 5 – 200 
bacteria per macrophage. Irrespective of the MOI used, a greater number of viable P. 
aeruginosa cells were recovered from the RAW-264.7 than the J774A.1 cells (Figure 
4.6). On this basis RAW-264.7 macrophages were chosen for infection model 
development. 
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Figure 4.6. Viable P. aeruginosa recovered from RAW-264.7 and J774A.1 
macrophages 
Replicate cultures of RAW-264.7 or J774A.1 macrophages were infected for 2 h with PBS-washed P. 
aeruginosa resuspended in pre-warmed CMEM at MOIs of 5-200. Infection was followed by a 100 μg/mL 
gentamycin treatment for 45 min. The infected macrophages were washed free of externally located 
bacteria. The internalised bacteria were then recovered from infected macrophages by application of 
macrophage lysis solution and resuspension of the pellet from the second stage of differential 
centrifugation (400x g followed by 4000x g for 4 min). Viable bacteria were then stained with flow 
cytometry staining solution and quantified using flow cytometry, measuring the ratio of bacteria signals 
to Bacteria Counting Kit bead signals. The data presented in this graph indicates the mean of three 
independent experiments ± 1 standard deviation.  
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Preliminary tests indicated no significant statistical differences in the number of 
viable bacteria recovered from RAW-264.7 macrophages at MOIs of 25, 50 and 100; 
the latter was chosen for this assay because more total prokaryotic RNA was collected 
at a MOI of 100 than at a MOI of 50 according to the percent total area as 
computationally predicted by the Agilent 2100 Bioanalyzer software (Agilent 
Technologies; Santa Clara, CA, USA; Figure 4.7).  
 
 
Figure 4.7. Total prokaryotic RNA recovered from RAW-264.7 macrophage-engulfed 
P. aeruginosa 
Total RNA was recovered by application of 1 mL Trizol to RAW-264.7 macrophages infected for 2 h by a 
PAO1 MOI of 50 (A) and a MOI of 100 (B). After total RNA purification (manufacturer’s specifications; 
QIAGEN RNAeasy Kit), prokaryotic RNA was then enriched using the MICROBEnrich™ kit with the 
recommended protocol (Ambion®, Life Technologies) and quantified using the Agilent 2100 Bioanalyzer. 
The enriched bacterial RNA represented by virtual gel (left) or electropherogram (right), showed 
band/peaks corresponding to the eukaryotic 18S and 28S and prokaryotic 16S and 23S ribosomal 
subunits. RNA abundance of prokaryotic RNA was calculated as the 16S plus 23S area under the curve as 
a percentage of total eukaryotic plus prokaryotic surface area. This was repeated in two separate 
experiments in duplication. This figure presents data from one replicate.  
 
 
Additionally, internalisation of P. aeruginosa by RAW-264.7 macrophages was 
visually confirmed by confocal microscopy using both SYTO® BC from the Bacteria 
Counting Kit and the Image-IT®LIVE Plasma Membrane and Nuclear Labelling Kit 
Counterstains For GFP-Expressing Cells (Molecular Probes). Pre-infection staining of 
the bacteria in concentrated SYTO® BC (2x in 0.9% NaCl) allowed internalised PAO1 to 
be visually confirmed via green fluorescence compared to non-infected controls 
(Figure 4.8). However, because SYTO® BC is a permeable nucleic acid dye, background 
levels of dye were also visible in the cytoplasm of the infected macrophages.  
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Figure 4.8. Confocal images of RAW-264.7 infected with P. aeruginosa 
(A) Prior to macrophage infection, 1 mL of PBS-washed P. aeruginosa cultures were pelleted by 
centrifugation at 10,000x g for 30 s and resuspended in 1:500 in 0.9% NaCl. After staining with SYTO® BC 
for 15 min at room temperature in the dark, the bacteria were diluted to a MOI of 100 in 2 mL pre-
warmed, phenol red-free CMEM and applied to the macrophage monolayer seeded in a 35 mm glass-
bottom FluoroDish™ cell culture dish (World Precision Instruments). After 2 h infection followed by 100 
μg/mL gentamycin treatment for 45 min, extracellular bacteria were washed free of the monolayer in 
PBS and the remaining RAW-264.7 monolayer was then stained with 5 μg/mL Alexa Fluor 594 WGA and  
1 µM Hoechst 33342 in 1 mL of phenol red-free CMEM for 10 min at 37 
o
C, 5% CO2. Stained live-cell 
cultures were washed three times in PBS, covered in 1 mL of phenol red-free CMEM and imaged using a 
laser-scanning confocal microscope (FlowView® FV1000, Olympus). (B) Uninfected RAW-2654.7 cells 
were prepared by washing the monolayer in PBS and staining with Alexa Fluor 594 WGA and Hoechst 
33342 as above. All samples were excited sequentially at 405, 473 and 559 nm. Images were processed 
using Olympus FV10-ASW Viewer v2.0b.  
 
 
4.4.3. Optimisation of the infection environment  
 
In a hypothetical infection scenario, human subjects would almost certainly have been 
previously exposed to P. aeruginosa at some point in their lives; as such, bacteria 
would naturally be opsonised (coated by complement proteins for macrophage 
recognition) upon entry into the system. We therefore decided to opsonise the P. 
aeruginosa cells prior to macrophage challenge, unless this was found to lead to a 
substantial reduction in the total number of cells recovered post-internalisation. In this 
experiment, opsonisation was found to have little effect on the number of viable P. 
aeruginosa recovered (Figure 4.9).   
Another common treatment is stimulation of macrophage cultures by addition 
of interferon-gamma (INF-ɣ) and lipopolysaccharide (LPS) prior to application in an 
immunological assay. However, in the context of this in vivo cell culture model, the 
influence of priming RAW-264.7 cells with INF-ɣ caused a significant reduction in the 
number of P. aeruginosa recovered and this pre-treatment was therefore not used in 
subsequent assays (Figure 4.9).  
A      B 
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Figure 4.9. Effect of opsonisation and INF-ɣ on P. aeruginosa uptake 
RAW- 264.7 macrophages with or without 100 U/mL IFN-ɣ pre-treatment for 24 h were infected with 
either untreated or opsonised P. aeruginosa for 2 h.  Opsonised bacteria were prepared by resuspending 
PBS-washed PAO1 in 10% C57/BL6 male mouse serum PBS for 30 min at 37 oC, 5% CO2 before diluting to 
a MOI of 100 in pre-warmed CMEM for application to the macrophage monolayer. Infection was 
followed by a 100 μg/mL gentamycin treatment for 45 min. The infected macrophages were then 
washed free of externally located bacteria and the internalised bacteria. The bacteria were then 
recovered from infected macrophages by application of macrophage lysis solution and differential 
centrifugation at 400x g (4 min) then 4000x g (4 min). Bacteria were then stained with flow cytometry 
staining solution and the number of viable cells quantified using the ratio of bacteria signals to Bacteria 
Counting Kit bead signal, measured by flow cytometry. Plotted data indicate the mean data from three 
independent experiments ± 1 standard deviation.  
 
 
After confirming that (i) P. aeruginosa was being internalised by RAW-264.7 
macrophages, (ii) viable bacteria could be recovered and quantified post infection, and 
(iii) pre-infection priming with INF-ɣ was unnecessary (and indeed counter-productive), 
the next step in method development was to determine the time point at which 
internalised bacteria would ultimately be isolated to maximise RNA isolation. For this, 
bacteria from infected RAW-264.7 macrophage replicates were recovered at a range of 
different times (0, 2, 4, 8 and 24 h) post infection. As noted previously, time 0 h (T0) 
was taken as the point immediately after 2 h infection and 45 min gentamycin 
treatment (T0) which allows the macrophage phagosome to mature (e.g. a series of 
events ultimately leading to the formation of the phagolysosome), and which can 
dramatically change the environment to which bacteria are exposed. Phagosomal 
maturation leading to lysosomal fusion has previously been reported to complete 
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between 60 minutes and 4 hours post phagocytosis depending on the infection 
conditions (176,224–228).  
Initial results indicated a significant reduction in the number of viable bacteria 
between T0 and after 2 h of phagosomal maturation and even more so at 8 h. 
However, if allowed to incubate for a total of 24 h, the wild type PAO1 P. aeruginosa 
was able to recover to near T0 levels (Figure 4.10). PAO1 lacking the KatA catalase 
(∆katA) was also tested for viability during phagosomal maturation in tandem with 
wild type PAO1. Consistent with the in vitro assays in Chapter 3, ∆katA was unable to 
survive infection as effectively as wild type at T0. However, like wild type, ∆katA was 
able to recover after 24 h (Figure 4.10). Given the detrimental effect of the subsequent 
stages of phagosomal maturation on PAO1 viability and our initial goal to investigate 
early-stage macrophage interactions, the T0 time point was chosen for this study.  
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Figure 4.10. Recovery of viable P. aeruginosa post-phagosomal maturation 
RAW-264.7 macrophages were infected for 2 h with a MOI of 100 of opsonised wild type PAO1 or 
opsonised ∆katA-deletion mutant followed by a 100 μg/mL gentamycin treatment for 45 min. The 
infected macrophages were washed free of externally located bacteria and the internalised bacteria 
were allowed to incubate within the maturing phagosomal environment for 0, 2, 8 or 24 h. The bacteria 
were then recovered from infected macrophages by application of macrophage lysis solution and 
differential centrifugation at 400x g (4 min) then 4000x g (4 min). Bacteria were then stained with flow 
cytometry staining solution and the number of viable cells quantified using the ratio of bacteria signals 
to Bacteria Counting Kit bead signal, measured by flow cytometry. Plotted data represent the means of 
three independent experiments ± 1 standard deviation.  
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4.4.4. Observations made during phagosomal maturation 
 
In the process of monitoring P. aeruginosa viability across a phagosome maturation 
time course, two observations were made with respect to (i) the number of viable wild 
type bacteria collected at 2 h maturation using a MOI of 50 compared to a MOI of 100, 
and (ii) the phenotypic profile changes to P. aeruginosa during maturation as 
represented on the flow cytometry visual cytogram output.  
 As noted previously, wild type P. aeruginosa (MOI 100) left to mature within 
the phagosomal environment for an additional 2 h post infection showed a significant 
reduction in viability. This reduction in survival was even more pronounced at 8 h. 
However, during the process of optimisation, an MOI of 50 was examined under 
identical infection and phagosomal maturation conditions, and found to give an 
entirely different result. At a MOI of 50, the number of viable wild type bacteria 
significantly increased 14-fold (p < 0.0001) at 2 h phagosomal maturation. By 8 h this 
number then dropped to below the number recorded at 0 h (Figure 4.11).  We 
hypothesise that this effect resulted from differences in the P. aeruginosa population 
density and associated quorum sensing signals relative to the MOI 100 scenario. This 
observation was not pursued due to lack of relevance to the primary objectives of the 
project, however it does emphasise the profound difference that seemingly minor 
changes in an experimental parameter can have on the outcome of a study. 
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Figure 4.11. Viability of PAO1 during phagosomal maturation at MOIs of 50 and 100 
RAW-264.7 macrophages were infected for 2 h with a MOI of 100 opsonised wild type PAO1 followed by 
a 100 μg/mL gentamycin treatment for 45 min. The infected macrophages were washed free of 
externally located bacteria and the internalised bacteria were allowed to incubate within the maturing 
phagosomal environment for 0, 2 or 8 h. The bacteria were then recovered from infected macrophages 
by application of macrophage lysis solution and differential centrifugation at 400x g (4 min) then 4000x 
g (4 min). Bacteria were then stained with flow cytometry staining solution and the number of viable 
cells quantified using the ratio of bacteria signals to Bacteria Counting Kit bead signal, measured by flow 
cytometry. Plotted data represent the means of three independent experiments ± 1 standard deviation.  
 
 
As per the above maturation profile (Figure 4.10), an interesting observation 
regarding phenotypic profile changes in the flow cytometry graphical output was also 
noted for the MOI 50 infection conditions. In short, at 2 h post phagosomal 
maturation, the physical location of the wild type PAO1 population on a cytogram of 
SYTO® BC vs. PI was consistently seen to shift from the SYTO® BC+ PI- quadrant to the  
SYTO® BC+ PI+ quadrant (Figure 4.9). Although this population appears to acquire the 
dead cell stain at 2 h post maturation, it was previously determined by cell sorting 
(Figure 4.2), that the double positive bacterial populations are viable and therefore 
counted towards total survival. It is unknown why this shift occurred and was possibly 
related to a staining artefact, biological event or another unknown factor. As this 
observation was only seen with a MOI of 50, it was not deemed relevant and infection 
studies proceeded with a MOI of 100 as detailed earlier. 
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 Figure 4.12. Phenotypic changes of PAO1 viabilty (MOI 50) as represented on 
cytogram 
(A) RAW-264.7 macrophages were infected for 2 h with opsonised wild type PAO1 (MOI 50) followed by 
a 100 μg/mL gentamycin treatment for 45 min. The infected macrophages were washed free of 
externally located bacteria and the internalised bacteria were allowed to incubate within the maturing 
phagosomal environment for 0, 1 or 2 h. The bacteria were then recovered from infected macrophages 
by application of macrophage lysis solution and differential centrifugation at 400x g (4 min) then 4000x 
g (4 min). The bacteria were stained with flow cytometry staining solution and the number of viable cells 
quantified using the ratio of bacteria signals to Bacteria Counting Kit bead signal, measured by flow 
cytometry. This observation appeared in as many as 16 replicates. This figure presents a representative 
of one replicate. (B) Total live cell events (SYTO® BC +) as a percentage of total plotted events at 0, 1, 
and 2 h phagosomal maturation were overlaid on the respective cytograms of wild type PAO1 (MOI 50). 
 
 
 In summary, by sequentially testing individual parameters, an in vivo cell 
culture infection model to evaluate P. aeruginosa response to murine macrophages 
was developed. It was determined that for maximal RNA isolation, RAW-264.7 
macrophages were best able to take up opsonised-P. aeruginosa in the absence of IFN-
ɣ and that an initial MOI of 100 generated the greatest yield of total prokaryotic RNA. 
Additionally, harvesting the bacteria immediately after an infection of 2 h, plus 45 min 
gentamycin treatment (i.e. T = 0), resulted in the greatest harvesting of viable bacteria, 
as opposed to situations where the phagosomal environment was allowed to mature 
post infection.   Although some surprising apparent changes in cellular responses or 
phenotype were observed during phagosomal maturation at a MOI of 50, these 
phenomena were not pursued further in this study. Instead, having finalised the 
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experimental parameters, the next step was to apply the optimised in vivo cell culture 
model to (i) characterise the relative survival of NQOR-deleted or over-expressing 
PAO1 strains (and also clinical isolates) post phagocytosis, and (ii) assess the global 
transcriptional response of wild type PAO1 post internalisation by RAW-264.7 
macrophages.  
 
4.5. In vivo cell culture infection screening of  P. aeruginosa strains 
 
4.5.1. Clinical isolates 
 
Several New Zealand P. aeruginosa clinical isolates were evaluated for survival post 
RAW-264.7 macrophage exposure (Figure 4.13). The five clinical isolates tested came 
from a total of four patients and represented non-mucoid strains identified in 
numerous biological samples from blood to urine to tracheal aspirates (Chapter 2, 
Table 2.2). All five clinical isolates were tested in vitro for sensitivity to H2O2 compared 
to PAO1 as described in Section 2.10, but this indicated no differential sensitivities 
(data not shown). Consistent with the in vitro characterisation, macrophage 
engulfment of clinical isolates ARL1079 (tracheal aspirate), ARL1205 (thigh), and 
ARL1236 (blood) demonstrated no substantial difference in survival when compared to 
PAO1. However ARL0011323, isolated from cystic fibrosis sputum, was able to 
withstand macrophage exposure >4 fold better than wild type PAO1 (p < 0.01). 
ARL1024, a sample from a catheter, was also significantly more sensitive to RAW-264.7 
macrophage exposure (p < 0.01).  
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Figure 4.13. Viable P. aeruginosa clinical strains recovered from macrophage 
infection 
RAW-264.7 macrophages were infected for 2 h with a MOI of 100 opsonised clinical P. aeruginosa 
isolates, followed by a 100 μg/mL gentamycin treatment for 45 min. The infected macrophages were 
then washed free of externally located bacteria. The internalised bacteria were recovered from infected 
macrophages by application of macrophage lysis solution and differential centrifugation at 400x g (4 
min) then 4000x g (4 min). The bacteria were then stained with flow cytometry staining solution and the 
number of viable cells quantified using the ratio of bacteria signals to Bacteria Counting Kit bead signal 
measured by flow cytometry. Plotted data represent the means of three independent experiments ± 1 
standard deviation. Significance is reported where p < 0.01 (**). 
 
 
4.5.2. Mutant and over-expression strains 
 
The macrophage model was also used to expand upon the preliminary NQOR enzyme 
characterisation described in Chapter 3. Although the single mutant ∆1204 did not 
previously exhibit heightened sensitivity to H2O2 challenge in vitro, this mutant did 
appear to be more sensitive to macrophage infection (Figure 4.14A).  When the ∆1204 
mutant was compared to the ∆katA mutant there was no significant difference 
between either strain; whereas both of these strains were significantly more sensitive 
than wild type PAO1 (p < 0.05 for both the ∆1204 and ∆katA mutants).  
As demonstrated in the number of viable ARL1323 and ∆1204 P. aeruginosa 
recovered from infection (Figure 4.13 and Figure 4.14A respectively), compared to wild 
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type PAO1, the in vivo cell culture model was able to distinguish differential 
sensitivities between (i) clinical isolates and (ii) NQOR-deleted strains that had not 
previously been identified. In contrast, over-expression strains (in a katA-null 
background) recovered from macrophages exhibited similar patterns of survival as 
observed in Chapter 3 (Section 3.3.2.2) when over-expression strains were challenged 
in vitro with H2O2 (Figure 4.14B). The over expression of PA2580, PA0949, or KatA
 
(PA4236) enabled PAO1 to withstand engulfment by murine macrophages 3.8 – 5.5 
fold better than wild type PAO1 (Figure 4.14B). 
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Figure 4.14. Viable P. aeruginosa NQOR-deletion and NQOR over-expression strains 
recovered from macrophage infection 
RAW-264.7 macrophages were infected for 2 h with a MOI of 100 opsonised (A) NQOR gene-deleted 
PAO1 strains, or (B) NQOR over-expressing PAO1 strains (including empty pSX vector controls in wild 
type PAO1 and PAO1, ∆katA where over-expression was induced and maintained by amending the 
growth media with 0.25 mM IPTG and 10 μg/mL gentamycin) followed by a 100 μg/mL gentamycin 
treatment for 45 min. The internalised bacteria were recovered from infected macrophages by 
application of macrophage lysis solution and differential centrifugation at 400x g (4 min) then 4000x g (4 
min). The bacteria were then stained with flow cytometry staining solution and the number of viable 
cells quantified using the ratio of bacteria signals to Bacteria Counting Kit bead signal measured by flow 
cytometry. Plotted data represent the means of three independent experiments ± 1 standard deviation. 
Significance is reported where p < 0.05 (*) and p < 0.001 (***) are compared to WT (A) and PAO1 (B) 
controls. Data presented in (B) is indicative of a ratio of viable bacteria to the PAO1 control because of 
day-to-day variations; between same-day replicates variation was low, and general trends were highly 
reproducible. 
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The NQOR over-expression strains recovered from macrophage infection were 
additionally phenotypically represented on a cytogram to demonstrate changes in 
viability of selected strains between 0 and 2 h of phagosomal maturation (Figure 
4.15A). It was noted that the 2 h phagosome-matured viable populations responded to 
macrophage infection in a manner consistent with their response to in vitro 1.5 mM 
H2O2 challenge as previously described in Chapter 3 (section 3.3.2.2; reproduced in 
Figure 4.15B). The pSX::PA1204 over-expression strain, like ∆katA (with pSX::empty) 
showed sensitivity to macrophage infection after 2 h phagosomal maturation; whereas 
the pSX::katA and pSX::PA2580 strains, like PAO1 (with pSX::empty), were able to 
survived engulfment at the same time point. 
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Figure 4.15. Comparison of survival patterns of NQOR over-expression strains 
following macrophage infection and in vitro H2O2 challenge 
(A) 3 mL cultures of NQOR over-expression strains were grown overnight in LB supplemented with 0.25 
mM IPTG and 10 μg/mL gentamycin to induce NQOR over-expression. RAW-264.7 macrophages were 
then infected for 2 h with PBS-washed opsonised NQOR over-expression strains (MOI 100) in media 
supplemented with 0.25 mM IPTG. Infection was followed by 100 μg/mL gentamycin treatment for 45 
min. The internalised bacteria were then recovered from infected macrophages by application of 
macrophage lysis solution and differential centrifugation at 400x g (4 min) then 4000x g (4 min). The 
bacteria were stained with flow cytometry staining solution and the viable bacterial populations were 
visualised on a cytogram of SYTO® BC vs. PI. This was repeated in three independent experiments with 
consistent results. Panel A is a representative cytogram of one replicate. (B) Over-expression strains 
were inoculated to an initial OD660 of 0.1 in LB amended with 0.25 mM IPTG, 10 μg/mL gentamycin and ± 
1.5 mM H2O2. The OD660 of challenged and unchallenged cultures was measured hourly for 9 h. The 
plotted data are means of 3 independent experiments, each performed in duplicate, and error bars are 
± 1 standard deviation. 
 
 
 
A 
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4.6. Modification of infection conditions for RNA isolation 
 
For gene expression profiling of P. aeruginosa by microarray, three distinct samples of 
RNA were prepared - from: (i) Internal PAO1 - bacteria engulfed by macrophages, (ii) 
External PAO1 - bacteria exposed but not internalised by macrophages, and (iii) 
Control PAO1 – bacteria incubated in CMEM free of macrophages for the same 
duration as (i) and (ii). A total of 30 μg of prokaryotic RNA was required for each of the 
three experimental conditions (10 μg for each of three replicates) in the microarray 
application. To maximise the number of bacteria harvested for RNA isolation to 
achieve 30 μg, the macrophage monolayer in all experimental conditions (except for 
Control PAO1) was prepared by seeding 6-well plates with 2.5 x 105 cells in a volume of 
3 mL CMEM. The MOI of 100 was then maintained by adjusting the concentration of 
PAO1 to proportionately match the increased number of RAW-264.7 macrophages in 
culture.  
To isolate RNA from Internal PAO1, RAW-264.7 macrophages were infected for 
2 h (including 45 min gentamycin treatment) as described previously.  The post-
infection washing steps were completed in less than 2 min for each sample (as 
described in section 4.4.2) before covering the washed monolayer in 1 mL TRIzol®/cm2 
for 5 min at room temperature to preserve both eukaryotic and prokaryotic RNA. This 
was to minimize artefactual changes in RNA expression due to the collection process.  
The TRIzol®-lysed mixtures for each of the 24 wells collected were then combined in an 
RNase-free 15 mL conical tube and stored at -80 oC overnight prior to RNA purification. 
To isolate RNA from External PAO1, macrophages were infected as above, but 
instead of discarding each of the four PBS washes post infection, the supernatant from 
the infection and each wash was combined and pelleted by centrifugation at 4,000x g 
for 5 min at 4 oC in a 15 mL RNase-free conical tube. The pellet was initially 
resuspended in 1 mL TRIzol®, then further diluted to a final volume of 3 mL TRIzol®. 
This TRIzol®-lysate was then stored overnight at -80 oC.  
RNA from Control PAO1 (incubated in CMEM at the same concentration as that 
administered to achieve a MOI of 100 when macrophages were present) was prepared 
by incubating the washed and opsonised PAO1 (as above) in CMEM in 6-well culture 
plates free of macrophages. These were incubated for 2.75 h at 37 oC, 5% CO2, such 
that they were maintained under cell culture conditions for the same duration as the 
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Internal PAO1 and External PAO1 bacteria.  Control PAO1 were then harvested and 
treated per the External PAO1 samples, above. 
 
4.6.1. RNA quality control  
 
Purified RNA from all three sample types was assessed for concentration, purity and 
integrity by the Agilent 2100 Bioanalyzer. Concentrations were calculated from the 
total area of prokaryotic 16S and 23S ribosomal subunit peaks as a percentage of total 
surface area (x-axis) of each respective electrophoretic trace. The integrity of each RNA 
sample was computationally predicted by the Bioanalyzer software using the RNA 
Integrity Number (RIN) scoring tool. RIN assessment uses the electrophoretic trace of 
the RNA sample to assign a value of 1 -10, where level 10 represents completely intact 
RNA. The RIN algorithm is independent of sample concentration, instrument and user 
bias (229). All RNA samples submitted for this microarray experiment possessed RIN 
scores ≥8.5. RNA sample preparation purity was visually assessed using the 
electrophoretic trace (Figure 4.16). Enrichment of Internal PAO1 was found to remove 
>90% of eukaryotic RNA contamination (Figure 4.16AB). The External PAO1 RNA was 
found to contain minor traces of eukaryotic RNA (Figure 4.16C). Control PAO1 RNA was 
almost 100% pure (Figure 4.16D).  
 
Figure 4.16. RNA quality control 
Purified Internal PAO1, External PAO1, and Control PAO1 RNA samples in 1.5 μL RNase-free water 
assessed for concentration, purity and integrity by the Agilent 2100 Bioanalyzer. Electrophoretic traces 
of each RNA samples indicated quantitative peaks for eukaryotic 18S and 28S and/or prokaryotic 16S 
and 23S ribosomal subunits by calculating the area under the curve. (A) Internal PAO1 pre-enrichment, 
(B) Internal PAO1 post-enrichment, (C) External PAO1, (D) Control PAO1.   
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4.7. Transcriptional profile of internalised P. aeruginosa 
  
Purified RNA samples were submitted to the Centre for Genomics, Proteomics and 
Metabolomics (CGPM) at the University of Auckland for processing and scanning. Raw 
expression data of triplicate samples, as performed by Dr Donia Macartney-Coxson of 
ESR, were averaged and expression values normalised by RMA (robust multi-array chip 
averaging) as instigated in the Affy and Oligo packages in the open source 
Bioconductor analysis software. Expression fold change for genes in Internal PAO1 and 
External PAO1 samples were calculated in relation to Control PAO1.  Tables of all genes 
meeting quality control conditions and the statistical cut of p < 0.05 are listed in 
Appendix A2 and summarised in Table 4.3. Additionally, each gene, taking the 
expression fold change into consideration, was assigned a B-score. The B-score is a 
statistical measurement of the log odds that a gene is differentially expressed where a 
score of 0 is equal to a 50% probability of differential expression and 3 is ~95% 
probability (230,231). 
Using generic cut off measures of >2 fold expression change (FC) there 
appeared to be some overlap in genes regulated by P. aeruginosa both in Internal 
PAO1 and External PAO1 samples relative to the unchallenged Control PAO1. However, 
the vast majority of gene groups were unique to each respective sample with the 
exception of the down-regulated genes of External PAO1, in which 78 (30.5%) genes 
overlap with the 255 Internal PAO1 down-regulated genes (Figure 4.13).  
 
Table 4.3. Gene expression compared to Control PAO1 (p < 0.05)  
Sample 
Total genes with 
p < 0.05 
>2 FCa >3 FCa 
Internal PAO1    
Up-regulatedb 1856 151 30 
Down-regulatedb 1691 255 79 
External PAO1    
Up-regulatedb 1274 105 14 
Down-regulatedb 1667 87 11 
a Fold change expression compared to Control PAO1. 
b ”Up-regulated” and “down-regulated” refer to a positive or negative change in expression fold change 
respectively.  
 
 
100 
 
 
Figure 4.17. Distribution of activated and repressed genes between Internal PAO1 
and External PAO1 in relation to Control PAO1 
Bold values indicate >2 FC whereas bracketed numbers indicate total genes up- or down- regulated with 
p < 0.05.   
 
 
Top tables of expression data were sorted by functional characterisation of the 
gene groups as annotated in the Pseudomonas Genome Database to identify possible 
trends in regulation.  “Hypothetical, unclassified, unknown” or “Putative” gene 
annotations made up the bulk of each the four data sets (37.75%, Internal PAO1–up-
regulated; 46.52%, Internal PAO1–down-regulated; 14.05%, External PAO1–up-
regulated; 54.46%, External PAO1–down-regulated) (Appendix A2). For the genes of 
known function, in response to challenge by macrophages the internalised P. 
aeruginosa appear to be up-regulating transcriptional regulators, two-component 
regulatory systems, secreted factors, chemotactic proteins, and genes related to 
motility and attachment – all of which are consistent with a defensive response to a 
threat (Figure 4.14, complete set Appendix A3). Interestingly, 128 intergenic regions 
were up-regulated as well. Intergenic regions have largely been thought to contain 
small non-coding RNAs; however, more recent studies suggest that intergenic regions 
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may possess functional small-length coding regions not normally annotated in gene 
prediction programs (232–234).  Microbial genomes have now been found to contain 
functional elements like insertion sequences (transposable elements) contained within 
the intergenic regions (235,236). 
 
 
 
Figure 4.18. Functional classification of Internal PAO1 genes 
Internal PAO1 genes with >2 FC expression are listed by functional annotation as a percentage of 
annotation occurrence within the data set. “Hypothetical, unclassified, unknown” genes were excluded 
from this analysis.  
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4.7.1. Interpretation and analysis of functional gene groups 
 
Of the wealth of information provided by the microarray, expression data sets were 
categorised according to two different strategies. Firstly, genes were grouped by 
functional relationship using the Database for Annotation, Visualization and Integrated 
Discovery (DAVID) v6.7.  DAVID is a web-based tool that provides functional annotation 
for large lists of genes and enriches for biological themes and function-related gene 
groups (156,237). DAVID uses gene ontology (GO)-based functional similarity and 
assigns genes to “functional group” based either on the number of genes within a 
category or by the EASE-score. The DAVID EASE score estimates the likelihood that a 
functional association is due to random chance (the higher the score the more 
functionally enriched (i.e. the more likely the biological significance of the gene group; 
(156,237)). After assigning genes to a category and ranking enrichment by EASE score, 
individual genes within that group are further assigned a Benjamini score. Benjamini 
scores are adjusted p-values used to indicate “false discovery in the case of weak 
induction” meaning that, like the p-value, the lower the Benjamini score the more 
likely a “true” expression signal (238). The statistical scores (EASE, p-value, and 
Benjamini), in combination, are used to assess the likelihood each gene within a 
“cluster” is involved in a similar biological mechanism.  
A secondary approach to classifying the P. aeruginosa response to 
macrophages was to match expression data with corresponding operons listed in the 
Database of prOkaryotic OpeRons (DOOR) v2.0 (239). In bacteria, genes are generally 
organised into operons or co-regulated clusters. Genes within the same operon 
typically share only small intergenic regions and are co-expressed. DOOR uses known 
operon characteristics to computationally predict operons consisting of conserved 
hypothetical genes.  
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4.7.2. Functional Clustering using DAVID 
 
Because of the numerous genes in each data set, computationally predicted gene 
groups which share functional relationships could be diluted. Essentially, the more that 
genes which share only a small degree of functional congruence are “forced” into a 
functional relationship, the more generic a functional annotation becomes. To avoid 
this scenario, functional clustering was performed using only genes that possessed ≥3 
FC expression over Control PAO1.  The narrowed data set clustering was performed 
under the highest stringency settings in DAVID. 
Using the Internal PAO1-up-regulated data set as an example, of the >5,500 
open reading frames (ORF) and intergenic regions of internalised P. aeruginosa 
screened, 1856 unique sequences had an Benajmini scores ≤0.05 (Benjamini method 
to control false discovery rate; (238)). Of those, 30 ORFs were up-regulated >3 FC and 
assessed for functional clustering using DAVID. Only 19 of the 30 ORFs were identified 
as belonging to an enriched functional gene group cluster. This is in part due to the fact 
that over 27.8% of the genes present in the Internal PAO1-up-regulated Top Table are 
currently not annotated in the Pseudomonas Genome Database and are otherwise 
characterised as being “hypothetical” (Appendix Table A2.1).  
The five functional clusters detected in the Internal PAO1-up-regulated data set 
represent DNA repair proteins, heat shock / chaperone proteins, RNA polymerase 
sigma factors, the LexA repressor, and alginate regulation (Table 4.4). The two down-
regulated functional clusters include pyocin-S2, cellular detoxification processes, and 
fimbrial assembly proteins (Table 4.5). However, these down-regulated groups 
possessed low enrichment (EASE) scores <0.1 suggesting that the functional 
association between genes within those clusters were more likely to have been due to 
chance. 
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Table 4.4. Internal PAO1 up-regulated functional clustering  
 
ID Gene Name 
  1 DNA Repair/Response to DNA Damage Stimulus Enrichment Score: 1.69 
 
PA3007_lexA_at LexA repressor P_Value  Benjamini 
 
PA3617_recA_at Protein RecA 2.20E-03 2.10E-02 
 
PA0404_i_at Putative Holliday junction resolvase 
  2 Heat shock/Chaperone/Protein folding Enrichment Score: 1.03 
 
PA4386_groES_at 10 kDa chaperone P_Value  Benjamini 
 
PA4760_dnaJ_at Chaperone protein DnaJ 6.20E-05 7.40E-03 
 
PA4761_dnaK_at Chaperone protein DnaK 
  
 
PA1596_htpG_at Chaperone protein HtpG 
  
 
PA4762_grpE_at Heat shock protein GrpE 
  3 Transcription Regulation Enrichment Score: 0.46 
 
PA3161_himD_at Integration host factor subunit beta P_Value  Benjamini 
 
PA3007_lexA_at LexA repressor 8.40E-02 4.70E-01 
 
PA3006_at transcriptional regulator PsrA 
  
 
PA3815_at Iron-sulfur cluster assembly transcription factor  
  
 
PA3617_recA_at Protein RecA 
  
 
PA0762_algU_at RNA polymerase sigma-H factor 
  
 
PA0376_rpoH_at RNA polymerase sigma-32 factor 
4 Metal Ion Binding 
 
Enrichment Score: 0.43 
 
PA4760_dnaJ_at Chaperone protein DnaJ P_Value  Benjamini 
 
PA1847_at Fe/S biogenesis protein NfuA 6.40E-01 9.70E-01 
 
PA0665_at Iron-sulfur cluster insertion protein ErpA 
  
 
PA3524_gloA1_at Lactoylglutathione lyase 
  
 
PA3815_at Iron-sulfur cluster assembly transcription factor  
 
 
PA0376_rpoH_at RNA polymerase sigma-32 factor 
  5 Cell Membrane 
 
Enrichment Score: 0.1 
 
PA3665_at Putative threonine efflux protein P_Value  Benjamini 
 
PA0763_mucA_at Sigma factor AlgU negative regulatory protein 6.40E-01 9.70E-01 
 
PA2604_at Conserved hypothetical protein  
 
 
  
   
 
 
Table 4.5. Internal PAO1 down-regulated functional clustering.  
 
ID Gene Name 
  1 Metal Ion Binding 
   
 
PA1155_nrdB_at Ribonucleotide reductase, beta subunit Enrichment Score: 0.1 
 
PA3520_at Hypothetical protein  P_Value  Benjamini 
 
PA1150_pys2_at Pyocin-S2 7.70E-01 1.00E+00 
 
PA1317_cyoA_at Ubiquinol oxidase subunit 2 
  2 ATP Binding 
   
 
PA1393_cysC_at Adenylyl-sulfate kinase Enrichment Score: 0.03 
 
PA1386_at Serine O-acetyltransferase 8.60E-01 1.00E+00 
 
PA4526_pilB_at Type 4 fimbrial assembly protein PilB 
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In general, according to the functional clusters, internalised P. aeruginosa 
looked to have down-regulated systems required for cell detoxification, DNA repair 
and motility (potential virulence factor) and up-regulated systems that repress the SOS 
DNA damage response (LexA repressor), protect from protein aggregates, and signal 
alginate production. Unlike previously conducted in vitro microarray studies with P. 
aeruginosa and H2O2 (Table 4.1), the catalase genes, katA, katB and katE, did not make 
the 3 fold up-regulation cut off for any of the samples. Indeed, all three catalase genes 
were down-regulated (-1.25, -1.99, and -1.53 respectively) which is in direct contrast to 
published microarray data sets that attempted to model the infectious state by in vitro 
challenge with H2O2 (78,197–199).  This result was particularly surprising given that 
KatA has on several accounts been characterised as essential for resistance, 
osmoprotection and virulence (111,112).   
 
4.7.3. Expression data cross referenced with annotated operons in DOOR  
 
Overall the functional clusters above did not indicate many clear themes in up- or 
down-regulation despite key genes like the lexA SOS repressor and algU alginate sigma 
factor being represented in functionally-related gene groups. This may be a 
consequence of overly stringent parameters for recognition of altered expression; 
however, relaxing these parameters substantially rapidly leads to overwhelming levels 
of confounding “noise” in the data sets.  
 As an alternative approach to infer biological relevance from the microarray 
data, a cross referencing of the expression data with predicted operons in the DOOR 
database was performed. Using this approach, inclusive of all expression values 
regardless of fold change, it was revealed that operons or predicted operons were up-
regulated intermittently throughout the genome (some regions with as many as 110 
contiguous genes). Additionally, many of the transcription regulators of the identified 
operons (as defined by Galán-Vásquez et al (2011; (240)) were also found to be up-
regulated. In contrast to the functional clustering by DAVID, identification of 
transcription regulators and their associated operons using the DOOR database 
seemed to paint a clearer picture of the overall response by the bacterium. Table 4.6 
lists the transcriptional regulators and their target(s) as found in the Internal PAO1 up-
regulated data set. 
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Table 4.6. Transcriptional regulators (Internal PAO1 up-regulated data set) 
Gene 
Locusa 
Fold 
Changeb 
Gene 
Namec 
Mode of 
Regulationd 
Target 
Genee 
Functional Node
f
 
PA0763   4.166582 mucA - algU Alginate biosynthesis 
PA3161   4.002567 ihf* + lasR Quorum sensing 
   + alg Alginate biosynthesis 
PA3006   3.984992 psrA - psrA Quorum sensing 
   + rpoS Virulence factors 
PA0762   3.740111 algU + algU Alginate biosynthesis 
   + algR Biofilm formation 
   - fleQ Motility 
PA3351   3.502843 flgM - fliA Motility 
PA5471   3.024732 - + mexZ Antibiotic resistance 
PA2432   2.032438 bexR + PA1204 Virulence factors 
PA4227   1.917573 pchR + pchA-F Virulence factors 
   - pchR Virulence factors 
PA0037   1.912055 trpI - trpI Amino acid metabolism 
PA4957   1.659655 psdR - dppA-F Amino acid metabolism 
PA0424   1.635855 mexR - mexAB Antibiotic resistance 
PA4764   1.379012 fur* - gbuR Alginate biosynthesis 
   - pvdS Iron metabolism 
   - pchR Virulence factors 
PA5255   1.295903 algQ - lasR Quorum sensing  
   + rpoD Virulence factors 
PA4726   1.284049 cbrB + cbrB Amino acid formation 
PA5261   1.260185 algR* + algR Biofilm formation 
   + alg Alginate biosynthesis 
PA5253   1.215288 algR3 - rhlR Quorum sensing  
PA0779   1.214325 - - fhpR Antibiotic resistance 
   + fhp  
PA3583   1.204159 glpR - glpDFKT  
PA2020   1.195608 mexZ - mexXY Antibiotic resistance  
PA2388   1.161584 fpvR - pvdS Iron metabolism 
PA1455   1.122992 fliA + fliCLMN Motility 
*Top ten most influencing regulators (Galán-Vásquez et al 2011) 
a Gene Locus, P. aeruginosa genes found in the Internal PAO1 up-regulated data set that Galán-Vásquez 
et al identified as transcriptional regulators.      
b Fold Change, expression as determined when compared to Control PAO1 
c Gene Name, as annotated by www.pseudomonas.com  
d Mode of Regulation, acts in a positive (+) or negative (-) feedback effector 
e Target Gene, example of a common gene know to be the target of regulation  
f Functional Node, the associated biological function theme of the effector 
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4.7.3.1. The three P’s: Pyocin, Pyoverdine, and Pyochelin 
 
Pyocin, a secreted bacteriocin of P. aeruginosa, is synthesised when the bacterium 
encounters the presence of a mutagen such as ROS produced by macrophages (241). 
Pyocin activation is also known to be a result of  increased recA expression or the 
pyocin activator prtN (242,243). In the event of pyocin production, the bacterium 
would also be expected to up-regulate the imm2 immunity protein rendering P. 
aeruginosa protected from its own bacteriocin production (243,244). However, despite 
both recA and prtN being up-regulated greater than two-fold in both Internal PAO1 
and External PAO1 data sets, the entire R- and F- type pyocin ORFs, including the imm2 
and S-type pyocin-containing operons, were either down-regulated or not present in 
the expression data. 
 Also known to be involved in pathogenesis are the siderophores pyoverdine 
(Pvd) and pyochelin (Pch) which aid in sequestering iron from the intercellular iron 
stores in eukaryotic hosts for the purpose of supporting bacterial growth (245,246).  
Although Pvd has been characterised as critical for P. aeruginosa virulence, literature 
suggests that the role of the Pch siderophore in pathogenesis is minor due to the 
observations that Pvd-deficient Pch-rich strains exhibit significantly slowed growth 
under iron limitation, but not vice versa (247–249).  Relative to the Control PAO1, the 
Pvd synthesis genes (PA0610 – PA0650) were repressed in the Internal PAO1, and 
conversely activated in the External PAO1.  In contrast, the pchA-F, flanking operons, 
including the pch receptor fptA and regulator pchR, were activated in the Internal 
PAO1.  
Both the macrophage and bacteria would be expected to produce siderophores 
and compete with one another for limited iron to support growth (250,251). The host 
protects its iron by a) storing it intracellularly, and b) binding it to transferrin which can 
also be used to transport the iron (i) to other host cells, or (ii) into the phagosome 
where excess amounts of iron contribute to oxidative stress and antimicrobial activity 
via Fenton chemistry (252–256).  
The observation that Pvd was up-regulated in the External PAO1 sample is 
consistent with previous literature, as Pvd has been shown to acquire iron bound to 
transferrin during extracellular transport between macrophages (247,257–260). It also 
makes sense that P. aeruginosa might prefer to not activate Pvd within the phagosome 
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due to Fenton chemistry (rapid iron-catalysed H2O2 conversion to the hydroxyl radical). 
However, there is little in the literature that would indicate an intracellular role for 
Pch, although extracellularly produced Pch has been shown to be able to enter the 
cytoplasm (261). In in vitro pulmonary infection studies, Pch has also been implicated 
in intensifying oxidative damage leading to endothelial cell damage  (262–264). 
Secondary siderophores of Pseudomonas species have previously been implicated in 
both defensive and virulence roles unrelated to their iron-transporting capabilities 
(265–267), and it may be that the apparent up-regulation of Pch production in the 
Internal PAO1 cells reflects a similar role for Pch in this infection model. 
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4.7.3.2. Oxidoreductases activated by phagocytosis 
 
One of the original aims of this project was to identify NQORs that may play a role in 
protecting P. aeruginosa from oxidative stress, in particular ROS generated during 
phagocytosis by immunocompetent cells such as macrophages. Firstly, and irrespective 
of operons, two hypothetical NQORs were significantly down-regulated in Internal 
PAO1: PA0804 (-1. 79 FC) and PA2580 (-3.02 FC) with B-scores of 5.8 and 5.6 
respectively. PA2580 shares 56% protein sequence identity with the MdaB homologue 
in H. pylori which has been shown to confer oxidative stress resistance in the animal 
model (128). In our over-expression studies (Figure 4.14B), we also demonstrated that 
PA2580 had potential to defend against H2O2, however, the native enzyme does not 
appear to be playing such a role in the in vivo cell culture infection model.  
In contrast, twelve hypothetical NQORs (characterised and putative) were 
activated in the Internal PAO1 when compared to Control PAO1. Genes were 
determined to be a putative NQOR by shared protein identity (as defined in Chapter 3) 
and by annotation at www.pseudomonas.com which indicated a cytoplasmic location 
for the gene product and an NAD(P)H dependency. Additionally, 5 of these redox 
genes (PA2906, PA3208, PA3567, PA4975, and PA4986) were found to be within 
predicted operon regions and to possess B-scores greater than 2 (log odds that the 
gene is differentially expressed where a score of >0 = 50% probability and >3 = 95%, 
Table 4.7). Furthermore, several of the operons were surrounded by contiguous 
sequences of up-regulated genes. Although many of these adjacent genes are 
hypothetical, it is possible that these operon-adjacent sequences may be biologically 
related as bacterial genomes often have functionally related genes located near each 
other.  
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Table 4.7. Putative NQORs identified in Internal PAO1 up-regulated operons 
 
Gene Fold Change B-score Description 
1 
PA0017 - PA0022 expressed (incl. 2 operons)   
PA0023_qor_at 1.72 1.68 Quinone-oxidoreductase 
PA0024 - PA0038 expressed (incl. 5 operons)   
2 
PA0438_codB_at 1.16 -2.68   
PA0439_at 1.2 -3.36 Dihydropyrimidine dehydrogenase 
PA0440_at 1.25 -2.98 Putative NQOR 
3 
PA1028  N.D.   Quinone-oxidoreductase 
PA1029_at 2.73 12.45  Hypothetical 
PA1030_at 1.18 -4.51  Hypothetical 
4 
PA1259-PA1265 expressed (incl. 1 operon)   
PA1266_at 2.56 4.33 Putative NQOR 
PA1267_at 1.74 2.03 Hypothetical 
PA1268_at 1.76 2.50 Hypothetical 
PA1269 – PA1284 expressed (incl. 1 operon)   
5 
PA1600_at 1.39 2.96 Putative cytochrome c 
PA1601_at 1.42 4.40 Putative aldehyde dehydrogenase 
PA1602_at 1.31 0.44 Putative NQOR 
6 
PA2354_at 1.42 1.15 Putative transcriptional regulator 
PA2355_at 1.3 -2.23 Putative FMNH2-dependent monooxygenase 
PA2356_msuD_at 1.69 2.29 Methanesulfonate sulfonatase MsuD 
PA2357_msuE_at 1.54 1.38 NADH-dependent FMN reductase MsuE 
7 
PA2900 - PA 2901 expressed (incl. 1 operon)   
PA2903_cobJ_at 1.49 1.03  Precorrin-3 methylase CobJ 
PA2904_cobI_at 1.56 -0.99  Precorrin-2 C(20)-methyltransferase 
PA2905_cobH_at 1.77 2.01  Precorrin-8X methylmutase 
PA2906_at 2.01 4.83 Putative NQOR 
PA2907 - PA2915 expressed (incl. 2 operons)   
8 
PA3192 - PA3207 expressed (incl. 4 operons)   
PA3208_at 2.05 4.12 Putative NQOR 
PA3209_at 1.23 -3.74 Hypothetical 
PA3211 - PA 3222 expressed (incl. 2 operons)   
9 
PA3552 - PA3566 expressed (incl. 3 operons)   
PA3566_at 1.51 3.02 Hypothetical 
PA3567_at 2.03 5.42 Putative NQOR 
PA3568 - PA3569 expressed      
10 
PA3746 - PA3767 expressed (incl. 2 operons)   
PA3768_at 2.5 -0.75 Putative NQOR 
PA3769 - PA3807 expressed (incl. 10 operons)   
11 
PA4888_at 1.29 -4.26 Acyl-CoA delta-9-desaturase, DesB 
PA4889_at 1.87 -3.66 Putative NQOR 
PA4890 - PA4896 expressed (incl. 1 operon)   
12 
PA4942 - PA4974 expressed (incl. 6 operons)   
PA4975_at 1.62 4.10  NAD(P)H quinone oxidoreductase 
PA4976_aspC_at 2.25 3.31  Arginine:Pyruvate Transamina, AruH 
PA4977_at 2.16 1.80  Hypothetical 
PA4978_at 2.04 3.33  Hypothetical 
PA4979_at 1.98 5.86  Putative acyl-CoA dehydrogenase 
PA4980_at 1.65 6.63  Putative enoyl-CoA hydratase/isomerase 
PA4981 - PA4985 expressed (incl. 1 operon)   
PA4986_at 2.28 7.38 Putative NQOR 
PA4987_at 2.07 9.31 Putative transcriptional regulator 
PA4988 - PA4996 expressed (incl. 3 operons)   
Key 
Operons with putative NQOR. 
NQOR in bold. 
Contiguous genes  
up-regulated and adjacent to 
NQOR-containing operon 
Not expressed in data set 
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4.7.3.3. Miscellaneous observations 
 
P. aeruginosa is capable of hydrogen cyanide biosynthesis during infection, and 
cyanide, a potent inhibitor of mitochondrial respiration, is known to promote or even 
be a dominant factor in host cell killing (58,268). During human infection it may be that 
cyanide production impacts macrophages more severely than neutrophils because 
macrophages have more mitochondria (62,269,270). Although Internal PAO1 did not 
appear to activate the cyanide biosynthesis operon (hcnABC), the rhdA-psd (PA4954-
4957) operon, which catalyses detoxification of cyanide (271,272), was strongly up-
regulated (PA4954 = +2.16 FC,  and PA4957 = +1.66 FC  with B-scores of 8 and 4 
respectively).  
 P. aeruginosa cyanide production has been shown to be  controlled by several 
regulators such as the master regulator AlgR (240,273) and the anaerobic regulator 
ANR (274), but most importantly by the quorum-sensing regulators LasR and RhlR 
(274,275). As with cyanide biosynthesis, quorum sensing can also play an important 
role in virulence. Two operons known to be activated by quorum-sensing stood out in 
the Internal PAO1 data set. These two operons (PA2301-PA2305 and PA3327-PA3333) 
have both been predicted to be activated during quorum sensing (276), and both 
contain non-ribosomal peptide synthetase (NRPS) genes. NPRSs are large enzymes that 
condense amino acids in an assembly-line fashion and are of great interest due their 
role in generating a wide variety of biologically active metabolites (277). Though no 
literature could be found identifying the end-product of the PA3327 NRPS, one 
reference was found that indicated preliminary characterisation of the PA2302 NRPS. A 
doctoral thesis by Yang Fan (2008, National University of Singapore) proposed that the 
PA2302 NRPS is required to make an endogenous quorum sensing inhibitor 
“tentatively named PAi”, which provides feedback regulation of quorum sensing (278). 
In support of the “PAi” inhibitor and the up-regulation of the PA2302 NRPS, the 
quorum sensing regulators LasR and RhlR were both down-regulated in the Internal 
PAO1 data set (-1.82 FC and -1.20 respectively and both with B-scores of 2). 
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4.8. Discussion 
 
In the 1995 edition of Free Radicals in Biology and Medicine, there was a call to  
move away from studies of isolated cell systems under non-physiological  conditions 
and  from reactions involving constituent H2O2 in media (70). Although our study is in 
some respects still an “isolated cell system”, we believe it was a positive step in the 
direction of studying complex P. aeruginosa interactions by simulating an in vivo 
environment for the bacteria, as opposed to in vitro H2O2 stimulation in nutrient rich 
culture media as per the studies noted in Table 4.1. We were interested primarily in 
how P. aeruginosa tolerates the oxidative stress encountered during initial contact 
with the innate immune system; therefore we used established macrophage-like cell 
lines to optimise a flow cytometry-based method for infecting and recovering viable P. 
aeruginosa that had been engulfed by macrophages. We used this method to recover 
P. aeruginosa RNA from viable bacteria located within the macrophage, a technical 
accomplishment that has not previously been reported. 
A robust and reliable infection model was developed by successive evaluation 
of different parameters of infection, selecting the optimal cell line to be infected, a 
suitable bacterial MOI, whether the bacteria should be opsonised, and the influence 
that different macrophage stimuli (IFN-ɣ) have on uptake of P. aeruginosa. This 
advancement in P. aeruginosa specific techniques also allowed for the ability to assess 
multiple gene deletion and over-expression strain variants in parallel, by employing 
flow cytometry-base enumeration in a high-throughput style assay.  
 Using the in vivo cell culture infection model, the NQOR over-expression 
strains, ∆katA + pSX::PA2580 and ∆katA + pSX::PA0949, were found to be less sensitive 
to challenge by activated macrophages than controls. This observation was similar to 
results obtained by H2O2 challenge in vitro (Figure 4.15 and section 3.3.2.2). Similarly 
the NZ clinical isolates ARL1079, ARL1205, and ARL1236 demonstrated no substantial 
difference in survival when compared to wild type PAO1 in the in vivo cell culture 
model. This too reflected observations made with in vitro H2O2 challenge. Moreover, 
while some of the NQOR over-expression strains or clinical isolates behaved in a 
consistent fashion in each of the two stress models, some additional NQOR over-
expressing or gene-deleted strains that did not appear to differ from the wild type 
control in in vitro H2O2 assays did now exhibit a phenotypic difference from wild type 
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in response to macrophage challenge. For example, in Chapter 3, the P. aeruginosa 
mutant ∆1204 did not exhibit heightened sensitivity to H2O2 even in the absence of the 
katA gene. Conversely, in the in vivo cell culture model, the ∆1204 mutant exhibited 
sensitivity to macrophage infection with katA present. Although any conclusions to be 
drawn at this stage remain highly speculative, these minor phenotypic differences may 
suggest that PA1204 does play some role in virulence. Additional support for this 
hypothesis comes from the observation that the bexR virulence regulator was also up-
regulated in the Internal PAO1 cells, as BexR is known to positively regulate the 1204 
operon (240,279). 
In similar fashion, the ∆katA gene deletion both conferred sensitivity to in vitro 
H2O2 challenge (section 3.3.2.1) as well as reducing survival to macrophage infection 
(section 4.5.2). Surprisingly however, during the transcriptional response of wild type 
PAO1 to macrophage infection (section 4.7.2) levels of katA gene expression as well as 
katB and katE were down-regulated. One possible explanation for the down-regulation 
these catalases, as well as other known virulence factors such as pyoverdine and the 
mdaB orthologue (PA2580), is that P. aeruginosa has previously been found to turn off 
essential virulence determinants in the presence of various stressors thus accelerating 
its rate of hypermutability (280–282). It has also been reported that mutants lacking 
DNA mismatch repair systems, such as mutS, mutL, or uvrD, significantly contribute to 
hypermutation rates found at high frequencies in chronic lung infections 
(280,283,284). The down-regulation of virulence determinants such as katABE, 
PA2580, and pyoverdine related genes supports the idea that P. aeruginosa is reducing 
its defence mechanisms in the presence of macrophages to (possibly) enhance the rate 
of mutation accumulation.  
An alternative argument is that the down-regulation of katABE and pyoverdine 
may be indicative of a need by P. aeruginosa to restrict intracellular iron which, as a 
result, limits the ability of the bacteria to produce these catalases. The reason for this 
may be that the bacterial cell can “cope” with superoxide and H2O2 challenge, but 
generation of substantial levels of the particularly damaging hydroxyl radical species 
from H2O2 via iron-catalysed Fenton chemistry might prove too much of a challenge for 
bacterial survival. This argument is not entirely inconsistent with the “hypermutation” 
hypothesis presented in the previous paragraph; rather it is just suggesting that P. 
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aeruginosa may need to carefully control the balance between too little and too much 
stress-induced damage. 
 Furthermore, several studies have indicated that P. aeruginosa may antagonise 
macrophages into producing ROS for extended periods thus manipulating the 
inflammatory response and promoting programed cell death of the macrophage and 
other phagocytic cells (285–288). It has been well documented that P. aeruginosa 
stimulates the production of ROS by activating the host cell’s NADH oxidase (285,286). 
In early stages of infection, oxidant/antioxidant balance is maintained by the host, 
however, under prolonged exposure to ROS and the resulting ROS accumulation, the 
host cell undergoes bacteria-induced apoptosis (287–290). It may therefore be that P. 
aeruginosa-generated ROS in tandem with the down-regulation of DNA repair systems 
has a two-fold value in that (i) it allows for accumulation of mutations that may bring 
about beneficial evolutionary changes, and (ii) it provides a means to counter the 
macrophage defence.  
  Based on the literature, it also seems possible that P. aeruginosa may be 
preferentially driving uptake of itself by macrophages over neutrophils. Neutrophils, 
recruited by the presence of P. aeruginosa  (291), have been shown to be essential for 
P. aeruginosa  clearance during infection (292). However, P. aeruginosa can interfere 
with neutrophil function by (i) masking complement deposition through the 
production of the Psl protein during initial attachment (293–295), (ii) reducing P. 
aeruginosa uptake and ROS production by neutrophils (17), and (iii) stimulating 
neutrophil apoptosis (92,211,296–298).  Additionally, mannose receptors of 
macrophages facilitate phagocytosis of  non-opsonized P. aeruginosa (299) and Psl is 
mannose-rich (300) which brings the story full circle to P. aeruginosa preferentially 
driving uptake of itself by macrophages.   
To further elucidate the biological significant of the NQOR PA1204, and other 
NQORs, or the down-regulation of katABE in Internal PAO1 would require not only 
quantitative RT-PCR validation of expression levels, but also an extensive investigation 
into the influence of P. aeruginosa population density and macrophage exposure time. 
As demonstrated in section 4.4.4, P. aeruginosa in the presence of murine 
macrophages behaved differently at MOIs of 50 and 100 indicating that population 
density influences the bacterial response. Levels of survival of PAO1 also changed with 
time. These are important points to consider given that all of the studies in Table 4.1 
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used different P. aeruginosa densities and H2O2 challenge times for their 
investigations, and consequently saw quite different transcriptional profiles. It is well 
established that P. aeruginosa intercellular communication is critical to virulence and 
that quorum sensing not only senses, but also induces major cellular responses to 
variations in population density (2,301).  A model to elucidate virulence factors 
contributing to pathogenesis should be able to take this into consideration and with 
the in vivo cell culture model described above, it is now possible to investigate 
individual parameters side-by-side in a high-throughput fashion.  
While these experiments demonstrated the potential for screening P. 
aeruginosa strains en masse, robust validation through further in vitro and in vivo 
study should be undertaken before concluding any biological roles for specific NQORs 
as unexpected results emerged intermittently throughout optimisation. Fluctuations in 
the bacterial incubation times could easily distort the number of viable bacteria 
recovered, as could undesirable temperature changes during the extensive wash steps 
for the phagosomal maturation studies. Additionally the changing “age” of the 
immortal RAW-264.7 macrophages made it difficult to directly compare bacteria cell 
numbers between experiments conducted at distant time periods. Variations of cell 
density and the culture surface of the immortal RAW-264.7 cells also influenced the 
survival of PAO1. Although we aimed to accommodate many of these factors by 
instigating rigorously timed protocols, we cannot rule out that unaccounted 
fluctuations in some or all of these parameters may have influenced some results.  
We also hypothesise that this in vivo cell culture method will likely have 
sufficient flexibility to be adapted for evaluation of the P. aeruginosa response to 
challenge by other phagocytic cell types (e.g. neutrophils) as well as to gauge, in 
tandem, how the eukaryotic host acts in response to the bacteria by employing 
established immunological assays.  For example, this system might be used to address 
how common chemical signals in the innate immunological response, like IFN-ɣ, can 
affect the P. aeruginosa regulation of virulence factors via the transcriptional response. 
This may enable further elucidation of how pathogens like P. aeruginosa control 
production of specific virulence factors and identification of key genes involved in 
pathogenesis. Thus, this infection model has many more potential applications, 
ranging from pure microbiological studies to investigations into immunological and 
host-pathogen interactions.  
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One of the major caveats of studying bacterial transcription, however, is the 
instability and rapid half-life of microbial mRNAs (188–192). With bacteria able 
degrade expressed RNA in less than 2 minutes, and sometimes even mid translation, 
methods of prokaryotic RNA isolation need to be highly efficient to prevent artefactual 
results (191,193–195). Thus, any global microbial expression profiles should be 
carefully considered in the context of their specific experimental design.  
In future applications it could be advantageous to incorporate the use of 
primary cell lines into this infection model. Although we chose to use the established 
RAW-264.7 cell line for the optimisation of this infection model, the heterogeneous 
nature of primary cells would most likely have yielded a different transcriptional 
response by P. aeruginosa. Additionally, had sufficient funds been available, it would 
have been interesting to compare the transcriptional response to primary cell lines by 
PAO1 over time, to address questions raised in section 4.4.3 where internalised PAO1 
viability changed with time (Figure 4.7 and Figure 4.8). It would also be interesting to 
compare the laboratory strain PAO1 with the response of NZ clinical isolates to gauge 
how appropriate the universal PAO1 type strain is for modelling infection. However, 
microarray analysis is expensive and financial constraints precluded us from 
considering more than three samples (Internal PAO1, External PAO1, and Control 
PAO1) to address the basic question of “what genes do P. aeruginosa activate when 
engulfed by macrophages?” 
Whilst our study perhaps raises more questions than answers in regard to the 
P. aeruginosa response to challenge by activated macrophages, it nonetheless 
provides a clear benchmark for future studies to be compared against, as well as 
contributing a valuable tool with many potential applications for understanding of the 
greater biological process encompassing the establishment of disease. Current trends 
in immunology appear to be leaning towards interdisciplinary approaches to 
investigating host-pathogen interactions; and although macrophage responses to 
bacterial pathogens have been well characterised, the advancement of microarray 
technology and the addition of in vivo cell culture models now lend valuable insights as 
to how the bacteria are in turn responding to macrophages. This is a different 
approach to the same question and perhaps reflects a changing approach to 
identification of therapeutic targets for bacterial infections like those caused by P. 
aeruginosa; instead of exploiting immune cell strategies to prevent disease, we are 
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now investigating what the bacteria do to cause disease. Now that more 
experimentation is being conducted on whole systems (addressing the interaction of 
overlapping virulence systems), therapeutic target identification is moving beyond 
isolated constituent stressor studies to a more complex map of crosstalk between host 
and pathogen in the presence of  naturally produced immune compounds in 
physiologically correct conditions.  
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Chapter 5: Activation of the nitro-chloromethyl benzindoline 
prodrug SN 26438 by P. aeruginosa NfsB-like NQOR: A novel 
enzyme-prodrug pairing for GDEPT  
 
5.1. Introduction 
 
During the course of this research we had the opportunity to test the reductive 
capacity of P. aeruginosa NQORs with a promising next-generation prodrug for GDEPT, 
and saw some very promising preliminary results. GDEPT is a targeted approach to 
cancer management wherein tumour cells are sensitised, via selective transgene 
delivery, to a systemically administered prodrug. An important characteristic of GDEPT 
is the bystander effect – the ability of activated prodrugs to transport either passively 
or actively out of the cell of origin, and into neighbouring, non-transfected cells – as 
this provides an elegant solution to the unavoidable issue of low cell transfection rates, 
historically viewed as a key limitation of GDEPT (302,303). Studies employing prodrugs 
with high bystander effects have demonstrated that significant tumour reduction can 
occur when less than 0.1% of the tumour population expresses the activating enzyme 
(304).  
Therapeutic genes employed in GDEPT are typically non-human in origin, to 
minimise the potential for prodrug activation by endogenous enzymes in healthy 
tissue. Two of the most widely studied genes for GDEPT are herpes simplex virus 
thymidine kinase, which was evaluated in phase III clinical trials in combination with 
the nucleotide analogue prodrug ganciclovir (305); and cytosine deaminase from 
Escherichia coli, which has undergone phase I trial in combination with another 
nucleoside analogue prodrug, 5-fluorocytosine (306). These systems enjoy the 
substantial benefit  that their prodrugs have each achieved independent clinical utility; 
but they also suffer from the limitations that only actively dividing cells are targeted, 
that their activated metabolites inhibit replication of viral vectors, and that their cell-
to-cell bystander effects are largely dependent on functional gap junctions, which 
many tumour cells lack (302,303,307,308). 
A third enzyme-prodrug combination that has undergone clinical evaluation for 
GDEPT is E. coli NfsB in combination with CB1954 [5-(aziridin-1-yl)-2,4-
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dinitrobenzamide] (309,310). Successive 2-electron reductions of CB1954 by NfsB 
results in activated metabolites that can freely diffuse across cell membranes, forming 
adducts and DNA crosslinks and inducing apoptosis in both replicating and quiescent 
tumour cells (136,141,142,311). Nonetheless, results of the clinical trials were 
somewhat equivocal – while there was evidence for mild anti-tumour effects, CB1954 
was also discovered to exhibit dose-limiting hepatotoxicity (309,310). In our on-going 
research we have sought to improve the efficacy of CB1954 GDEPT through 
identification and engineering of nitroreductases that exhibit superior activity to NfsB 
at concentrations of prodrug that are attainable in vivo (139,312,313). However, we 
have also found that CB1954 exhibits a relatively modest bystander effect relative to 
other nitro-aromatic prodrugs with potential utility in GDEPT (this work; (314)). Thus, 
we have a strong interest in identifying superior prodrug substrates for nitroreductase 
GDEPT. 
One class of bioreductive prodrugs that is of particular interest is the nitro-
chloromethylbenzindolines (nitro-CBIs). These compounds were designed as hypoxia-
activated prodrugs of the cyclopropylindoline anti-tumour antibiotics, exemplified by 
CC-1065 and duocarmycin SA (315). The potent cytotoxicity of the cyclopropylindoline 
antibiotics is due to sequence selective alkylation of the N3 of adenine in the minor 
groove of DNA, generating ‘stealth lesions’ that are not easily repaired (Figure 5.1; 
(315,316)). The nitro-CBI prodrug analogues of these molecules were generated by 
replacing the key phenol of the alkylating subunit with nitro functional groups, which 
can be enzymatically reduced to the DNA alkylating form (317).  As the primary human 
reductases for these molecules act via successive one electron steps, the presence of 
molecular oxygen establishes a futile reduction cycle, conferring hypoxia-selectivity to 
these prodrugs. In contrast, NfsB reduces these molecules via oxygen-independent 
two electron steps, yielding end metabolites that exhibit substantial bystander effects 
(317). This finding suggests that the nitro-CBIs are likely to prove effective prodrugs for 
nitroreductase GDEPT. 
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Figure 5.1. Nitro-CBIs 
(A) The structure of two anti-tumour antibiotics and their nitro-CBI analogue, SN 26438. (B) Metabolic 
activation of nitro-CBI and (C) computer modelling example of the interaction between the activated 
nitro-CBI metabolite with adenine. Panels (B) and (C) were reproduced with permission from Dr Sophie 
Syddall’s University of Auckland PhD thesis (318). 
 
 
 
 
 
 
Duocarmycin SA 
 
CC-1065 
N
Cl
O
N
H
NO2
O
NMe2
SN 26438 
A 
B C 
121 
 
This chapter describes our efforts to identify a suitable nitroreductase to 
partner with the lead nitro-CBI prodrug, SN 26438 (also known as nitro-CBI-DEI (317)). 
Preliminary tests indicated that some of the P. aeruginosa NQORs were substantially 
more active with SN 26438 than the previous “gold standard” GDEPT nitroreductase, E. 
coli NfsB, and thus the P. aeruginosa NQORs became the focus of a detailed 
characterisation of their activities with SN 26438 as well as CB1954. 
 
 
 
Figure 5.2. Schematic representation of the bystander effect 
Prodrug activated by a single NQOR-expressing tumour cell can be transported either passively or 
actively out of the cell of origin, and into neighbouring, non-transfected cells, killing them also.  
 
 
5.2. Objectives 
 
 Screen the P. aeruginosa NQORs for activity with CB1954 and SN 26438 relative to 
E. coli NfsA and NfsB.  
 Develop a novel model system for measuring the ability of preferred NQOR 
candidates to sensitise human tumour cells to prodrugs without a requirement for 
generating stably transfected cell lines. 
 Determine the bystander effect of SN 26438 in combination with a preferred NQOR 
activating enzyme. 
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5.3. Results 
 
5.3.1. Evaluation of  CB1954 and SN 26438-reducing activity of candidate  P. 
aeruginosa NQORs through their ability to induce the E. coli SOS response 
 
Candidate P. aeruginosa NQORs were selected on the basis of shared amino acid 
sequence identity (>25 %) to previously identified E. coli nitroreductase candidates 
(139) and evaluated for CB1954 and SN 26434-reducing activity (Table 5.1). A total of 
12 P. aeruginosa NQOR candidates were selected whose E. coli orthologues had 
previously demonstrated various degrees of reductive capacity when partnered with 
the prodrug CB1954 (13).  
 
Table 5.1. Candidate P. aeruginosa NQOR Selection 
Gene Locus % Identitya 
Closest E. coli 
Orthologue 
Accession Numberb 
PA5190 25 NfsB AP_001223 
PA2357 26 SsuE AAC_74023 
PA0949 39 WrbA AP_001635 
PA2580 64 MdaB AP_003578 
PA3223 45 AzoR AP_002037 
PA1962 41 AzoR AP_002037 
PA3208 42 Ydja AP_002384 
PA1204 45 YieF AP_004074 
PA4975 37 KefF AP_000710 
PA0853 27 YcaK AP_001531 
PA1225 33 YcaK AP_001531 
PA2932 52 NemA AP_002272 
AShared amino acid identity with the closest E. coli ortholouge. 
B
E. coli gene orthologue accession number in the NCBI protein databases. 
 
 
The selected P. aeruginosa NQOR candidates were first tested for the ability to 
activate CB1954 or SN 26438 in E. coli SOS assays, a quantitative system for measuring 
the level of activation of genotoxic prodrugs that was previously developed in the 
Ackerley laboratory. The basis of the SOS assay for prodrug activation is that candidate 
nitroreductases are cloned into a custom-made expression plasmid (pUCX) and over-
expressed in a strain of E. coli that has a lacZ reporter gene under control of an SOS 
responsive promoter (139). This strain is then challenged with sub-lethal levels of a 
nitro-aromatic prodrug, whereupon nitroreductase activity causes DNA damage, 
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inducing the SOS (DNA damage repair) response and production of quantifiable levels 
of β-galactosidase. For this study the E. coli reporter strain SOS-R2 was used. Whereas 
the first generation reporter strain SOS-R1 had the native nfsA and nfsB genes deleted 
from its genome (139), SOS-R2 contains additional nemA and azoR gene deletions also, 
as these have been shown to lower background levels of prodrug activation in empty 
plasmid control cells (Dr David Ackerley, personal communication). Moreover, SOS-R2 
also contains a tolC gene deletion. TolC is an outer membrane pore protein that plays a 
key role in expulsion of some toxins and xenobiotics from the cell (319), and tolC gene 
deletion has previously been found to improve SOS assay sensitivity for some 
genotoxic compounds (320,321). Additionally, work by former lab member, Dr Gareth 
Prosser, exetensively demonstrated that NQORs from a wide range of bacterial hosts 
are expressed at similar levels in the E. coli SOS-R2 strain (139,322). 
The selected P. aeruginosa NQOR genes were individually cloned into pUCX and 
over-expressed in SOS-R2 alongside an empty plasmid negative control and E. coli nfsA 
and nfsB positive controls (Figure 5.3). When these strains were challenged with 20 
μM CB1954, both the NfsA and NfsB positive control strains exhibited a strong (ca. 5-
fold) increase in SOS response relative to the empty plasmid control strain (as 
measured in Miller Units of LacZ activity resulting from induction of the lacZ reporter 
gene; Figure 5.4A). However, of the P. aeruginosa NQOR candidates, only PA5190 
exhibited a small (2.3-fold) increase in SOS activity with CB1954. In contrast, challenge 
with 5 μM SN 26438 generated a strong (> 11-fold) induction of SOS response by two 
P. aeruginosa NQORs as well as E. coli NfsB and NfsA (Figure 5.4B).   
 
Figure 5.3. Expression of P. aeruginosa NQORs in SOS-R2 
SDS-PAGE analysis of expression levels of P. aerufinosa NQORs from pUCX in SOS-R2. Samples for 
electrophoresis were taken from a single replicate at 3 hours of IPTG induced expression. Samples were 
normalised for cell density (OD600) prior to gel loading.  
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Figure 5.4. CB1954- and SN 26438-induced SOS responses from NQOR over-
expression strains of SOS-R2 
NQOR over-expressing strains of SOS-R2 were   challenged with (A) 20 M CB1954 or (B) 5 M SN 26438 
and levels of SOS induction (-galactosidase Miller Units) were measured as described in section 2.18. 
Data is the mean of three independent experiments each carried out in duplicate and error bars are ± 1 
standard deviation. A black dotted line represents the SOS activity of the empty vector control. 
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5.3.2. In vitro kinetics of purified NQOR candidates with CB1954 and SN 26438 
 
Candidate NQORs were cloned into pET28a+ vector, expressed as N-terminal His6 
tagged proteins in E. coli strain BL21, and purified by nickel affinity chromatography (as 
described in section 2.8). Apparent steady-state kinetic parameters were measured 
with CB1954 as substrate as previously reported (139), following the appearance of 
reduced hydroxylamine metabolites spectrophotometrically at 420 nm where both the 
2- and 4-hydroxylamine end-products have equal absorbance (ε= 1200 M-1cm-1 (323)). 
Unfortunately it was not possible to derive any meaningful kinetic data for SN 26438 
due to insufficient solubility in aqueous solution.  
Consistent with the SOS data, the only P. aeruginosa NQOR to exhibit 
measurable activity with CB1954 in these biochemical assays was PA5190. As a point of 
comparison the kinetic parameters were also calculated for NfsB, and it was shown 
that the E. coli enzyme was almost two orders of magnitude more efficient (in terms of 
specificity constant; kcat/Km) with CB1954 as substrate than its P. aeruginosa orthologue 
(Table 5.2).  
 
Table 5.2. Steady-state kinetics of purified enzymes for CB1954 reduction 
Enzyme Km (M)
a kcat (s
-1)a kcat/Km(M
-1s-1) 
NfsB 3600 ± 1100 26 ± 5 7,200 
PA5190 580 ± 210 0.057 ±0.006  98 
PA2357 N.D.b N.D.b N.D.b 
a Apparent steady state kinetic parameters of the corresponding purified recombinant (His6-tagged) 
enzymes for CB1954 reduction. Data was derived from three individual experiments, and errors are ± 1 
standard deviation. 
b 
No activity detectable by spectroscopic methods. 
 
 
5.3.3. Sensitisation of the human colon carcinoma cell line HCT-116 to CB1954 
and SN 26438 using the in vivo cell culture IC50 assay 
 
To evaluate the relative efficacy of the P. aeruginosa NQORs to sensitizing human 
tumour cells to SN 26438 and CB1954, we first sought to create human colon 
carcinoma (HCT-116) cell lines stably transfected with genes encoding these enzymes. 
However, previous experiences in transfecting HCT-116 have indicated that only a 
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subset of NQORs would likely be stably expressed as shown in Figure 5.5 (Gareth 
Prosser, personal communication and (139,313)). As an alternative means to test 
cytotoxicity of activated prodrug towards human cells, a bacteria delivered enzyme 
prodrug therapy (BDEPT) assay was developed, using E. coli as a vector; such that 
NQORs would be stably maintained and expressed by E. coli, which would also provide 
a source of reduced NAD(P)H cofactor, but allow activated prodrug to diffuse out and 
kill human cells in co-culture. 
 
 
 
Figure 5.5. Expression of E. coli NTRs in the human colon carcinoma cell line HCT-116 
as detected by V5 readthrough western blotting 
(A) HCT-116 cells were transiently transfected with F527-V5 vectors containing each of the E. coli NTRs 
fused to a C-terminal V5 epitope downstream of an amber stop codon. Cells were concurrently infected 
with Tag-On-Demand™ Suppressor Supernatant (which enables transient readthrough of the amber stop 
codon and hence V5 epitope expression), lysed, and immunoblotted for induced C-terminal V5 tag. A 40 
kDa V5 tag positive control is included in the right hand lane. (B) HCT-116 cells engineered for stable 
expression of each of the E. coli NQOR candidates were infected, lysed, immunoblotted and quantified 
as in (A). Note that although all NQORs were expressed transiently to some degree, YcdI and YcaK were 
not detectable in stably transfected cell lines. (C) Representative β-actin loading control (in this instance 
derived from the transiently transfected immunoblot in (A)). This figure was reproduced from Dr Gareth 
Prosser’s Victoria University of Wellington PhD thesis with permission by Dr David Ackerley (322).   
 
 
The BDEPT cytotoxicity model towards human cancer cell lines was modified 
from a previously described protocol wherein purified NQOR proteins were applied to 
cell culture in media supplemented with prodrug, NADPH and FMN cofactor (138). 
Rather than applying purified enzymes, we sought to examine the relative potency of 
candidate NQORs for sensitising HCT-116 human carcinoma cell lines through direct 
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application of NQOR-expressing E. coli to the human cells. This adaptation was 
necessary to overcome (i) difficult-to-purify proteins (313), (ii) unstably expressed 
NQORs in transfected human cell lines, and (iii) prodrug solubility limitations. 
In short, overnight cultures of NQOR over-expressing strains of E. coli were 
initially prepared as for the SOS assays (section 2.18).  The day cultures of E. coli and 
prodrug titrations were, however, prepared in complete cell culture media (CMEM) 
(without antibiotics, section 2.11) rather than LB amended with ampicillin, IPTG and 
glucose as for the SOS assays. Mixtures of E. coli were mixed 1:1 with 2-fold dilutions 
of CB1954 or SN 26438 in CMEM (final concentration ranges of 25 M to 400 M and 
0.06 M to 15 M, respectively, together with a no prodrug control), and applied to a 
monolayer of cultured human carcinoma HCT-116 cells. The mixtures were then 
incubated for 4 h at 37 oC, 5% CO2, after which the HCT-116 cells were washed several 
times to remove all bacteria and prodrug. They were then allowed to recover from 
prodrug-induced DNA damage for 48 h, at which point cellular respiration was 
measured by formazan production from metabolised tetrazolium compound at OD490 
and IC50 values (the concentration of prodrug required to inhibit growth of HCT-116 to 
50 % of unchallenged control levels) were calculated (Figure 5.5).  
 
 
Figure 5.6. Summary of modified BDEPT assay 
The potency of over-expressed NQOR-prodrug partnerships was evaluated by challenging human HCT-
116 cells for 4 h with a 1:1 mixture of NQOR-expressing E. coli and 2-fold dilutions of prodrug at 37 oC, 
5% CO2. After washing to remove residual bacteria and prodrug, the HCT-116 cells were allowed to 
recover from prodrug-induced DNA damage for 48 h at 37 oC, 5% CO2. Irreversible DNA damage 
generated by the NQOR-activated prodrug was measured by the cell population’s inability to metabolise 
the tetrazolium compound and enabled calculation of the IC50 for that NQOR-prodrug combination.  
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Surprisingly, PA2357 was nearly as effective as NfsB at promoting CB1954-
mediated killing of the HCT-116 cells (IC50 of 74.95 M vs. 57 M, respectively; Figure 
5.6A) even though it did not evoke an E. coli SOS response to CB1954 challenge and 
purified PA2357 enzyme was not seen to metabolise CB1954 at detectable levels in 
vitro. PA3223 (AzoR orthologue), PA2580 (MdaB orthologue), and PA2932 (NemA 
orthologue) enzymes also promoted intermediate levels of killing of HCT-116 cells (IC50 
of 185 M, 196 M, and 212 M respectively, vs. 436 M for the empty plasmid 
control strain) which had not previously been demonstrated with the SOS or protein 
assays. However, no P. aeruginosa NQORs exhibited improved activity over E. coli NfsB 
or NfsA in this BDEPT model.  
The results of the BDEPT assays with SN 26438 as substrate were more 
consistent with the previous SOS assays. The P. aeruginosa NQORs PA2357 and PA5190 
were able to metabolise the SN 26438 prodrug and exhibited significantly improved 
prodrug-mediated killing of the HCT-116 cells, yielding IC50 values of 0.65 and 0.13 M 
respectively (relative to 7.8 M for the empty plasmid control). Furthermore, PA5190 
showed significantly improved activity (p< 0.005) over NfsB in the BDEPT assay (Figure 
5.6B).  One technical point of difference from the CB1954 BDEPT was that SN 26438 
BDEPT was assessed using the NQOR-expression E. coli strain ∆6KO, not SOSR-2. The 
∆6KO strain, like SOSR-2 lacks the native NQORs nfsA and nfsB but also azoR, yieF, 
ycaK, and mdaB; perhaps more importantly, the ∆6KO still possesses an intact tolC 
outer membrane pore gene. When the BDEPT assay was performed for SN 26438 using 
SOS-R2 cells, little difference in cytotoxicity was observed for the different NQOR-
expressing strains, perhaps indicating that TolC plays an important role in efflux of the 
activated metabolite of SN 26438 from the bacterial cell (a factor that would have less 
impact on relative E. coli SOS measurements than in the BDEPT assay, which mandates 
a bystander effect to transfer the activated metabolite from the bacterial to the 
human tumour cells).   
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Figure 5.7. HCT-116 human carcinoma BDEPT model assay 
HCT-116 colorectal carcinoma cells were challenged with 1:1 mixtures of (A) SOSR-2 NQOR over-
expressing strains mixed with 25 M – 400 M CB1954, or (B) ∆6KO strains with 0.06 M – 15 M SN 
26438. HCT-116 cells were challenged for 4 h and then recovered for 48 h before application of CellTiter 
96® AQueous One Solution (Promega) as described in section 2.19. Data is the mean of three independent 
experiments each carried out in duplicate and error bars are ± 1 standard deviation.  
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5.3.4. Determination of the P. aeruginosa candidate PA5190 bystander effect 
using three dimensional cell culture assays 
 
Both NfsB and PA5190 had previously been cloned into the Gateway™ compatible 
expression plasmid F527-V5puro and transfected into HCT-116 cells. Although previous 
studies have indicated that, for unknown reasons, only a minority of bacterial 
nitroreductases are retained and expressed stably using this system, successful stable 
transfection for both NfsB and PA5190 was confirmed by concurrent cell infection with 
TAG stop suppressor adenovirus (Tag-On-Demand™, Invitrogen) which produced an 
immunoreactive V5 epitope at the C-terminus of TAG-terminated NQORs detectable 
by Western Blot (318). Densitometry of the V5 bands in each lane indicated that 
PA5190 was expressed at approximately 1.4 times the level of NfsB in these cells (318). 
As we were fortunate to have obtained confirmed stable cell lines expressing NfsB and 
PA5190, these two NQORs were carried forward to be examined using direct in vitro 
IC50 and 3D cell culture (bystander effect) assays.  These studies were performed by Dr 
Sophie Syddall and our collaborators at the Auckland Cancer Society Research Centre, 
University of Auckland. 
The sensitivity of each of the transfected HCT-116 cell lines towards SN 26438 
and CB1954 was evaluated using an in vitro proliferation assay as described by Wilson 
et al (324).  Briefly, replicate monolayers of NfsB, PA5190 or non-transfected HCT-116 
cells were evaluated for cell proliferation 5 days post 4-18 h exposure to a range of 
concentrations of either CB1954 or SN 26438. The IC50 of each cell line was determined 
as the concentration of prodrug required to inhibit cell growth by 50% relative to 
untreated controls and was reported as the mean value of two independent 
experiments (Table 5.3).  
Consistent with the results of the BDEPT assay, transfected HCT-116 cell lines 
over-expressing PA5190 exhibited a greater than 50-fold sensitivity to SN 26438 
compared to wild-type controls (Table 5.3). PA5190 also conferred a >6-fold increased 
sensitivity relative to NfsB, again reflecting the trend seen in the BDEPT assay. The 
results of CB1954 challenge were likewise consistent with the earlier assays in that the 
NfsB expressing cells were >7-fold more sensitive than wild-type controls, but PA5190 
was relatively inactive.   
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Table 5.3. Fold decrease in IC50 of transfected HCT-116 cells
*† 
Compound PA5190 NfsB 
SN 26438 >50 8 
CB1954 2 3000 
* IC50 is reported as the fold decrease in IC50 for transfected cell lines relative to wild-type HCT-116 and 
NQOR- expressing HCT-116 
†
 This data was reproduced with permission from Dr Sophie Syddall’s University of Auckland PhD thesis 
(318). 
 
 
 
The PA5190-SN 26438 partnership was subsequently analysed for ability to 
generate a bystander effect and thereby kill neighbouring non-transfected cells (Figure 
5.1). This was investigated through use of a mixed 3D cell culture model as described 
by Wilson et al (324). In short, multicellular layers (MCL) of HCT-116 cells were grown 
on collagen-coated inserts before being challenged with SN 26438. The MCLs were 
initially seeded with a randomly-distributed mixture of cells which were 10% NQOR-
expressing (activators) and 90% wild type HCT-116 (targets). To determine the 
bystander effect efficiency (BEE) post-challenge, MCLs were disrupted into a single cell 
suspension, counted, and then plated in duplicate on to petri dishes to enumerate 
survival of activators and targets. Determination of clonogenic survival was achieved 
by treating one of the two petri-dish replicates with puromycin (which the NQOR-
transfected cells are resistant to, owing to the presence of a puromycin resistance 
cassette in the F527-V5puro plasmid backbone, while the target cells are sensitive). The 
difference in surviving cell numbers between puromycin treated and untreated cells 
were used to calculate the clonogenic survival of activators and targets, and therefore 
the BEE of SN 26438 in tandem with either NfsB or PA5190.  
Surprisingly there was a large difference between the bystander activity 
demonstrated with NfsB-dependent activation of SN 26438 and PA5190-dependent 
activation (Figure 5.7). Whereas the minority population of PA5190 activator cells was 
able to almost completely eradicate the target HCT-116 population, the NfsB activators 
did not appear to exhibit a particularly strong bystander effect (an exact value for the 
NfsB BEE was unable to be calculated as the co-culture cell killing did not fall below 
10%, precluding the C10 from being estimated accurately). It should be noted that 
despite both experiments being seeded with 10% activator cells, a higher population of 
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activator cells was ultimately found to be present in the PA5190 co-culture (9%) 
relative to the NfsB co-culture (3.7%). However, the difference in bystander effect 
cannot be attributed solely to this, as in a preliminary experiment a very high BEE value 
(84%) was also achieved for the PA5190 cells when only 2.6% activator cells were 
present (results not shown).  
 
 
 
  
Figure 5.8. Enhanced bystander efficiency of SN 26438 was demonstrated with 
PA5190-dependent activation compared to NfsB 
(A) Representative bystander efficiency graphs of NfsB-activation of SN 26438. Values are from one MCL 
experiment. The prodrug concentration for 10% survival (C10) of target cells (wild-type HCT-116) grown 
without activators (T), targets in co-culture (Tc) and 100% activators (NQOR-expressing cells) in co-
culture (Ac) were determined by interpolation. (B) IC50 and MCL data from SN 26438 activation. As per 
Table 5.3 the IC50 is the concentration of prodrug required to inhibit growth by 50% of untreated 
controls following 18 h drug exposure and regrowth for 5 days. BEE bystander effect efficiency 
calculates the drug bystander effect: ((LogC10T-LogC10TC)/(LogC10T-LogC10Ac)). The T/Ac ratio is the 
ratio of the average target C10 divided by the activator C10. This data was reproduced with permission 
from Dr Sophie Syddall’s University of Auckland PhD thesis (318). 
 
  
NfsB     PA5109 
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5.4. Discussion 
 
The primary objective of this work was to identify novel enzymes for GDEPT with 
greater efficacy than the “gold standard” E. coli enzyme NfsB, which under clinical 
evaluation with CB1954 was found to have a Km ca. 100-fold higher than the 
concentration achievable in patient serum at the maximum tolerated dose (8,9). 
Although PA5190, the most active of the purified P. aeruginosa enzymes, did possess a 
lower apparent Km for CB1954 than NfsB as measured at 250 µM NADH, it also had a 
very low apparent kcat, and was nearly two orders of magnitude less efficient than NfsB 
in terms of kcat/Km. This low level of activity at a purified enzyme level was mirrored by 
only low levels of SOS induction observed in SOS-R2 when the PA5190 over-expressing 
strain was challenged with 20 µM CB1954, and by an inability to substantially sensitise 
HCT-116 cells to this prodrug. In contrast, PA5190 metabolism of the lead nitro-CBI 
prodrug candidate SN 26438 consistently yielded high levels of activity in all assay 
systems tested.  
Our laboratory has previously demonstrated the effectiveness of the -
galactosidase based-SOS assay for rapid evaluation of novel nitroreductase candidates 
for GDEPT (139,312).  As an additional method for evaluating the ability of P. 
aeruginosa-derived NQORs to bioreductively activate CB1954 and SN 26438 prodrugs, 
we developed a BDEPT model to evaluate killing of human tumour cells by different 
NQOR over-expressing E. coli strains. This model appears to be able to detect low 
levels of activation of CB1954 and SN 26438 that could not be detected in the SOS 
assay or by spectrophotometric analysis of purified enzyme activities. Most 
significantly, exposure of HCT-116 cells to E. coli over-expressing PA5190 or PA2357 
resulted in > 26 fold and >13 fold heightened sensitivity to SN 26438, respectively, 
relative to E. coli over-expressing NfsB.  PA2357 also conferred substantially 
heightened sensitivity to CB1954 in this model, which was unexpected given that this 
enzyme had not appeared to metabolise CB1954 in either E. coli SOS or purified 
protein assays.  It is unclear whether recombinant His6 tagged PA2357 enzyme might 
have been inactive in its purified form, therefore limiting kinetic assessment, or if over-
expression of PA2357 might have sensitised HCT-116 cells to CB1954 by some indirect 
process. Irrespective, as even the BDEPT assay did not indicate any of the P. 
aeruginosa NQORs to be superior to either NfsA or NfsB from E. coli in terms of 
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CB1954 metabolism, this anomaly was not pursued further. In the BDEPT assays, SN 
26438 was also more toxic to HCT-116 than CB1954. While this heightened toxicity is a 
very attractive feature, what is more important is the therapeutic index of the drug, 
which will derive from the maximum tolerated dose that can be administered to 
patients and the maximum concentration that can then be achieved at tumour cells. 
To the best of our knowledge these measurements have not yet been made in humans 
using SN 26438. Thus, exactly how promising SN26438 might prove for next generation 
clinical GDEPT therapies remains to be determined. 
Despite the unexplained result with PA2357 and CB1954, we believe that the 
BDEPT assay is a very useful tool for evaluating enzyme-prodrug combinations for their 
potential use in GDEPT by circumventing experimental difficulties with protein 
purification and stable transfection of human cell lines. It may also provide greater 
sensitivity than the SOS assay in its ability to indicate intermediate levels of prodrug 
metabolism, however, rigorous evaluation is still required to determine whether this is 
truly the case. Nonetheless, the BDEPT assay is certainly capable of generating highly 
reproducible results; but one caveat is that day-to-day values appeared to be directly 
proportional to the “age” of the HCT-116 cell line, although variations between same-
day replicates were low. Because of this, experimental replicates are recommended to 
be completed with HCT-116 cells lines within 1-3 passages of one another.  
Whereas none of the P. aeruginosa NQORs were superior to E. coli NfsA or NfsB 
in terms of CB1954 metabolism, the BDEPT assay indicated that PA5190 was 
substantially more active than these enzymes with SN 26438, and this enzyme prodrug 
combination was taken forward for further analysis alongside NfsB in stably 
transfected HCT-116 cell lines.  Further indication of PA5190 as a superior enzyme for 
SN 26438 GDEPT applications was evident in multi-cell layered cultures when PA5190 
was found to mediate the strongest bystander effect hitherto seen in this system (Dr 
Adam Patterson, personal communication). In contrast, NfsB bystander activity was 
insufficiently strong to enable a BEE value to be calculated, as the co-culture cell killing 
did not fall below 10%. This is one of the first experiments to compare two different 
enzymes for bystander activity with the same prodrug, and to our knowledge, the first 
time that this has led to profoundly different bystander outcomes. It is possible that 
PA5190 may metabolise SN 26438 to a different end-metabolite but further 
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investigation of this would require liquid chromatography-mass spectrophotometry to 
define the products generated by each enzyme.   
Importantly, the disparity between PA5190 and NfsB cell killing due to SN 
26438 activation in the in vitro IC50 proliferation assay and in the 3D multi-cell layers 
highlights the importance of evaluating potential GDEPT enzyme-prodrug partnerships 
in a 3D bystander model, as low cell density may dramatically underestimate cytotoxic 
potential. We surmise that the cytotoxic potential of high-bystander prodrugs may be 
dramatically underestimated in low cell density proliferation assays due to washout 
and loss in the media. 
SN 26438 may exhibit a uniquely strong bystander effect due to its lipophilicity 
and also its target specificity. Reduced nitro-CBI very selectively binds adenine in the 
minor groove of DNA (Figure 5.1BC; (317,318)); whereas CB1954-derived DNA lesions 
appear to result from  non-selective crosslinking (141,142). The lipophilicity and target 
specificity of SN 26438 may contribute to the enhanced bystander efficiency relative to 
CB1954 (314) in that (i) its reduced metabolites are more easily transferred through 
lipid membrane of neighbouring cells, and that (ii) fewer targets exist per cell, which 
may enable the activated SN 26438 metabolite to diffuse through more cells before 
ultimately reacting with DNA.  Further experimentation will be required to determine if 
this result is unique to SN 26438, and also to evaluate the potential of the PA5190 / SN 
26438 combination for GDEPT in in vivo models. 
In other work we have shown that the SOS assay can not only be used for 
enzyme evaluation, but also to improve the catalytic activation of genotoxic prodrug 
substrates by directed evolution (in this case, a process of random mutation applied at 
a single gene level followed by cloning of gene variants into a plasmid vector and 
screening for improved activity in a suitable bacterial reporter strain; (313)). Using the 
SOS assay along with targeted mutagenesis of PA5190, there is potential to further 
improve SN 26438 metabolism by generating PA5190 variants with enhanced catalytic 
efficiency.  This could possibly prove effective in enhancing the potency of the PA5190 
/ SN 26438 paradigm for GDEPT.  
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Chapter 6: Summary, conclusions, and future directions 
 
6.1. Research Motivation and Summary 
 
P. aeruginosa is a genetically flexible and innately drug-resistant pathogen (2).  The 
ability of this organism to adapt and defend itself in the face of a complex and 
constantly changing host immune response make  P. aeruginosa a major contributor to 
increased morbidity and mortality  rates from nosocomial infections (3). As such, there 
is much interest in characterising the P. aeruginosa defence mechanisms that allow the 
organism to persist and establish disease.  As a one of the first major antibacterial 
assaults by the immune systems includes a concentrated release of H2O2, oxidative 
stress tolerance by P. aeruginosa is an area of intense research interest.  
 Soluble quinone oxidoreductases have been identified in mammals as being 
involved in oxidative stress protection; and although NQORs have been found to be 
widely distributed throughout bacterial species (119), few bacterial NQORs have been 
shown to definitively confer a protective phenotype under oxidative stress. One 
bacterium where such a phenotype was observed, however, was in another species of 
Pseudomonas, P. putida. Based on this previous work, the research described in this 
thesis initially aimed to characterise an in vitro biological role for H2O2 protection by 
NQORs in P. aeruginosa.  
  Additionally, and in appreciation of the complex interaction between the host 
and pathogen in disease establishment, an in vivo cell culture infection model was 
developed. This sought to investigate the role of P. aeruginosa NQORs in a more 
multifaceted scenario whereby the bacteria would not only be exposed to the H2O2 but 
also to other naturally released immune effector signals by murine macrophages. We 
also used this method to recover P. aeruginosa RNA from viable bacteria located 
within the macrophage, a technical accomplishment that has not previously been 
reported. In doing so, we were able to address the potential of NQORs at the level of a 
global transcriptional response.  
 In a separate but related aspect of NQOR activity, the simultaneous two 
electron reductive mechanism of P. aeruginosa NQORs was explored in the therapeutic 
application of GDEPT. A very attractive emerging focus in the field is the use of oxygen-
independent (i.e. divalent) reductase enzymes to leverage the wealth of compounds 
137 
 
that have been developed to target tumour hypoxia (146),  and thereby expand their 
utility to aerobic tumour tissues also. Whereas the ‘gold standard’ enzyme E. coli NfsB 
has been found to have a very high kcat with nitro-aromatic prodrugs in general, it also 
tends to have a very high (millimolar) Km, and this is likely to limit its clinical utility in 
GDEPT, with most plausible prodrug partners only able to achieve micromolar 
concentrations in patient serum (138,139,146,318,322). In an effort to improve on this 
we tested the ability of the P. aeruginosa NQORs to activate the lead nitro-CBI prodrug 
candidate SN 26438, and found that the P. aeruginosa NfsB orthologue (PA5190) was 
greatly superior to E. coli NfsB in terms of its ability to generate cytotoxic damage and 
a high bystander effect; both very important features for GDEPT. 
 
6.2. Key Findings  
 
6.2.1. Potential functional redundancy of NQORS in P. aeruginosa  
 
In an early funding application for this study it was hypothesised that P. aeruginosa 
would possess two soluble quinone oxidoreductase enzymes with antioxidant 
potential, based on homology searches and the general state of knowledge at the 
time. Instead, we ultimately identified 10 unique genes with >25% amino acid identity 
to quinone oxidoreductases that have been proposed to play such a role in other 
bacteria. Using a select subset of NQORs with either (i) shared identity with P. putida 
ChrR; (ii) shared identity with mammalian DT-diaphorase; or (iii) shared identity with E. 
coli WrbA, MdaB, or NfsB, we found that gene-deletion or over-expression of a single 
NQOR candidate was unlikely to yield a measurable H2O2 tolerance phenotype in P. 
aeruginosa due to a masking effect from the potent KatA catalase. Moreover, 
comparison of NQOR over-expression phenotypes in a katA-null P. aeruginosa strain 
with the effect of over-expressing the same NQORs in a ΔchrR strain of P. putida 
indicated that functional redundancy of the numerous endogenous P. aeruginosa 
NQORs might also mask the contribution of any individual NQOR candidate to 
oxidative stress resistance. If nothing else, these findings collectively indicate that our 
original goal of finding inhibitors to individual NQORs as a means of combating the 
beneficial effect of these hypothesised virulence factors was probably misguided, and 
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for numerous reasons specific NQOR inhibitors would be unlikely to provide any 
therapeutic benefit in combatting P. aeruginosa infections.  
 
6.2.2. Development of an in vivo cell culture infection model for the isolation 
of RNA from viable, macrophage-engulfed P. aeruginosa 
 
We next reported development of an in vivo cell culture infection model whereby 
viable, macrophage-engulfed P. aeruginosa are recovered for analysis. Recovering P. 
aeruginosa RNA from viable bacteria located within the macrophage is a technical 
accomplishment that has not previously been reported. Additionally, this method 
demonstrated the potential for evaluating the survival of P. aeruginosa strains en 
masse, using flow cytometry to achieve rapid enumeration.  
 In one of its first applications the in vivo cell culture model revealed a 
phenotype for both NQOR gene-deleted and over-expression strains, suggesting that 
the ∆PA1204 mutant was more sensitive to macrophage engulfment than wild type 
PAO1. Given the lack of sensitivity of this mutant strain to H2O2 challenge in vitro it 
may be that PA1204 plays some additional role beyond just H2O2 tolerance in enabling 
the bacterium to withstand phagocytosis.  Other results were more consistent with our 
observations in vitro, with over-expressed PA2580 and PA0949 both promoting H2O2 
tolerance in vitro (albeit only in the katA-null background) and enhancing survival in 
the macrophage model. Overall, the results from this aspect of the study strongly 
support the investigation of P. aeruginosa oxidation stress mechanisms in a more 
complex model rather than an isolated cell system whereby the stressor is a 
constituent in nutrient rich growth media.  
 
6.2.3. The transcriptional response of macrophage-engulfed P. aeruginosa 
 
The in vivo cell culture model also enabled microarray analysis of macrophage-
engulfed P. aeruginosa. First, and perhaps most importantly, the transcriptional 
response of macrophage-engulfed P. aeruginosa indicated that the bacteria are, to a 
degree, turning off or down-regulating mechanisms that are “known” virulence 
factors. For example, katA catalase, an accepted virulence determinant (111,325) was 
downregulated in Internal PAO1, as were katB and katE, various DNA repair genes, and 
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the putative NQOR PA2580, which we had shown to promote survival in the presence 
of macrophages. The idea that P. aeruginosa intentionally down-regulates “protective” 
processes is consistent with previous research themes that indicate P. aeruginosa may 
adapt to assault from the immune system by enhancing its own mutation rate  to 
generate variants with enhanced long term survival (281,283,284,326). However, it is 
also possible to get too much of a bad thing, and it may be that down-regulation of the 
pyoverdine genes in the macrophage internalised cells was not just a consequence of 
iron no longer being required to power the (down-regulated) KatA/B/E catalases, but 
an attempt by the cell to limit iron uptake because of the danger of generating 
hydroxyl radicals via Fenton reactions. 
  The transcriptional response also indicated that several potential NQORs were 
up-regulated in the presence of macrophages. As our primary motivation to do 
microarray analysis was to facilitate a more targeted investigation of NQOR function, 
this outcome may facilitate future NQOR characterisation studies.  
 
6.2.4. PA5190 and SN 26438: A novel enzyme-prodrug pairing for GDEPT 
 
In a different aspect of this study we explored the potential of P. aeruginosa NQORs to 
activate hypoxia targeting anti-cancer prodrugs, thereby exploiting the simultaneous 
two electron transfer mechanism noted in Chapter 3. We found that a lead prodrug 
candidate, SN 26438, became highly toxic upon reduction by the P. aeruginosa NQOR 
PA5190; and that its activation by PA5190 was >26 fold more cytotoxic to cultured 
HCT-116 cells in a BDEPT-like model system than activation by the “gold standard” E. 
coli NfsB.  Perhaps the most exciting aspect of this work was the demonstration that 
PA5190 activation of SN 26438 produced an unprecedented bystander effect, with 
94% transfer of toxicity from a minority of PA5190-expressing cells to the target cell 
population in a 3D multi-cell layer model. This was one of the first times two different 
NQORs have been compared for bystander efficiency using the same prodrug. The 
profoundly different bystander outcomes – whatever the reason for it – further 
implicates PA5190 as a superior enzyme for GDEPT therapy and suggests that a more 
thorough investigation into this novel enzyme-prodrug partnership is warranted. 
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6.3. Future Directions 
 
6.3.1. Elucidating a biological role for P. aeruginosa NQORs 
 
As noted in section 6.2.1 we believe that there may be functional redundancy between 
the numerous P. aeruginosa NQORs. Although gene-deletion efforts proved 
troublesome in this study, a next step to elucidating an H2O2 -protective role for 
NQORs in P. aeruginosa could be to generate multiple NQOR deletions in a single 
(presumably also katA-null) strain. If the bacterium can tolerate a single gene-deletion 
through functional redundancy, it may be that generating and evaluating different 
combinations of multi-NQOR knockouts would prove this redundancy. Again, assessing 
the viability of multiple isogenic deletion strains in parallel would be greatly facilitated 
by the flow cytometry protocols developed in this work.  
Additionally, just because an NQOR deletion does not result in an H2O2 -
sensitive growth phenotype it does not mean that other important cellular processes 
are not being perturbed. Phenotype MicroArrays, developed by Biolog Inc. which can 
screen over 2000 phenotypes (http://www.biolog.com), are a powerful tool that could 
aid in understanding the implications of NQOR deletion on a wide range of metabolic 
processes relevant to P. aeruginosa survival. The Biolog Inc. system has the capacity to 
screen for acquired metabolic and chemical sensitivities under a vast array of culture 
conditions. Demonstrating the potential of the Phenotype MicroArray , several studies 
have uncovered new phenotypes using this assay (327–330). Although the Phenotype 
MicroArray may require a significant financial investment, in the long run, especially 
with redundant enzyme activities, the “shot-gun” approach may prove to be the most 
cost-effective and time-effective approach to understanding P. aeruginosa NQOR 
function.  
 
6.3.2. Implications of research for P. aeruginosa therapy 
 
Intravenous iron treatment has been well documented as increasing the risk of 
bacterial infection in the clinical setting (331). In P. aeruginosa, a known virulence 
determinant, pyoverdine, aids in sequestering iron from the intercellular iron stores in 
eukaryotic hosts for the purpose of supporting bacterial growth (245,246); therefore 
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the siderophore has been investigated as a potential therapeutic target (332–336). The 
approaches to siderophore-based therapy encompass (i) iron starvation, (ii) inhibition 
of siderophore biosynthesis, and (iii) siderophore-mediated drug delivery (336). To 
date, the only method to show promising antimicrobial activity in animal models is 
siderophore-mediated drug delivery, whereby a siderophore is used to selectively 
deliver either a toxic heavy metal or a conjugated cytotoxin to the bacterial cells 
(336,337).  
In our analysis of the transcriptional response of P. aeruginosa to phagocytosis 
we found that 8 of the 11 pyoverdine synthesis genes were uniformly down-regulated. 
This may suggest that the efforts to combat bacterial infection by iron starvation or 
inhibition of siderophore biosynthesis are misguided. We speculate that pyoverdine 
biosynthesis may prove disadvantageous to macrophage-internalised bacteria as the 
increase in pyoverdine would increase iron levels and therefore increase H2O2 
sensitivity via Fenton chemistry. Although perhaps now moving beyond the bounds of 
reasonable speculation, it would be interesting indeed if inhalation of iron-loaded 
pyoverdine as an aerosol were to prove beneficial in combatting P. aeruginosa airway 
infections. 
 A more reasonable strategy for treating P. aeruginosa infection may come from 
our findings that novel anti-cancer prodrugs can be activated by endogenous P. 
aeruginosa NQORs, in particular PA5190 and PA2357 (MsuE).  Findings from our 
microarray analysis suggest that DNA damage repair mechanisms are being down-
regulated during infection. We hypothesise that this is to increase hypermutation, 
however, we may be able to take advantage of P. aeruginosa “letting its guard down” 
by administering DNA damaging prodrugs. For example, both PA5190 and PA2357 
were able to metabolise SN 26438 effectively. Obviously the profound bystander effect 
of the activated drug would not be advantageous for therapy as cytotoxic transfer 
would also debilitate the host cell and most likely have a negative impact on total 
bacterial clearance. However, the Ackerley lab has been investigating other 
nitroaromatic prodrugs that completely lack a bystander effect, which should enable 
ablation of the bacterial cell without harm to the eukaryote host; and indeed, there 
are several examples of genotoxic prodrug antibiotics in current use that employ this 
mechanism (338–341). PA5190 and PA2357 have yet to be tested with these nil-
bystander prodrugs, but the SOS assay is ideally suited for conducting such an analysis. 
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Moreover, according to our microarray data, PA2357 is upregulated at the same time 
that DNA repair systems are down-regulated in the phagocytosed bacteria, and may 
therefore prove a particularly suitable target. Better yet, if a nil-bystander prodrug can 
be identified that is activated by multiple P. aeruginosa NQORs, then this would greatly 
diminish the chances of drug resistance arising during therapy.   
 
6.4. Concluding Remarks 
 
In addition to the primary research findings, a number of novel experimental protocols 
were developed during this study that have already demonstrated relevance to the 
wider scientific community and have been applied to other research endeavours. The 
first of these is the rapid flow cytometry protocol for enumeration of viable bacterial 
cells, which was used to assess the antimicrobial effect of novel fabrics. This data, 
together with supporting confocal micrographs for qualitative effect, has led to a co-
authored manuscript that is currently in preparation (CK Fonseca-Paris, LK Green, JH 
Johnston, DF Ackerley. Antimicrobial properties of palladium nanoparticles 
immobilized in and onto wool fibres. Intended for submission to Journal of 
Biotechnology). 
 A second co-authored manuscript has arisen from use of the BDEPT model to 
assess the cytotoxic potential of evolved variants of FRase I (Flavin Reductase I from 
Vibrio fischeri) in GDEPT, as FRase I, for an unknown reason, was unable to be stably 
expressed in HCT-116 cells. Application of BDEPT allowed us to determine prodrug 
activation and cytotoxic phenotypes for an enzyme-prodrug paradigm that was 
otherwise untestable in our existing models. This work is currently accepted in press in 
Biochemical Pharmacology (313).  
 A final example of how this work has already proven relevant to the wider 
scientific community is the interest our macrophage model has generated. The 
laboratory of Professor Steffen Thiel (Aarhus University, Denmark) has requested 
access to our protocol to test the impact of complement deposition on mannan-
binding proteins in pathogen recognition.  
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Appendix 1: Antimicrobial properties nanoparticle-coated wool fibres  
 
A collaborative approach with Carla Fonseca-Paris and James Johnston of the Victoria 
Univeristy of Wellington’s School of Chemical and Physical Sciences. Manuscript in 
preparation for publication. 
 
A1.1. Introduction 
 
Hospital-acquired infections (HAI) are a major concern for medical providers 
worldwide as they are a major cause of death and contributor to increased morbidity 
in patients (342). The financial impact of HAI attributed with extended hospital stays, 
additional care and infection control was estimated in 2007 to cost approximates 
USD$595,000 per individual hospital per annum (343). Particularly problematic are the 
increasingly drug resistant pathogens like the methicillin-resistant strains of 
Staphalcoccus aureus, a gram positive bacterium responsible for >25% of all 
nosocomial infections (344). As with S. aureus, many gram negative pathogens like 
enteropathogenic Escherichia coli are also acquiring antibiotic resistance at elevated 
rates (345). With increasing rates of resistance, there is currently much commercial 
interest in developing novel textiles that are able to control the growth of both gram-
positive and gram-negative bacteria alike (346–349).  Incorporating antimicrobial or 
even microbiocidal material in both hospital bedding and functional wear may have 
the potential to assist in reducing HAI transmission rates (346).  
 Silver metal and its compounds have long been known to exhibit a strong 
toxicity to a wide range of micro-organisms since ancient times. This biocidal property 
is being used in many commercial products and in biomedical applications like medical 
implant coatings and wound dressings. Metallic nanoparticles such as silver have 
increased chemical activity as a result of their large surface to volume ratios and 
crystallographic surface structures. They also exhibit antibacterial properties due to 
their strong binding to the electron-donating groups in the surface of the bacterial cells 
and because of their small size can penetrate into them, resulting in antimicrobial 
activity (350). This biocidal activity is also exhibited by nanoparticles of gold and 
palladium. This has promoted research in the activity of gold, palladium and silver 
nanoparticle-based compounds.  
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 This section presents and summarises a study were nano-palladium particles 
immobilised on wool fibres significantly affected the bactericidal qualities of merino 
wool fibres. It was demonstrated that multifunctional composite materials (metal-
coated nanoparticles) could be stably incorporated in to the wool, a natural and 
environmentally friendly support structure. It was also established that the particle 
size could be controlled by adjusting the temperature at which heat was applied to 
wool-palladium solutions for nanoparticle formation and that palladium-loading could 
be chemically controlled to vary palladium concentration. The bacteria quantification 
methods in this study were also used a proof of principle that flow cytometry could 
accurately be used to measure survivability for the Chapter 4 infection model.  
 
A1.2. Summary of findings 
 
To justify the use of palladium-coated nanoparticles, it was firstly demsonstrated that 
palladium-loading of merino had increase bacteriocidal qualities over the previously 
characterised silver hybrid as described by Kelly and Johnston in 2011. Additionally, the 
effect of nano-palladium concentraion (paritcle size) and particle immobilisation 
temperature was examined. Antimicrobial testing was performed by washing 
stationary-phase E. coli W3110  in PBS to remove traces of nutrient media. 50 μl of 
washed bacteria wash then absorbed into ~150 mg of wool in triplicate and stored at 
room temperature protected from light. After 7 days incubation, E. coli was washed 
free of the woolen plug and examined by CFU, flow cytomentry or confocal 
microscopy.  
 The key findings were:  
1. Palladium, in comparisoin to silver-based compsites, increased the killing efficiency 
of merio wool-nanoparticle hybrids by nearly 100% depending on metal 
concentration (Figure A2.1).  
2. Bacterial viability decreased as palladium concentration increased and composites 
containing >65 ppm Pd-merino (6.50 mg Pd/g-wool) were leathal in all cases (Figure 
A2.2).  
3.  Merino-palladium fibres have a greater biocidal properties than crossbred-
palladium at Pd concentrations  >6.5 ppm (Figure A2.3.). 
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Figure A1.1. E. coli killing ability of silver vs. palladium composites 
Nanosilver- and nanopalladium-merino wool composites of 65 ppm and 120 ppm were treated for 7 
days with PBS-washed E. coli. Bacteria were then quantified by CFU.  The data presented is a 
representative of three experimental replicates and error bars depict ± 1 standard deviation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A1.2. Nanopalladium-merino wool composite antimicrobial activity by 
palladium concentration 
Nanopalladium-merino wool composites (0.65 ppm, 6.5 ppm, and 65 ppm) were prepared at room 
temperature, 80 oC, and 50 oC. The wool composites were treated for 7 days with PBS-washed E. coli. 
Bacteria were then quantified by CFU.  The data presented is a representative of three experimental 
replicates and error bars depict ± 1 standard deviation. 
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Figure A1.3. Merino- and crossbred-palladium composite biocidal activity of particles 
prepared at 80 oC 
Nanopalladium merino or crossbred wool composites (6.5 ppm, 65 ppm, and 120 ppm) were prepared 
at 80 oC. The wool composites were treated for 7 days with PBS-washed E. coli. Bacteria were then 
quantified by CFU.  The data presented is a representative of three experimental replicates and error 
bars depict ± 1 standard deviation. 
 
 
  Bactericidal activity appeared to be positively related to palladium 
concentration. Particle sizes, relative to preparation temperature, were shown to 
range in diameter from 2 – 50 nm with the larger nanoparticles located mainly at the 
cuticle edges of the fibres. The larger the particle size the less bacterial killing was seen 
at any one palladium concentration. This would suggest that the greater the particle 
size the less palladium becomes available. 
  The merino fibre, smaller in diameter, possess a smoother surfaces structure 
than crossbred fibres. Therefore, by weight, more surface area is available on merino 
fibres for functional palladium groups to be absorbed and for particles to form. The 
observation by scanning electron microscopy suggested that merino imbedded 
particles were also more uniform in size and distribution among the fibres.  This may 
indicate that some unknown characteristic of merino wool may also be contributing 
the antimicrobial qualities of the functional composite hybrids which will require 
additional investigation.  
  This project demonstrates that new hybrid materials of wool fibre and 
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palladium nanoparticles can be successfully synthesized and control bacterial growth. 
Nanopalladium-wool fibres therefore provide the opportunity to develop new hybrid 
materials for application where the antibacterial properties are desired to prevent the 
proliferation and growth of bacteria that can cause diseases. 
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Appendix 2: Microarray Top Tables of Gene Expression 
 
 
Table A2.1. Top Table: Internal PAO1 vs. Control PAO1,  up-regulated >3FC 
  Gene ID Name Fold 
Change  
P-value Protein description and/or interspecies homology Functional Class 
 PA3126 ibpA 12.6 8.86E-09 Heat-shock protein IbpA  Chaperones & heat shock proteins 
PA3819 
 
8.05 4.97E-07 Conserved hypothetical, 57% homologous to ycfJ  (E. coli) Hypothetical, unclassified, unknown; Membrane proteins 
PA4762 grpE 8.05 3.13E-08 Heat shock protein GrpE   
DNA replication, recombination, modification and repair; Chaperones & 
heat shock proteins 
PA3732 
 
7.79 3.38E-08 Conserved hypothetical  Hypothetical, unclassified, unknown 
ig_3874653_3873835 7.21 9.89E-07 Intergenic region between PA3539 and PA3540 Intergenic region between PA3539 and PA3540 
PA0665 
 
6.67 2.36E-07 
Conserved hypothetical, 86% homologous to iron-sulfur cluster 
insertion protein ErpA (P. putida) 
Hypothetical, unclassified, unknown 
PA5053 hslV 6.58 5.60E-08 Heat shock protein HslV  Chaperones & heat shock proteins 
PA3731 
 
6 5.60E-08 Conserved hypothetical, putative phage shock protein Hypothetical, unclassified, unknown 
PA2604 
 
5.06 1.07E-06 
Conserved hypothetical, putative TEGT family carrier/transport 
protein, 81% homologous (P. fluorescens)  
Hypothetical, unclassified, unknown 
PA1592 
 
4.67 2.58E-07 Hypothetical protein, putative lipoprotein, cytochrome c class I Hypothetical, unclassified, unknown 
PA0729 
 
4.47 3.12E-07 
Hypothetical protein, 56% homologous to plasmid stabilization 
system protein (P. syringae) 
Hypothetical, unclassified, unknown 
PA5470 
 
4.25 1.70E-08 Probable peptide chain release factor  Translation, post-translational modification, degradation 
PA3524 gloA1 4.24 3.58E-07 Lactoylglutathione lyase Central intermediary metabolism 
PA0763 mucA 4.17 1.07E-06 Anti-sigma factor MucA  Transcriptional regulators 
PA3533 
 
4.03 5.37E-06 
Conserved hypothetical protein, 90% homologous glutaredoxin-
like protein (P. putida) 
Hypothetical, unclassified, unknown 
PA3161 himD 4 3.59E-05 Integration host factor beta subunit  Cell wall / LPS / capsule 
PA3006 
 
3.98 9.06E-06 Probable transcriptional regulator  Transcriptional regulators 
PA4761 dnaK 3.81 1.70E-08 DnaK protein  
Adaptation, protection; Chaperones & heat shock proteins; DNA replication, 
recombination, modification and repair 
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PA3664 
 
3.81 1.36E-07 
Conserved hypothetical protein, 81% homologous to putative 
oxidoreductase, FAD-binding protein (P. putida) 
Hypothetical, unclassified, unknown 
PA0762 algU 3.74 5.36E-06 Sigma factor AlgU Transcriptional regulators 
PA0376 rpoH 3.72 1.90E-06 Sigma factor RpoH  Transcriptional regulators 
PA3665 
 
3.53 3.33E-07 Hypothetical protein, putative transporter, LysE family Hypothetical, unclassified, unknown; Membrane proteins 
PA3351 flgM 3.5 2.77E-06 
Hypothetical protein, negative regulator of flagellin synthesis 
(anti-sigma28 factor)  
Hypothetical, unclassified, unknown 
PA3815 iscR 3.49 1.83E-05 
Conserved hypothetical, iron-sulfur cluster assembly 
transcription factor IscR 
Hypothetical, unclassified, unknown 
PA1596 htpG 3.29 5.62E-07 Heat shock protein HtpG  Chaperones & heat shock proteins 
PA2952 etfB 3.21 1.30E-06 Electron transfer flavoprotein beta-subunit  Energy metabolism 
PA4386 groES 3.2 4.71E-06 GroES protein  Chaperones & heat shock proteins 
PA3183 zwf 3.17 3.09E-07 Glucose-6-phosphate 1-dehydrogenase Carbon compound catabolism; Energy metabolism 
PA5528 
 
3.07 2.13E-07 
Hypothetical protein, 74% homologous to import inner 
membrane translocase, subunit Tim44 (P. syringae) 
Hypothetical, unclassified, unknown; Membrane proteins 
PA5471 
 
3.02 1.36E-07 
Hypothetical protein, 64% homologous to RtcB (S. enterica) 
distantly related to arsenate reductase 
Hypothetical, unclassified, unknown 
PA4944 hfq 3.02 7.08E-05 Conserved hypothetical protein Hypothetical, unclassified, unknown 
 
       
 
      Table A2.2. Top Table: Internal PAO1 vs. Control PAO1, down-regulated >3 FC 
  Gene ID Name Fold 
Change  
P-value Protein description and/or interspecies homology Functional Class 
 PA0823 
 
6.89 1.70E-08 
Hypothetical protein, 57% homologous to VRR-NUC domain-
containing protein (P. syringae) 
Hypothetical, unclassified, unknown 
PA0718 
 
6.5 2.62E-08 Hypothetical protein of bacteriophage Pf1  
Hypothetical, unclassified, unknown; Related to phage, transposon, or 
plasmid 
PA3868 
 
6.21 3.12E-07 
Hypothetical protein, 82% homologous to phage integrase 
family site specific recombinase (P. syringae) 
Hypothetical, unclassified, unknown 
PA0499 
 
5.92 1.36E-07 Probable pili assembly chaperone Motility & Attachment; Chaperones & heat shock proteins 
PA0621 
 
5.9 1.70E-08 
Conserved hypothetical protein, putative tail fiber assembley 
protein 
Related to phage, transposon, or plasmid 
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PA0260 
 
5.86 5.60E-08 Hypothetical protein  Membrane proteins; Hypothetical, unclassified, unknown 
PA1387 
 
5.39 5.79E-07 Hypothetical protein Hypothetical, unclassified, unknown 
PA0821 
 
5.1 2.36E-07 Hypothetical protein Hypothetical, unclassified, unknown 
PA0978 
 
5.07 2.87E-07 Conserved hypothetical protein, putative transposase Related to phage, transposon, or plasmid 
PA0713 
 
5.06 1.29E-06 Hypothetical protein  Hypothetical, unclassified, unknown 
PA2103 
 
5.04 5.59E-06 Probable molybdopterin biosynthesis protein MoeB  Biosynthesis of cofactors, prosthetic groups and carriers 
PA0827 
 
4.88 1.36E-07 Hypothetical protein Hypothetical, unclassified, unknown 
PA3520 
 
4.74 8.07E-07 
Hypothetical protein, 39% homologous to heavy metal 
transport/detoxification protein (P. putida) 
Hypothetical, unclassified, unknown 
PA1388 
 
4.69 2.98E-06 Hypothetical protein Hypothetical, unclassified, unknown 
PA0717 
 
4.67 1.77E-05 Hypothetical protein of bacteriophage Pf1 
Hypothetical, unclassified, unknown; Related to phage, transposon, or 
plasmid 
PA0826 
 
4.59 1.27E-06 Hypothetical protein Hypothetical, unclassified, unknown 
PA0574 
 
4.58 2.12E-06 
Hypothetical protein, 87% homologous to filamentation induced 
by cAMP protein Fic (P. putida) 
Hypothetical, unclassified, unknown 
PA0261 
 
4.42 1.37E-07 Hypothetical protein Hypothetical, unclassified, unknown 
PA0726 
 
4.42 1.34E-06 Hypothetical protein of bacteriophage Pf1 
Hypothetical, unclassified, unknown; Related to phage, transposon, or 
plasmid 
PA0979 
 
4.38 9.27E-06 Conserved hypothetical protein, putative transposase Related to phage, transposon, or plasmid 
PA1394 
 
4.36 3.38E-07 Hypothetical protein Hypothetical, unclassified, unknown 
PA0992 
 
4.3 8.43E-06 Probable fimbrial subunit protein Motility & Attachment 
PA1150 pys2 4.26 6.81E-06 Pyocin S2  Adaptation, protection; Secreted Factors (toxins, enzymes, alginate) 
PA1391 
 
4.26 3.88E-06 Probable glycosyl transferase Putative enzymes 
PA1383 
 
4.15 6.53E-07 Hypothetical protein Hypothetical, unclassified, unknown 
PA0727 
 
4.13 3.86E-07 Hypothetical protein from bacteriophage Pf1  
Hypothetical, unclassified, unknown; Related to phage, transposon, or 
plasmid 
PA1395 
 
4.12 3.69E-07 Hypothetical protein Hypothetical, unclassified, unknown 
PA1153 
 
4.12 4.89E-08 Hypothetical protein Hypothetical, unclassified, unknown 
PA4526 pilB 4.1 4.31E-07 Type 4 fimbrial biogenesis protein PilB  Motility & Attachment 
PA0819 
 
4.08 2.04E-07 Hypothetical protein Hypothetical, unclassified, unknown 
PA4528 pilD 4.04 5.62E-07 Type 4 prepilin peptidase PilD  Motility & Attachment; Protein secretion/export apparatus; Secreted 
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Factors (toxins, enzymes, alginate) 
Pae_tRNA_Gly tRNA 3.98 3.60E-05 tRNA_Glycine tRNA_Glycine 
PA1936 
 
3.9 1.12E-06 Hypothetical protein Hypothetical, unclassified, unknown 
PA2104 
 
3.9 8.31E-06 Probable cysteine synthase Amino acid biosynthesis and metabolism 
PA0257 
 
3.86 3.38E-08 Hypothetical protein Related to phage, transposon, or plasmid 
PA1746 
 
3.81 5.49E-06 Hypothetical protein Hypothetical, unclassified, unknown 
PA2570 pa1L 3.74 1.30E-06 PA-I galactophilic lectin  Adaptation, protection; Motility & Attachment 
PA0730 
 
3.73 8.93E-06 Probable transferase Putative enzymes 
PA1155 nrdB 3.73 1.27E-06 Ribonucleoside reductase, small chain  Nucleotide biosynthesis and metabolism 
PA0256 
 
3.72 1.36E-07 Hypothetical protein Hypothetical, unclassified, unknown 
PA0263 hcpC 3.72 9.33E-06 Secreted protein Hcp  Secreted Factors (toxins, enzymes, alginate) 
PA2038 
 
3.71 2.44E-06 Hypothetical protein Hypothetical, unclassified, unknown 
PA0982 
 
3.7 4.66E-06 Hypothetical protein Hypothetical, unclassified, unknown 
PA0714 
 
3.7 5.75E-07 Hypothetical protein Hypothetical, unclassified, unknown 
PA0824 
 
3.69 3.38E-07 Hypothetical protein Hypothetical, unclassified, unknown 
PA1389 
 
3.66 5.58E-07 Probable glycosyl transferase  Putative enzymes 
PA1386 
 
3.64 4.89E-05 Probable ATP-binding component of ABC transporter Transport of small molecules 
PA3867 
 
3.6 2.76E-05 Probable DNA invertase DNA replication, recombination, modification and repair 
PA0987 
 
3.57 2.30E-06 Conserved hypothetical protein Related to phage, transposon, or plasmid 
PA0042 
 
3.53 3.35E-06 Hypothetical protein Hypothetical, unclassified, unknown 
Pae_tRNA_Asnt tRNA 3.43 1.45E-05 tRNA_Asparagine tRNA_Asparagine 
PA2460 
 
3.4 9.28E-05 Hypothetical protein  Hypothetical, unclassified, unknown 
PA0620 
 
3.4 3.75E-05 Probable bacteriophage protein  Related to phage, transposon, or plasmid 
PA0264 
 
3.38 6.28E-07 Hypothetical protein  Hypothetical, unclassified, unknown 
PA2733 
 
3.36 1.12E-05 Conserved hypothetical protein  Hypothetical, unclassified, unknown 
PA1149 
 
3.35 3.12E-07 Hypothetical protein  Hypothetical, unclassified, unknown 
PA0728 
 
3.34 5.95E-06 Probable bacteriophage integrase  Putative enzymes; Related to phage, transposon, or plasmid 
PA0259 
 
3.33 1.86E-07 Hypothetical protein  Hypothetical, unclassified, unknown 
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PA4239 rpsD 3.32 1.27E-06 30S ribosomal protein S4 Translation, post-translational modification, degradation 
PA3151 hisF2 3.27 1.05E-05 Imidazoleglycerol-phosphate synthase, cyclase subunit Amino acid biosynthesis and metabolism 
PA0594 surA 3.25 4.25E-06 Peptidyl-prolyl cis-trans isomerase SurA  
Adaptation, protection; Chaperones & heat shock proteins; Translation, 
post-translational modification, degradation 
PA1317 cyoA 3.25 2.36E-07 Cytochrome o ubiquinol oxidase subunit II  Energy metabolism 
PA1393 cysC 3.24 9.29E-07 Adenosine 5'-phosphosulfate (APS) kinase 
Central intermediary metabolism; Nucleotide biosynthesis and metabolism; 
Amino acid biosynthesis and metabolism 
ig_3526677_3527428 3.2 2.26E-06 Intergenic region between PA3159 and PA3160 Intergenic region between PA3159 and PA3160 
PA4523 
 
3.17 1.68E-05 Hypothetical protein  Hypothetical, unclassified, unknown 
PA0820 
 
3.17 3.66E-05 Hypothetical protein  Hypothetical, unclassified, unknown 
PA0985 
 
3.14 5.59E-05 Probable colicin-like toxin  Membrane proteins; Secreted Factors (toxins, enzymes, alginate) 
PA4238 rpoA 3.1 2.48E-05 DNA-directed RNA polymerase alpha chain Transcription, RNA processing and degradation 
PA4558 
 
3.09 8.43E-06 Probable peptidyl-prolyl cis-trans isomerase, FkbP-type 
Chaperones & heat shock proteins; Translation, post-translational 
modification, degradation 
PA2670 
 
3.08 5.71E-06 Hypothetical protein  Hypothetical, unclassified, unknown 
PA0619 
 
3.07 1.36E-07 Probable bacteriophage protein  Related to phage, transposon, or plasmid 
PA1935 
 
3.07 6.82E-06 Hypothetical protein  Hypothetical, unclassified, unknown 
PA3488 
 
3.07 2.77E-07 Hypothetical protein  Hypothetical, unclassified, unknown 
PA2105 
 
3.07 4.74E-05 Probable acetyltransferase Putative enzymes 
PA1390 
 
3.06 3.38E-06 Probable glycosyl transferase Putative enzymes 
PA0818 
 
3.05 2.04E-07 Hypothetical protein  Hypothetical, unclassified, unknown 
PA2146 
 
3.04 1.05E-06 Conserved hypothetical protein  Hypothetical, unclassified, unknown 
PA2577 
 
3.03 5.05E-07 Probable transcriptional regulator Hypothetical, unclassified, unknown; Membrane proteins 
PA2580 
 
3.02 1.76E-05 Conserved hypothetical protein  Putative enzymes 
PA0817 
 
3.01 5.60E-08 Probable ring-cleaving dioxygenase Putative enzymes 
PA0614 
 
3.01 2.87E-07 Hypothetical protein  Hypothetical, unclassified, unknown 
PA0722 
 
3 4.73E-08 Hypothetical protein of bacteriophage Pf1  
Hypothetical, unclassified, unknown; Related to phage, transposon, or 
plasmid 
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Table A2.3. Top Table: External PAO1 vs. Control PAO1, up-regulated >3 FC 
Gene ID Name 
Fold 
Change 
P-value Protein description and/or interspecies homology Functional Class 
 PA1852 
 
5.36 1.85E-06 Hypothetical protein Hypothetical, unclassified, unknown 
PA2412 
 
4.46 6.34E-06 
Conserved hypothetical protein, 88% homologous to mbtH 
domain-containing protein (P. putida) 
Hypothetical, unclassified, unknown 
Intergenic 
 
4.34 1.22E-05 Intergenic region between PA3539 and PA3540 Intergenic region between PA3539 and PA3540 
PA3151 hisF2 4.29 8.57E-06 Imidazoleglycerol-phosphate synthase, cyclase subunit  Amino acid biosynthesis and metabolism 
PA3533 
 
4.22 1.16E-05 Conserved hypothetical protein, glutaredoxin-related protein Hypothetical, unclassified, unknown 
Pae_tRNA_Tyr tRNA 4.21 7.63E-06 tRNA_Tyrosine tRNA_Tyrosine 
Pae_tRNA_Asn tRNA 4.17 1.38E-05 tRNA_Asparagine tRNA_Asparagine 
Pae_tRNA_Lys tRNA 3.82 7.10E-06 tRNA_Lysine tRNA_Lysine 
PA3266 capB 3.7 2.04E-05 Cold acclimation protein B  Adaptation, protection; Transcriptional regulators 
PA0665 
 
3.62 7.10E-06 
Conserved hypothetical protein, 86% homologous to iron-sulfur 
cluster insertion protein ErpA (P. putida) 
Hypothetical, unclassified, unknown 
PA0579 rpsU 3.49 7.57E-06 30S ribosomal protein S21  Hypothetical, unclassified, unknown 
PA3621 fdxA 3.39 7.73E-06 Ferredoxin I  Energy metabolism 
Pae_tRNA_Gly tRNA 3.38 1.26E-04 tRNA_Glycine tRNA_Glycine 
PA2967 fabG 3.26 1.26E-06 3-oxoacyl-[acyl-carrier-protein] reductase Fatty acid and phospholipid metabolism 
PA4753 
 
3.19 1.47E-05 Conserved hypothetical protein, putative RNA-binding protein Hypothetical, unclassified, unknown 
PA4466 
 
3.13 3.32E-06 Probable phosphoryl carrier protein Transport of small molecules 
PA2667 mvaU 3.07 7.10E-06 
Conserved hypothetical protein, putative transcriptional 
regulator 
Transcriptional regulators 
PA5049 rpmE 3 3.19E-04 50S ribosomal protein L31  Translation, post-translational modification, degradation 
PA2970 
 
3 3.34E-04 50S ribosomal protein L32  Translation, post-translational modification, degradation 
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Table A2.4. Top Table: External PAO1 vs. Control PAO1, down-regulated >3 FC 
  Gene ID Name Fold 
Change  
P-value Protein description and/or interspecies homology Functional Class 
 PA0718 
 
4.16 9.57E-07 Hypothetical protein of bacteriophage Pf1  
Hypothetical, unclassified, unknown; Related to phage, transposon, or 
plasmid 
PA0717 
 
4.01 5.66E-05 Hypothetical protein of bacteriophage Pf1  
Hypothetical, unclassified, unknown; Related to phage, transposon, or 
plasmid 
PA1746 
 
3.98 1.18E-05 Hypothetical protein  Hypothetical, unclassified, unknown 
PA2146 
 
3.96 1.63E-06 
Conserved hypothetical protein, 83% homologous to yciG (K. 
pneumoniae) positively regulated by rpoS 
Hypothetical, unclassified, unknown 
PA1387 
 
3.25 1.18E-05 Hypothetical protein  Hypothetical, unclassified, unknown 
PA3049 rmf 3.24 3.58E-05 Ribosome modulation factor Translation, post-translational modification, degradation 
PA0713 
 
3.24 1.71E-05 Hypothetical protein  Hypothetical, unclassified, unknown 
PA0714 
 
3.21 5.42E-06 Hypothetical protein phrD Hypothetical, unclassified, unknown 
PA0728 
 
3.15 1.72E-05 Probable bacteriophage integrase Putative enzymes; Related to phage, transposon, or plasmid 
PA0726 
 
3.09 1.52E-05 Hypothetical protein of bacteriophage Pf1  
Hypothetical, unclassified, unknown; Related to phage, transposon, or 
plasmid 
 
      
 
      Table A2.5. Top Table: Internal PAO1 vs. External PAO1, up-regulated >3 FC 
  Gene ID Name Fold 
Change  
P-value Protein description and/or interspecies homology Functional Class 
 PA3126 ibpa 32.54 1.45E-08 Heat-shock protein IbpA Chaperones & heat shock proteins 
PA3732 
 
9.71 1.48E-08 Conserved hypothetical protein Hypothetical, unclassified, unknown 
PA4762 grpE 9.66 1.45E-08 Heat shock protein GrpE 
DNA replication, recombination, modification and repair; Chaperones & 
heat shock proteins 
PA3731 
 
8.06 4.51E-08 Conserved hypothetical protein Hypothetical, unclassified, unknown 
PA3819 
 
6.05 1.05E-06 Conserved hypothetical protein Hypothetical, unclassified, unknown; Membrane proteins 
PA1029 
 
5.87 7.93E-08 Hypothetical protein Hypothetical, unclassified, unknown 
PA5053 hslV 5.58 3.61E-08 Heat shock protein HslV Chaperones & heat shock proteins 
PA5470 
 
5.25 3.95E-08 Probable peptide chain release factor Translation, post-translational modification, degradation 
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PA4761 dnak 5.18 1.78E-08 DnaK protein 
Adaptation, protection; Chaperones & heat shock proteins; DNA replication, 
recombination, modification and repair 
PA0763 mucA 4.99 1.48E-07 Anti-sigma factor MucA Transcriptional regulators 
PA2604 
 
4.91 1.41E-07 Conserved hypothetical protein Hypothetical, unclassified, unknown 
PA1596 htpG 4.61 3.59E-07 Heat shock protein HtpG  Chaperones & heat shock proteins 
PA5471 
 
4.06 2.54E-07 Hypothetical protein Hypothetical, unclassified, unknown 
PA0729 
 
4.01 2.27E-08 Hypothetical protein Hypothetical, unclassified, unknown 
PA3007 lexA 3.77 3.29E-07 Repressor protein LexA  
Adaptation, protection; Translation, post-translational modification, 
degradation 
PA4542 clpB 3.71 7.93E-08 ClpB protein  Translation, post-translational modification, degradation 
PA2952 etfB 3.46 1.65E-07 Electron transfer flavoprotein beta-subunit Energy metabolism 
PA4739 
 
3.41 1.92E-07 Conserved hypothetical protein  Hypothetical, unclassified, unknown 
PA0762 algU 3.38 2.45E-06 Sigma factor AlgU  Transcriptional regulators 
PA5528 
 
3.33 1.97E-06 Hypothetical protein Hypothetical, unclassified, unknown; Membrane proteins 
PA4386 groES 3.27 8.28E-08 GroES protein Chaperones & heat shock proteins 
PA0610 prtN 3.09 1.31E-06 Transcriptional regulator PrtN Transcriptional regulators 
PA3006 
 
3.01 1.05E-06 Probable transcriptional regulator Transcriptional regulators 
 
 
      Table A2.6. Top Table: Internal PAO1 vs. External PAO1, down-regulated >3 FC 
  Gene ID Name Fold 
Change  
P-value Protein description and/or interspecies homology Functional Class 
 PA3151 hisF2 20.98 1.45E-08 Imidazoleglycerol-phosphate synthase, cyclase subunit Amino acid biosynthesis and metabolism 
Pae_tRNA_Asn tRNA 19.7 1.87E-08 tRNA_Asparagine tRNA_Asparagine 
Pae_tRNA_Gly tRNA 16.68 2.16E-08 tRNA_Glycine tRNA_Glycine 
Pae_tRNA_Tyr tRNA 10.86 3.78E-07 tRNA_Tyrosine tRNA_Tyrosine 
PA3150 wbpG 9.7 1.41E-07 LPS biosynthesis protein WbpG  Cell wall / LPS / capsule 
PA3149 wbpH 8.8 1.65E-07 Probable glycosyltransferase WbpH Cell wall / LPS / capsule; Putative enzymes 
PA3152 hisH2 8.7 1.55E-08 Glutamine amidotransferase  Amino acid biosynthesis and metabolism 
PA2460 
 
8.29 1.48E-08 Hypothetical protein Hypothetical, unclassified, unknown 
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PA4239 rpsD 7.39 1.60E-07 30S ribosomal protein S4 Translation, post-translational modification, degradation 
PA0252 
 
7.35 8.46E-08 Hypothetical protein Hypothetical, unclassified, unknown 
PA2970 rpmF 7.05 2.76E-06 50S ribosomal protein L32 Translation, post-translational modification, degradation 
PA4525 pilA 6.33 1.89E-07 Type 4 fimbrial precursor PilA Motility & Attachment 
PA3148 wbpI 6.2 5.86E-07 Probable UDP-N-acetylglucosamine 2-epimerase WbpI Cell wall / LPS / capsule; Putative enzymes 
PA2386 pvdA 6.16 3.29E-07 L-ornithine N5-oxygenase Adaptation, protection 
PA0985 
 
6.05 4.07E-05 Probable colicin-like toxin  Membrane proteins; Secreted Factors (toxins, enzymes, alginate) 
PA4238 rpoA 5.99 2.64E-07 DNA-directed RNA polymerase alpha chain  Transcription, RNA processing and degradation 
PA4237 rpIQ 5.87 8.28E-08 50S ribosomal protein L17 Translation, post-translational modification, degradation 
PA5568 
 
5.85 1.48E-08 Conserved hypothetical protein Hypothetical, unclassified, unknown; Membrane proteins 
PA4247 rpIR 5.75 5.84E-06 50S ribosomal protein L18  Translation, post-translational modification, degradation 
PA4242 rpmJ 5.35 1.29E-05 50S ribosomal protein L36  Translation, post-translational modification, degradation 
PA0579 rpsU 5.35 1.05E-06 30S ribosomal protein S21 Hypothetical, unclassified, unknown 
PA5555 atpG 5.34 1.55E-08 ATP synthase gamma chain Energy metabolism 
PA2730 
 
5.31 6.20E-07 Hypothetical protein Hypothetical, unclassified, unknown 
PA2761 
 
5.31 1.01E-06 Hypothetical protein Hypothetical, unclassified, unknown; Membrane proteins 
PA4245 rpmD 5.29 3.78E-07 50S ribosomal protein L30 Translation, post-translational modification, degradation 
PA4240 rpsK 5.23 1.71E-07 30S ribosomal protein S11 Translation, post-translational modification, degradation 
PA1431 rsaL 5.17 1.65E-07 Regulatory protein RsaL 
Adaptation, protection; Transcriptional regulators; Secreted Factors (toxins, 
enzymes, alginate) 
PA1713 exsA 5.14 1.26E-07 Transcriptional regulator ExsA Protein secretion/export apparatus; Transcriptional regulators 
PA2398 fpvA 5.13 1.43E-05 Ferripyoverdine receptor  Transport of small molecules 
PA3266 capB 5.02 1.86E-06 Cold acclimation protein B  Adaptation, protection; Transcriptional regulators 
PA4407 ftsZ 4.94 1.65E-07 Cell division protein FtsZ Cell division 
PA1155 nrdB 4.88 7.93E-06 Ribonucleoside reductase, small chain Nucleotide biosynthesis and metabolism 
PA2412 
 
4.82 6.37E-06 Conserved hypothetical protein Hypothetical, unclassified, unknown 
PA1159 
 
4.82 2.03E-07 Probable cold-shock protein  Adaptation, protection; Transcriptional regulators 
PA5562 spoOJ 4.79 1.55E-08 Chromosome partitioning protein Spo0J  Cell division 
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PA1150 pys2 4.76 3.59E-07 Pyocin S2  Adaptation, protection; Secreted Factors (toxins, enzymes, alginate) 
PA4246 rpsE 4.74 2.44E-06 30S ribosomal protein S5  Translation, post-translational modification, degradation 
PA5554 atpD 4.74 1.69E-07 ATP synthase beta chain Energy metabolism 
PA4670 prs 4.63 5.40E-07 Ribose-phosphate pyrophosphokinase  Carbon compound catabolism; Nucleotide biosynthesis and metabolism 
PA2967 fabG 4.62 1.69E-07 3-oxoacyl-[acyl-carrier-protein] reductase  Fatty acid and phospholipid metabolism 
PA4558 
 
4.61 5.12E-06 Probable peptidyl-prolyl cis-trans isomerase, FkbP-type  
Chaperones & heat shock proteins; Translation, post-translational 
modification, degradation 
PA1852 
 
4.6 5.30E-07 Hypothetical protein Hypothetical, unclassified, unknown 
PA0668 tyrZ 4.57 8.25E-06 Tyrosyl-tRNA synthetase 2  
Amino acid biosynthesis and metabolism; Translation, post-translational 
modification, degradation 
PA5556 atpA 4.57 3.58E-06 ATP synthase alpha chain Energy metabolism 
PA1584 sdhB 4.53 5.98E-06 Succinate dehydrogenase (B subunit)  Energy metabolism 
PA1588 sucC 4.51 1.18E-06 Succinyl-CoA synthetase beta chain Energy metabolism 
PA4272 rpIJ 4.48 9.02E-08 50S ribosomal protein L10  Translation, post-translational modification, degradation 
PA2731 
 
4.42 1.43E-05 Hypothetical protein Hypothetical, unclassified, unknown 
PA4254 rpsQ 4.4 2.49E-06 30S ribosomal protein S17 Translation, post-translational modification, degradation 
PA4526 pilB 4.4 3.78E-07 Type 4 fimbrial biogenesis protein PilB  Motility & Attachment 
PA3645 fabZ 4.37 1.33E-07 (3R)-hydroxymyristoyl-[acyl carrier protein] dehydratase Cell wall / LPS / capsule; Fatty acid and phospholipid metabolism 
PA4429 
 
4.34 3.62E-07 Probable cytochrome c1 precursor Energy metabolism 
PA4671 
 
4.34 3.86E-06 Probable ribosomal protein L25  
Adaptation, protection; Translation, post-translational modification, 
degradation 
PA4269 rpoC 4.27 9.43E-07 DNA-directed RNA polymerase beta* chain Transcription, RNA processing and degradation 
PA1776 
 
4.24 1.06E-07 Probable sigma-70 factor, ECF subfamily  Transcriptional regulators 
PA4528 pilD 4.24 1.15E-06 Type 4 prepilin peptidase PilD  
Motility & Attachment; Protein secretion/export apparatus; Secreted 
Factors (toxins, enzymes, alginate) 
PA3809 fdx2 4.23 3.39E-07 Ferredoxin [2Fe-2S]  Energy metabolism 
PA2396 
 
4.21 1.89E-07 Hypothetical protein Hypothetical, unclassified, unknown 
Pae_tRNA_Lys tRNA 4.19 5.69E-06 tRNA_Lysine tRNA_Lysine 
PA0594 surA 4.18 9.43E-07 Peptidyl-prolyl cis-trans isomerase SurA  
Adaptation, protection; Chaperones & heat shock proteins; Translation, 
post-translational modification, degradation 
PA4248 rpIF 4.17 8.41E-07 50S ribosomal protein L6 Translation, post-translational modification, degradation 
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PA4241 rpsM 4.17 5.53E-06 30S ribosomal protein S13 Translation, post-translational modification, degradation 
PA1553 
 
4.12 1.65E-07 Probable cytochrome c oxidase subunit  Energy metabolism 
PA4466 
 
4.11 2.54E-07 Probable phosphoryl carrier protein Transport of small molecules 
PA2733 
 
4.07 1.29E-05 Conserved hypothetical protein Hypothetical, unclassified, unknown 
PA3158 wbpB 4.06 1.66E-07 Probable oxidoreductase WpbB  Cell wall / LPS / capsule; Putative enzymes 
PA0456 
 
3.98 2.77E-07 Probable cold-shock protein Adaptation, protection; Transcriptional regulators 
PA1710 excC 3.97 5.81E-05 Exoenzyme S synthesis protein C precursor  
Protein secretion/export apparatus; Translation, post-translational 
modification, degradation 
Intergenic 
 
3.96 1.01E-06 Intergenic region between PA3159 and PA3160 Intergenic region between PA3159 and PA3160 
PA4244 rplO 3.92 3.62E-07 50S ribosomal protein L15  Translation, post-translational modification, degradation 
PA4243 secY 3.89 6.09E-07 Secretion protein SecY Membrane proteins; Protein secretion/export apparatus 
PA1151 imm2 3.81 5.93E-06 Pyocin S2 immunity protein  Adaptation, protection 
PA4694 ilvC 3.8 2.96E-05 Ketol-acid reductoisomerase 
Amino acid biosynthesis and metabolism; Biosynthesis of cofactors, 
prosthetic groups and carriers 
PA2667 
 
3.73 9.43E-07 Conserved hypothetical protein Transcriptional regulators 
PA3147 wbpJ 3.68 2.83E-06 Probable glycosyl transferase WbpJ  Putative enzymes; Cell wall / LPS / capsule 
PA3163 cmk 3.66 5.73E-06 Cytidylate kinase  Nucleotide biosynthesis and metabolism 
PA4271 rplL 3.63 1.69E-07 50S ribosomal protein L7 / L12  Translation, post-translational modification, degradation 
Intergenic 
 
3.62 4.12E-06 Intergenic region between PA4581 and PA4582 Intergenic region between PA4581 and PA4582 
Intergenic 
 
3.58 1.02E-05 Intergenic region between PA2583 and PA2584 Intergenic region between PA2583 and PA2584 
PA1589 sucD 3.57 2.24E-06 Succinyl-CoA synthetase alpha chain Energy metabolism 
PA4550 fimU 3.54 3.60E-05 Type 4 fimbrial biogenesis protein FimU Motility & Attachment 
PA2397 pvdE 3.53 5.79E-05 Pyoverdine biosynthesis protein PvdE  Adaptation, protection; Membrane proteins; Transport of small molecules 
PA4266 fusA1 3.49 6.07E-06 Elongation factor G  Translation, post-translational modification, degradation 
PA1554 
 
3.45 3.16E-06 Probable cytochrome oxidase subunit (cbb3-type) Energy metabolism 
PA3190 
 
3.42 6.47E-07 Probable binding protein component of ABC sugar transporter  Transport of small molecules 
PA0260 
 
3.41 2.00E-07 Hypothetical protein  Membrane proteins; Hypothetical, unclassified, unknown 
PA2394 
 
3.37 1.52E-06 Probable aminotransferase  Putative enzymes 
PA4275 nusG 3.36 3.32E-07 Transcription antitermination protein NusG  Transcription, RNA processing and degradation 
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Pae_tRNA_Leu tRNA 3.35 3.59E-07 tRNA_Leucine tRNA_Leucine 
PA3155 wbpE 3.35 8.93E-07 Probable aminotransferase WbpE Cell wall / LPS / capsule; Putative enzymes 
PA2619 infA 3.34 5.40E-07 Initiation factor Translation, post-translational modification, degradation 
PA0982 
 
3.33 4.21E-06 Hypothetical protein  Hypothetical, unclassified, unknown 
PA3644 lpxa 3.33 5.45E-06 UDP-N-acetylglucosamine acyltransferase  Cell wall / LPS / capsule 
PA3646 lpxD 3.31 3.54E-06 UDP-3-O-[3-hydroxylauroyl] glucosamine N-acyltransferase  Cell wall / LPS / capsule 
PA5553 atpC 3.31 9.36E-06 ATP synthase epsilon chain  Energy metabolism 
PA4672 
 
3.3 5.34E-06 Peptidyl-tRNA hydrolase Translation, post-translational modification, degradation 
PA2453 
 
3.27 1.66E-06 Hypothetical protein Hypothetical, unclassified, unknown 
PA3046 
 
3.26 7.91E-07 Conserved hypothetical protein Hypothetical, unclassified, unknown 
PA2950 
 
3.25 4.66E-07 Hypothetical protein Hypothetical, unclassified, unknown 
PA0499 
 
3.24 6.17E-05 Probable pili assembly chaperone Motility & Attachment; Chaperones & heat shock proteins 
PA4563 rpsT 3.22 8.95E-07 30S ribosomal protein S20  
Translation, post-translational modification, degradation; Central 
intermediary metabolism 
PA0823 
 
3.19 5.35E-07 Hypothetical protein Hypothetical, unclassified, unknown 
PA3162 rpsA 3.17 2.77E-07 30S ribosomal protein S1  Translation, post-translational modification, degradation 
Intergenic 
 
3.16 3.71E-07 Intergenic region between PA0668 and PA0669 Intergenic region between PA0668 and PA0669 
PA4276 secE 3.16 1.93E-06 Secretion protein SecE Protein secretion/export apparatus 
PA1533 
 
3.16 1.12E-06 Conserved hypothetical protein Hypothetical, unclassified, unknown 
PA0821 
 
3.16 1.55E-06 Hypothetical protein Hypothetical, unclassified, unknown 
PA0992 
 
3.15 1.13E-05 Probable fimbrial subunit protein  Motility & Attachment 
PA0970 tolR 3.15 2.26E-05 TolR protein Transport of small molecules 
PA4441 
 
3.14 2.09E-06 Hypothetical protein Hypothetical, unclassified, unknown 
PA0837 slyD 3.13 3.54E-06 Peptidyl-prolyl cis-trans isomerase SlyD  
Chaperones & heat shock proteins; Translation, post-translational 
modification, degradation 
Pae_tRNA_Trp tRNA 3.11 7.75E-06 tRNA_Tryptophan tRNA_Tryptophan 
PA0820 
 
3.04 1.10E-06 Hypothetical protein  Hypothetical, unclassified, unknown 
PA3531 bfrB 3.02 8.96E-06 Bacterioferritin  Transport of small molecules; Adaptation, protection 
PA4273 rplA 3 5.78E-06 50S ribosomal protein L1 Translation, post-translational modification, degradation 
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Appendix 3: Microarray Data Sets by Functional Classification 
 
Genes with >2 FC expression compared to Control PAO1 are listed by functional 
annotation as a percentage of annotation occurrence within the data set. 
“Hypothetical, unclassified, unknown” genes were excluded from this analysis.  
 
 
Figure A3.1. Percent Internal PAO1 up-regulated vs. down-regulated  
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Figure A3.2. Percent External PAO1 up-regulated vs. down-regulated  
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Figure A3.3. Percent Internal PAO1 vs. External PAO1 up-regulated and down-regulated 
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Figure A3.4. Percent up-regulated genes Internal PAO1 vs. External PAO1 
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Figure A3.5. Precent down-regulated genes Internal PAO1 vs. External PAO1  
 
 
 
 
Table A3.1. Percent “Hypothetical, Unclassified, Unknown” genes by data set 
Direction Down- Down- Down Up- Up- Up 
Sample 
Externala 
PAO1 
Internala 
PAO1 
Internal-
Externalb 
PAO1 
Externala 
PAO1 
Internala 
PAO1 
Internal-
Externalb 
PAO1 
% 47.52 39.19 19.82 9.92 27.81 25.35 
aInternal PAO1 or External PAO1 as compared to Control PAO1 data set. 
bInternal PAO1 as compared to External PAO1 data set. 
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